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Abstract
Human immunodeficiency virus-1 (HIV-1) infection causes a progressive failure of
immune function which is fatal if untreated, and while current antiviral therapy slows
the progression of disease no cure has been found. CD8 lymphocytes form the
cytotoxic arm of the adaptive immune response and are vital in the control ofHIV
and other intracellular pathogens. HIV enters its target cell through binding to the
CD4 molecule and therefore preferentially infects cells that express CD4 on their
surface, such as CD4 lymphocytes and monocytes. CD8 lymphocytes are susceptible
to HIV infection in vitro, and there is increasing evidence to suggest that they are
also infected in vivo. Various mechanisms for the infection of CD8 lymphocytes
have been proposed. Experiments using the thy/hu mouse model support export of
intrathymically infected CD8 lymphocyte precursors, while recent in vitro data
suggest that mature CD8 lymphocytes upregulate CD4 on activation (generating a
CD8b"ghtCD4dirn phenotype) and become susceptible to HIV infection.
To confirm that CD8 lymphocytes are infected with HIV in vivo, and to investigate
the mechanism of infection, HIV long terminal repeat (LTR) DNA was quantified in
CD8 lymphocyte subsets of known purity, isolated from the blood of 20 subjects
with HIV infection. HIV LTR was demonstrated in CD8 lymphocytes of 18/20
subjects, and in the subjects with chronic infection the frequency of infection
increased with disease progression. HIV infection of CD8b"shtCD4dim lymphocytes
was significantly more frequent (median 1197 HIV LTR copies / million cells) than
that of CD8+CD4- lymphocytes (undetectable in 7/9 subjects, p<0.01), suggesting
infection on activation rather than during intrathymic development. The level of
infection in the CD8bnghtCD4dim lymphocytes approached that in CD4 lymphocytes
from the same subjects (median 3660 HIV LTR copies / million cells) and therefore
could not be explained by CD4 lymphocyte contamination.
Given the high level of infection of CBS^'^'CDd'1"11 lymphocytes their prevalence
and phenotype were assessed in 8 healthy and 16 HIV infected subjects. The
proportion ofCD8 lymphocytes with a CD8b"shtCD4dim phenotype ranged from 0.3 to
3.4%, with no significant difference between HIV infected and healthy subjects. The
majority displayed a CD45RA-ve CD27+ve (memory) phenotype, but in contrast to
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the populations generated in vitro, the circulating population was not uniformly
activated but rather comprised both activated and quiescent cells.
Thus HIV infected CD8 lymphocytes commonly circulate in HIV infected subjects,
and are likely to be infected on activation rather than during intrathymic
development. Targeted infection during activation could have a significant effect on
the immune control ofHIV and other infectious agents. Given that a proportion of
the circulating CD8bnghtCD4d,m lymphocytes have a quiescent phenotype, they may
act as a long lived proviral reservoir with implications for viral eradication.
12
Chapter 1: General introduction
In 1981 clinicians working in California were struck by the appearance of unusual
infections and malignancies in young homosexual men (Masur et al., 1981). By
1983 similar presentations were noted in intravenous drug users, haemophiliacs and
Hiatian refugees, and it became apparent that an immunodeficiency syndrome of
potentially epidemic proportions was spreading across the world. The new disease
was termed Acquired Immunodeficiency Syndrome (AIDS), and a scientific quest to
find the aetiological agent, treat the afflicted and control the epidemic began.
Over the last 23 years this quest has spawned an explosion of knowledge starting
with discovery of the HIV virus as the causative agent ofAIDS and progressing
through the unravelling ofmolecular mechanisms to the design of novel
antiretroviral agents. Through use of these drugs the immunodeficiency caused by
HIV can now be held in abeyance for years, even decades, but HIV has not yet been
eradicated from any infected individual, and the epidemic continues its uncontrolled
spread with an estimated 40 million people now infected worldwide. The holy grail
for the scientific community is the discovery of a vaccine to prevent transmission,
but while huge inroads have been made into understanding the natural immune
response to the virus and in developing novel strategies to maximise the
immunogenicity of vaccine candidates, the prospect of a fully preventative vaccine
remains elusive. In order to push forward from treatment to cure and from
therapeutic vaccine to preventative vaccine we need to better understand the details
of how HIV evades immune clearance, and how, over years of infection it slowly
weakens the immune system causing the characteristic progressive
immunodeficiency ofAIDS.
This thesis explores one aspect of the complex interrelationship between HIV and the
immune system: the infection of CD8 lymphocytes. CD8 lymphocytes, as the main
effector arm of the adaptive immune system are pivotal in the antiviral immune
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response and their infection and destruction could contribute to the failure of immune
control ofHIV as well as opportunistic infections. In addition long lived HIV
infected CD8 lymphocytes could form a reservoir of transcriptionally inactive HIV
provirus contributing to HIV persistence over years of antiretroviral therapy.
The first five sections of this introduction provide overviews of the discovery,
classification, structure and life cycle ofHIV, together with brief descriptions of the
natural history ofHIV disease and current therapeutics, and a summary of the
maturation and function of T lymphocytes. This is followed by more detailed
sections exploring topics directly relevant to the experiments performed. Section 1.6
reviews current thinking regarding the nature and cause ofHIV induced
immunodeficiency focusing on the numerical and functional decline in T
lymphocytes. Sections 1.7 and 1.8 explore the importance ofCD8 lymphocytes in
the initial control ofHIV replication, and their ultimate failure in the fight against
disease progression. The role ofproviral reservoirs for the persistence ofHIV
infection in the face of antiviral therapy is considered in section 1.9. Finally, in
section 1.10 the evidence for and against HIV infection ofCD8 lymphocytes is
debated, and proposed mechanisms of infection presented. At the end of the
introduction the scope of the thesis is presented, including a resume of the chapters to
follow.
1.1 Discovery of HIV.
A single issue of science in 1983 contained a paper from Barre-Sinoussi, Chermann,
Montagnier and associates at the Pasteur Institute reporting isolation of a retrovirus,
subsequently termed lymphadenopathy associated virus (LAV), from a man with
persistent lymphadenopathy syndrome (Barre Sinoussi et al., 1983) and a report from
Gallo and coworkers describing isolation of human T cell leukaemia virus (HTLV)
from an individual with AIDS (Gallo et al., 1983). Further work by these two groups
led to the propagation ofLAV and the isolation of additional HTLV like viruses
(termed HTLV III) from adult and paediatric AIDS patients. At the same time Levy
et al., (1984), identified retroviruses termed AIDS associated retroviruses (ARV)
which grew to high titre in peripheral blood mononuclear cells (PBMCs) and were
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cytotoxic to CD4 lymphocytes. By 1986 these three prototype viruses were
recognised as a single new retrovirus of the Lentiviridae family, and the new virus
was termed human immunodeficiency virus (HIV).
Discovery of the causative agent lead to development of diagnostic tests and the true
extent of the AIDS / HIV pandemic became apparent. The latest figures from the
World Health Organisation put the current numbers of people infected at 40 million
with the vast majority living in sub Saharan Africa.
1.2 The Origin and classification of HIV.
Genomic characteristics place HIV within the Lentivirus genus of the family
Retroviridae. Retroviridae are characterised by their life cycle, in which the viral
RNA genome is reversed transcribed into double stranded DNA that is then
integrated into the host genome. All have the genes gag, pol and env, which encode
essential structural proteins, enzymes and envelope proteins respectively. The
current classification splits the family into seven genera, grouped into 'simple'
viruses (alpha-, beta-, and gammaretroviruses whose genome contains only gag, pol
and env, and 'complex' viruses (delta- and epsilonretroviruses, lenti- and
spumaviruses) which contain additional genes encoding proteins with regulatory
functions (Table 1-1, Figure 1-1). Lentiviruses were so named due to the long
incubation period between infection and disease. They classically affect the
haematopoetic and central nervous system.
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Genus Examples Host species
Alpharetrovirus Rous sarcoma virus (RSV) Chicken
Avian leukosis virus (ALV) Birds
Betaretrovirus Mason-Pfizer monkey virus (MPMV) Primate
Jaagsiekte sheep retrovirus (JSRV) Sheep
Mouse mammary tumour vims (MMTV) Mouse
Gammaretrovirus Murine leukaemia virus (MuLV) Mouse
Feline leukaemia virus (FeLV) Cat
Gibbon ape leukaemia vims (GaLV) Gibbon
Deltaretrovirus Bovine leukaemia vims (BLV) Cow
Human T-lymphotropic vims (HTLV) -1,-2 Human
Epsilonretrovirus Walleye dermal sarcoma vims Fish
Lentivirus Human immunodeficiency vims (HIV)-l, -2 Human
Simian immunodeficiency vims (SIV) Primate
Feline immunodeficiency vims (FIV) Cat
Equine infectious anaemia vims (EIAV) Horse
Visna/maedi vims (VMV) Goat/Sheep
caprine arthritis-encephalitis vims Goat
Bovine immmunodeficiency vims Cattle
Spumavirus Primate foamy vims (PFV) Primates
Feline foamy vims (FFV) Cat
Bovine foamy vims (BFV) Cow




Figure 1-1. Phylogenetic relationship between retroviruses. A neighbour-joining tree based on the
RT protein sequences of retroviruses. All seven retrovirus genera are labelled. See Table 1-1 for full
virus names and descriptions. Phylogenetic tree courtesy of Dr. David Griffiths, Wohl Virion Centre,
Windeyer Institute ofMedical Sciences, University College London.
Extensive phylogenetic analysis ofHIV isolates from across the globe have
demonstrated two HIV viruses (HIV-1 and HIV-2), with HIV-1 being divided into
three groups: M, O and N (standing for Main, Outlier and Non-M non-O) (Simon et
al., 1998)(Figure 1-2). HIV-1 group M is responsible for the global pandemic, and is
further divided into 11 subtypes or 'clades' on the basis of sequence analysis. The
huge diversity of subtypes in Africa, and the phylogenetic relationship between HIV
and simian immunodeficiency virus (SIV) indicates that HIV originated following
transmission of SIV from monkeys into humans in Sub-saharan Africa. At least two
separate transmission events from chimpanzees are thought to be responsible for the
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M and O clades of HIV-1 (Gao et al., 1999), while HIV-2 is thought to have
originated from transmission from the sooty mangabey (Hirsch et al., 1999b).
SIV African green monkey
Figure 1-2. Phylogenetic relationship between HIV-1, HIV-2 and SIV. The positions of HIV-1
subgroups M, N and O are shown in relation to HIV-2 and various SIV isolates. Vervet, Grivet,
Sabeus and Tantalus are subspecies of African green monkeys. Adapted from (Reeves & Doms,
2002)
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1.3 The Structure, Genomic Organisation and Life Cycle of
HIV
1.3.1 Structure
Mature HIV virions are between 80 and lOOnm in diameter, and are composed of a
lipid bilayer envelope surrounding a cone shaped protein core containing the viral
RNA. The lipid bilayer envelope is acquired from the plasma membrane of the
infected cell during the budding process and contains the virally encoded envelope
glycoproteins: transmembrane glycoprotein gp41 and surface glycoprotein gpl20.
Heterodimers of gpl20 are non-covalently linked to gp41 to form a trimeric 'spike'
which is vital for attachment and entry to the host cell. Directly inside the lipid
bilayer lies the pi7 matrix protein which ensures structural integrity and plays a role
in the insertion of envelope proteins into the mature virion. The core is composed of
the viral capsid protein p24 containing two identical copies of the positive sense
RNA genome closely associated with reverse transcriptase (a viral DNA dependent
RNA polymerase), and the nucleocapsid protein p7. Also within the core lie the
virally encoded proteins Protease, Integrase, virion infectivity factor (Vif), Nef, Viral
protein R (Vpr), p6 and possibly Tat.
1.3.2 Genomic organisation.
The 9.8 kilobase HIV RNA genome encodes nine open reading frames flanked by
long terminal repeats. The three largest open reading frames (gag, pol and env) are
found in all Retroviridae, and encode nucleocapsid core proteins, enzymes (reverse
transcriptase, protease and integrase) and envelope glycoproteins respectively. The
remaining six open reading frames encode two regulatory proteins (Tat and Rev)
involved in the regulation of transcription and splicing, and four accessory proteins
Vif, Vpr, Vpu, and Nef, (Figure 1-3).
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Figure 1-3. Genomic organisation of HIV and processing of viral proteins. Dark grey shading
denotes the three genes common to all retroviruses (gag, pol and env), encoding structural proteins
and essential enzymes; black shading indicates regulatory genes; very pale grey represents accessory
genes. The LTR domains are represented as hatched boxes. Figure adapted with permission from Dr.
Samantha Willey, Laboratory of Clinical and Molecular Virology, University of Edinburgh.
1.3.3 Life Cycle.
At its simplest, the HIV life cycle can be summarised as entry into the host cell,
reverse transcription of the viral RNA with integration of newly formed viral DNA
into the host genome, use of the host cell machinery to transcribe and translate the
viral DNA, and finally post translational processing of viral proteins, followed by
formation and budding of the new virions (Figure 1-4). The process of cell entry is
of particular relevance to the question ofHIV infection of CD8 lymphocytes, and the
detail of reverse transcription and integration is of relevance to the quantification of
HIV. These aspects are considered in more detail.
HIV enters target cells through a process of attachment followed by fusion.
Attachment occurs through binding of the trimeric gpl20 on the virion surface to a
CD4 molecule on the target cell. This binding induces a confirmational change in
gpl20 exposing a chemokine receptor binding site (Kwong et al., 1998). Binding at
this site causes a conformational change in gp41 leading to the projection of three
peptide fusion domains through the cell membrane (Chan et al., 1997). Fusion of
the target cell and virion membranes then occurs with release of the viral core into
the target cell (Doms & Trono, 2000). Up to twelve chemokine receptors have been
shown to act as coreceptors in vitro, but only CCR5 and CXCR4 are frequently used
in vivo (Doms & Trono, 2000). Of note, transmitted virus generally uses CCR5 (and
is known as R5 virus), and subsequently diversifies to use both CCR5 and CXCR4
(and is termed X4 virus). This switch often occurs at the time of progression to
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AIDS but whether it is causative remains unknown (Scarlatti et al., 1997). HIV can
also enter cells through endocytosis, but this does not result in productive infection
(Greene & Peterlin, 2002).
. CD4 and coreceptor binding
CD4






and viral integration or
formation of circular DNA structures
Figure 1-4. Life cycle of HIV. The major stages in the life cycle of HIV from receptor binding to
virus particle budding. RTC, reverse transcription complex; PIC, pre-integration complex. Figure
adapted with permission from Dr. Samantha Willey, Laboratory of Clinical and Molecular Virology,
University of Edinburgh.
Following entry into the host cell viral uncoating occurs, the reverse transcription
complex (RTC) is formed and reverse transcription generates the HIV preintegration
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complex (PIC) containing double stranded viral cDNA. The error prone nature of
reverse transcriptase and RNA polymerase II, which lack proof reading ability, leads
to a high mutation rate estimated at 3xl0"5 per in vivo replication cycle (Mansky &
Temin, 1995). The PIC then travels through the nuclear membrane (an active
process which allows HIV to infect non-dividing cells) and either integrates
successfully into the host genome forming an HIV provirus (resulting in a productive
infection), or forms one or many circular DNA structures (Bukrinsky et al., 1993).
In common with all retroviruses, the HIV virion contains two RNA copies producing
a single provirus. (Hu & Temin, 1990). HIV DNA can integrate anywhere in the
host genome and in the presence of Tat efficient transcription of the viral genome is
initiated.
1.3.4 HIV cytopathicity
HIV can lead to cell death through a number ofmeans, including direct cytotoxic
effects on infected cells, cytotoxic T lymphocyte (CTL) mediated killing of infected
cells, and bystander cell death. Direct cytotoxic effects have been observed in cell
culture and include induction of cell fusion (Lifson et al., 1986a; Lifson et al.,
1986b) accumulation of viral DNA (Shaw et al., 1984), loss ofmembrane integrity
(Cloyd & Lynn, 1991), interference with cellular RNA processing (Agy et al., 1990),
and alteration in cytokine production (Macchia et al., 1991; Meyaard et al., 1994b).
These effects tend to be more severe when the infecting virus originates from an
individual with advanced disease, and virus isolates can be divided into 'syncytium
inducing' (SI) and non-syncytium inducing (NSI) on the basis of their ablity to
induce cell fusion in culture (Tateno & Levy, 1988).
CTL mediated killing ofHIV infected cells is covered in sections 1.6.7.4 and 1.7.
Bystander cell death is a process by which uninfected cells are killed, and has been
consistently observed in SIV infected macaques and HIV infected subjects (Meyaard
et al., 1992; Li et al., 2005). Bystander cell death is generally mediated by apoptosis,
which is more frequent amongst CD8 than CD4 lymphocytes (Lewis et al., 1994).
Apoptosis can be caused by the HIV proteins nef and env. Nef has been shown to
induce FAS-ligand expression on infected cells resulting in apoptosis of
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neighbouring uninfected cells expressing FAS (Geleziunas et al., 2001). Studies
using nef deficient SIV demonstrated that both CD4 lymphocytes and CD8
lymphocytes were killed through this mechanism (Xu et al., 1997). Env has been
shown to upregulate TNFa expression by macrophages, and TNF receptor expression
by CD8 lymphocytes. Subsequent contact between these two cell types resulted in
CD8 lymphocyte apoptosis by a TNFa dependent mechanism (Herbein et al., 1998).
Death by apoptosis is also a natural consequence of lymphocyte activation, and much
of the increased apoptosis in HIV may be due to activation induced cell death.
In addition to causing cell death, HIV can interfere with target cell function. This is
further discussed in relation to lymphocytes in sections 1.6.7.3 and 1.6.7.5.
1.4 The Natural history and current treatment of HIV
infection.
1.4.1 Primary infection
HIV is efficiently transmitted by sexual contact, inoculation via contaminated
needles or blood products, and from mother to child both perinatally and via breast
milk. During sexual contact the virus enters the mucosal layer where it is able to
infect CD4 lymphocytes and tissue macrophages. It is then transported to the
draining lymph nodes both in infected lymphocytes and by attachment to DC-SIGN
expressed on the surface of dendritic cells (Geijtenbeek et al., 2000). Rapid
multiplication and dispersal follows and within days of infection virus can be
detected at high levels in serum (Reimann et al., 1994; Kahn & Walker, 1998), and
found in diverse anatomical sites (Davis et al., 1992). The immune response to
infection is covered in more detail elsewhere (section 1.7). Briefly, the virus elicits a
specific anti HIV cytotoxic T lymphocyte response that reverses the rising viraemia,
bringing the viral load down to the so called 'set point'. Specific anti HIV antibodies
follow and are usually detectable in plasma within 12 weeks of infection (Busch et
al., 1995). During this period of high viraemia and early immune responses the
majority of infected individuals will experience a mild 'seroconversion illness' with
symptoms such as fever, rash and lymphadenopathy.
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1.4.2 Chronic infection
Following seroconversion the infected individual enters an asymptomatic period
lasting on average 6 to 8 years during which the viral load climbs and the CD4
lymphocyte count drops progressively (Lifson et al., 1994). During this period the
total CD8 lymphocyte count remains stable but the naive CD8 lymphocyte count
drops in parallel with the CD4 lymphocytes (Figure 1-5). When the CD4
lymphocyte count reaches a level of200 - 350 the infected individual becomes
increasingly susceptible to pathogens such as Mycobacterium tuberculosis, varicella-
zoster virus, Candida species and Streptococcuspneumoniae. The onset ofAIDS is
defined clinically through diagnosis of an AIDS defining illness (Castro etal., 1992).
The individual becomes vulnerable to opportunistic pathogens such as Pneumocystis
jirovecii, as well as malignancies, HIV associated wasting and dementia. Without
intervention AIDS is usually followed by death within 4 years (Michael & Burke,
1991). Typical changes in HIV viral load and CD4 and CD8 lymphocyte counts













Figure 1-5. Natural history ofHIV infection. Schematic diagram of the natural history ofHIV
infection during primary and chronic phases, indicating relative changes in CD4 and CD8 lymphocyte
counts and plasma viral load. The relative slopes of the CD4 and naive CD8 lymphocyte decline are
approximate and based on published data (Roederer et al., 1995).
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1.4.3 Long-term non-progressors.
Approximately 8 - 10% of individuals infected with HIV do not follow the normal
course of progression to AIDS, instead they maintain a normal CD4 lymphocyte
count and low viral load without recourse to antiviral treatment. A huge research
effort has been expended looking for the key to immune resilience in these
individuals, and many diverse factors, (reviewed in (Mikhail et al., 2003), have been
found to associate with non-progression to a greater or lesser extent. While defective
or slowly replicating viral strains, or heterozygosity for a CCR5 deletion are
sometimes implicated (Deacon et al., 1995; Kirchhoff et al., 1995), host factors
modulating the T lymphocyte response appear to be the major determinants. Thus
long term non-progressors characteristically have a broad CTL response, a ThI
cytokine expression pattern (Clerici et al., 1993), and a persistently strong CD8 non-
cytotoxic antiviral response (Levy, 1993). In addition the HLA types B27 and B-57
are represented at greater frequency in long term non-progressors than in the general
population (Kaslow et al., 1996a).
1.4.4 Current therapy and vaccine prospects.
1.4.4.1 Antiviral therapy
Antiviral therapy for HIV infection began with the approval of zidovudine (AZT), a
nucleoside analogue reverse transcriptase inhibitor (NRTI), in 1987. It soon became
apparent that the effect ofmonotherapy with AZT was shortlived, and the addition of
a second NRTI, didanosine (ddl), resulted in only limited improvement as the virus
rapidly developed resistance to the two drugs. HIV management was revolutionized
in 1995 with the advent of triple combination therapy, in which a protease inhibitor
or non-nucleoside reverse transcriptase inhibitor was used in combination with at
least two other antiretrovirals. These combinations, often refered to as highly active
antiretroviral therapy (HAART), brought HIV viral load down to undetectable levels
in a significant proportion of treatment na'ive patients (Hirsch et al., 1999a), allowed
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immune reconstitution (Autran et al., 1997; Li et al., 1998) and provided a
significant survival benefit (Hammer et al., 1997). More recently fusion inhibitors
have been added to the anti HIV pharmacopoeia, providing an additional option for
heavily pretreated patients. Even with the use of triple drug combinations resistance
remains a major problem, and transmission of drug resistant strains now occurs in
20% of new infections in the UK (Pillay, 2004).
1.4.4.2 Immunomodulatory therapy.
In the late 1990s it became clear that, due to reservoirs ofHIV within brain, semen
and quiescent T lymphocytes, and low levels of viral replication even in the presence
ofHAART, a lifetime of viral suppression with HAART will not eradicate the virus
(see section 1.6.4). Thus patients currently face lifelong antiviral medication with
the associated problems of viral resistance, side effects and pill burden, and the
attention of the research community has refocused on therapies to 'flush out' the
latent virus through activation of quiescent lymphocytes, and to stimulate the
immune response to successfully control low levels of viraemia. Strategies to
achieve these aims include structured treatment interruptions (reviewed in(Lori et al.,
2002), therapeutic vaccination (reviewed in (Lisziewicz et al., 2003) and immune
stimulants such as hydroxyurea and IL-2.
Structured treatment interruption involves repeated withdrawal of antiviral treatment,
allowing rebound viraemia and consequent stimulation of the immune response. In
macaques with acute SIV infection this approach led to development of strong HIV
specific T cell responses associated with complete control of viraemia (Lori et al.,
2000). Similar results were achieved in HIV infected individuals when treated within
three months of infection (Lisziewicz et al., 1999; Rosenberg et al., 2000), but these
successes have not generalized to subjects with chronic disease (Dybul et al., 2003).
Three major types of therapeutic vaccines have been trailed: subunit vaccines
containing HIV-1 proteins (both recombinant proteins (Goebel et al., 1999) and
whole inactivated virus (Churdboonchart et al., 1998)), recombinant viral vectors
encoding HIV-1 proteins (Jin et al., 2002), and DNA vaccines (Macgregor et al.,
1998). Many have demonstrated immunogenicity but none have yet achieved
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clinical benefit. A novel strategy in which a DNA vaccine is applied directly to
slightly exfoliated skin aims to stimulate expression of HIV proteins by Langerhans
cells which would then mature to dendritic cells and present the antigens to naive T
cells in draining lymph nodes. This approach has shown promise in combination
with HAART in macaques chronically infected with an HIV/SIV construct (SHIV)
(Lisziewicz et al., 2005).
11-2 and hydroxyurea have also undergone trials, with the hope that they will both
improve immune function and activate latently infected T lymphocytes thus
rendering them susceptible to viral cytotoxicity or CTL attack (Kulkosky et al.,
2002). Initial results demonstrated that IL-2 causes a marked increase in CD4
lymphocyte count (Arno et al., 1999) and a more rapid loss ofHIV infected cells
(Lafeuillade et al., 2001). In addition, IL-2 treatment in acute HIV infection leads to
augmentation of the CD8 lymphocyte non-cytotoxic anti-HIV response (Martinez-
Marino et al., 2004). The combination of IL-2 and therapeutic vaccination is
showing promise, leading to increased breadth ofHIV specific CD8 lymphocytes
(Levy et al., 2005).
1.4.4.3 Vaccines
Development of a protective vaccine is the holy grail ofHIV research. In general the
research community is pessimistic about the likelihood for developing a truly
protective vaccine within a reasonable timeframe, with generation of a vaccine that
decreases the efficiency of transmission being a more realistic goal. The magnitude
of the task is highlighted by a case of superinfection of an HIV infected subject, even
when mounting a good CTL response against epitopes present in the superinfecting
virus (Altfeld et al., 2002). In addition, passive immunization using immune sera did
not protect macaques challenged with SIV (Kent et al., 1994). Optimists argue that in
cases of superinfection the subjects' immune system is compromised by HIV and
that this would not be the case in vaccine induced immunity. Indeed, evidence from
highly exposed seronegative subjects, such as sex workers or the partners ofHIV
infected individuals, suggest that a degree of protective immunity against systemic
infection can be developed.
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Traditionally the stimulation of a good neutralizing antibody has been sufficient for a
vaccine, but HIV has evolved to resist antibody attack. The exposed envelope
proteins are highly glycosylated and flexible (Reitter et al., 1998). They vary by up
to 10% of amino acids within an individual, and any conserved regions are hidden
within clefts. In addition functional virions are outnumbered 1000:1 by non¬
functional particles displaying aberrant envelope structures. Finally the envelope
proteins are surrounded by an array ofhost cell derived proteins and serum proteins,
all inhibiting the attachment of antibody (Wyatt & Sodroski, 1998). Despite these
viral adaptations, following an extensive search in sera from HIV infected subjects
five monoclonal antibodies have been found that can neutralize a broad range of
primary clade B HIV isolates (Moore et al., 2001). These antibodies are directed
against the conserved regions ofHIV envelope protein, some ofwhich are only
exposed after CD4 binding. They can protect SCID mice reconstituted with human
lymphoid cells against challenge with HIV (Gauduin et al., 1997), and can protect
monkeys against SIV/HIV (SHIV) hybrid virus (Mascola et al., 2000; Hofmann-
Lehmann et al., 2001). However, the titres required are higher than are generally
achieved by immunization, and the technicalities of presenting the relevant protein
conformations to the immune system are considerable.
Difficulties generating neutralizing antibodies, together with evidence demonstrating
the importance of CTLs in control ofHIV (see section 1.7) have shifted the focus of
vaccine research towards T cell mediated immunity. T cells cannot prevent infection
as they are active against infected cells, but they can limit the extent of infection and
prevent disease, as demonstrated in mice vaccinated against influenza and
paramyxoviruses (Ulmer et al., 1998). Generating a CTL response broad enough to
be effective against all the common circulating HIV variants, in host populations of
varying HLA makeup, is a considerable challenge. Extensive investment has been
dedicated to finding the optimum number and type of epitopes to include, and the
optimal strategy for delivery (Boyer et al. 2000).
There has also been considerable progress in development of the international
cooperation required for large scale efficacy testing of candidate vaccines. The first
HIV vaccine to undergo efficacy trials, AIDSVAX (VaxGen's recombinant gpl20
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vaccine candidate), demonstrated no protective effect, but there are now over 30
further candidates undergoing phase I and phase II trials, with clinical sites in Africa,
Asia, Latin America, Europe and the USA (details available from The International
Aids Vaccine Initiative; http://www.iavi.org).
1.5 T lymphocytes
1.5.1 T lymphocyte function
T lymphocytes form the backbone of the adaptive immune response. All bear the T
cell receptor (TCR) which acts in conjunction with either CD4 or CD8 molecules to
bind antigen presented in conjunction with MHC on the surface of cells. CD4
lymphocytes have been referred to as the 'conductors of the immune system
orchestra', reflecting their ability to influence the behaviour of other components of
the immune system. They recognise antigen presented in conjunction with MHC
class II by professional antigen presenting cells, and provide co-stimulatory signals
to B lymphocytes, macrophages and CD8 lymphocytes. These signals may be
provided through direct cell contact or through the secretion of cytokines.
Depending on the nature of the antigen presentation and the cytokine environment,
CD4 lymphocytes may generate a ThI or a Th2 response. Though there is
considerable overlap, the TH1 response is dominated by release of IFN-y, IL-2 and
IL-3, and promotes a cellular response to the pathogen, while the Th2 response is
typified by release of IL-4 and IL-5 and promotes a humoral response.
The classic function of CD8 lymphocytes is to combat intracellular pathogens
through release of cytotoxic granules triggered by recognition of foreign peptide
presented in conjunction with MHC class I on the surface of infected cells.
Additional functions include secretion of antiviral cytokines such as IFNy, and P
chemokines, and recognition and destruction of neoplastic cells.
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1.5.2 T lymphocyte maturation
T lymphocytes develop in the thymus from bone marrow derived precursors. Within
thymocytes the TCR gene segments rearrange such that each cell expresses a
particular variant of TCR which will bind a limited range of antigen. The thymocytes
then undergo a process of positive then negative selection to retain only cells that
recognise selfMHC molecules but do not react against self antigens. They are then
released into the circulation as antigen nai've T lymphocytes. At this stage their
function is to patrol the lymphoreticular system awaiting contact with appropriate
activation signals. The thymus is at its most active in the neonate and rapidly wanes
through childhood. Some activity is retained in adult life but this continues to
decrease with age (Mackall et al., 1995). The nai've T cell population can be
replenished from the thymus, allowing generation of cells with novel TCR
specificities, or through regenerative proliferation of existent naive T lymphocytes.
Observations of T lymphocyte regeneration following myeloablative therapy show
that while naive CD8 lymphocytes can de repopulated by proliferation of circulating
cells, naive CD4 lymphocyte reconstitution is thymus dependent (Hakim et al.,
1997; Mackall et al., 1997).
Naive T lymphocytes are activated by interaction with professional antigen
presenting cells, and require two signals: the recognition of a foreign antigen bound
to a selfMHC molecule, and a second co-stimulatory signal. This process is usefully
referred to as priming to differentiate it from the activation ofmore mature T cells.
Antigen binding to the T cell receptor in the absence of co-stimulation leads to
anergy, a process that may be involved in HIV induced immunodeficiency. The co-
stimulatory signal is often provided by binding of CD28 on the lymphocyte to B7
molecules on the APC. CD8 lymphocytes require a stronger co-stimulatory signal
than CD4 lymphocytes, and the level of B7 expression on the APC may be
insufficient. In this case the APC must present the same antigen simultaneously to a
nai've CD8 lymphocyte and a primed CD4 lymphocyte. The CD4 lymphocyte then
induces upregulation ofB7 molecules on the APC, increasing the strength of the co-
stimulatory signal. Thus, efficient priming of nai've CD8 lymphocytes requires CD4
lymphocyte help (Matloubian et al., 1994).
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Priming leads to clonal expansion. Primed T lymphocytes stimulate their own
proliferation through synthesis of the growth factor IL-2 and its receptor, with a
single cell being capable of dividing two or three times a day. After 4 or 5 days of
proliferation the progeny cells differentiate into short lived effector lymphocytes. In
general the CD8 lymphocytes will differentiate into cytotoxic cells while CD4
lymphocytes develop helper capability, but there is some overlap of function and
CD4 lymphocytes with cytotoxic potential are expanded in HIV infection (Appay et
al., 2002b). On re-encounter with cognate antigen these effector cells are able to
function rapidly without the need for a co-stimulatory signal. A minority of the
primed T lymphocytes remain as memory cells after the effector response has
subsided.
For CD8 lymphocytes a linear model of differentiation has been proposed (further
discussed in section 3.1.1) in which primed cells first differentiate into cells with
high proliferative potential (termed memory cells) and then progress to terminally
differentiated effector cells loosing their ability to proliferate, but gaining cytotoxic
capability (Hamann et al., 1997; Kern et al., 1999; Hamann et al., 1999a;
Champagne et al., 2001). Memory CD8 lymphocytes have been subclassified into
central memory and effector memory depending on their expression of homing
molecules. Thus central memory cells express CCR7 and CD62L and home to
lymph nodes, while effector memory express neither of these two molecules and
home to sites of inflammation in the tissues (Sallusto et al., 1999). In well controlled
chronic viral infections the virus specific CD8 lymphocytes tend to have a memory
phenotype, but differentiate to the effector phenotype if viraemia rebounds (Zhang et
al., 2003).
1.5.3 CD8br'9htCD4dim lymphocytes
Until the 1980s it was generally accepted that CD4 and CD8 expression on mature T
lymphocytes were mutually exclusive. With the advent of two colour flow
cytometry in 1985 a small population ofCD4CD8+ lymphocytes were observed
making up 2-3% ofPBMCs in the blood of healthy subjects (Blue et al., 1985).
These cells were negative for the thymocyte marker T6 and had the size, granularity
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and expression profiles of activated cells. Further analysis demonstrated two
distinct subpopulations: CD8bnghtCD4d,m which were associated with acute viral
infection and thought to originate from CD8 lymphocytes, and CD4b"ghtCD8d,m
which were proposed variants ofCD4 lymphocytes (Ortolani et al., 1993).
Conclusive evidence that mature CD8 lymphocytes can upregulate CD4 to generate a
CD8bnghtCD4d,m phenotype came in 1998 with two papers in which highly purified
CD8 lymphocytes responded to in vitro stimulation by production ofCD4 mRNA
and cell surface CD4 expression (Flamand et al., 1998) (Kitchen et al., 1998). The
type of CD8 lymphocyte most likely to upregulate CD4, the nature of the signal
required and the phenotype of the resulting CD4b"ghtCD8dnTI lymphocytes are
discussed in more detail in section 5.1.
These findings led to the hypothesis that nai've CD8 lymphocytes in vivo may
temporarily upregulate CD4 expression following antigen specific activation,
generating the CD8bnghtCD4dim lymphocytes observed in the circulation. This
proposal is consistent with the observation that CD8bnghtCD4d,m lymphocytes in vivo
are more likely to display an antigen experienced phenotype than their CD4-ve
counterparts (Imlach et al., 2001; Nascimbeni et al., 2004).
1.6 HIV induced immunodeficiency.
The hallmark ofHIV infection is immunodeficiency and yet our understanding of its
nature is patchy with even the most fundamental aspects, such as the cause of the
CD4 lymphocyte decline, remaining controversial. Studies of other
immunodeficiency viruses in their natural hosts, including SIV in Sooty mangabeys
and African green monkeys, indicate persistent infection but little disease, and even a
species switch, as occurred with HIV-2 has not induced the devastating immune
collapse typical ofHIV-1. The immunodeficiency ofHIV-1 is pervasive, affecting
both the innate and adaptive responses, and compromising the function of
macrophages (Kedzierska et al., 2003), dendritic cells (Macatonia et al., 1990) and
natural killer cells (Cai et al., 1990) as well as B and T lymphocytes (Schnittman et
al., 1986). While acknowledging the importance of all these aspects, this review is
restricted to T lymphocyte immunodeficiency, a topic directly relevant to the
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potential role that HIV infection of CD8 lymphocytes may play in HIV pathogenesis.
The effect ofHIV infection on T lymphocyte numbers, turnover, distribution,
activation and function, are described first, and then the mechanisms behind the
defects observed are explored. The dynamics and function ofHIV specific T
lymphocytes are discussed separately (1.7 and 1.8 ). Before moving on to specifics it
is salutary to recall the degree to which advances in our understanding ofHIV have
been paralleled by advances in immunology. When HIV was first isolated the T cell
receptor had not been discovered, CD8 lymphocytes were not known to recognise
viral peptides, and the distinction between TH1 and TH2 subsets of CD4 lymphocytes
had not been made. Thus early observations often have to be re-evaluated in the
light ofmore recent advances.
1.6.1 T lymphocyte numbers.
1.6.1.1 Primary infection.
The recent demonstration that acute HIV infection causes a rapid and profound
depletion of antigen experienced CD4 lymphocytes has revolutionised our
understanding ofHIV immunopathology. Studies in SIV infected macaques
demonstrated that by day 10 post infection 60 - 80% of antigen experienced CD4
lymphocytes were lost from blood, lymph node and gastrointestinal mucosa
(Mansky, 2000; Mattapallil et al., 2005). The depletion was most profound for cells
expressing CCR5 with a CD95h'CCR7- (effector) phenotype, which are preferentially
located in mucosal tissue (Veazey et al., 1998; Veazey et al., 2000). Gut mucosae
together with gut associated lymphoid tissue (GALT) contain 60% of the total body
lymphocytes and have been identified as the major site ofCD4 lymphocyte loss in
both acute and chronic SIV infection (Veazey et al., 1998; Veazey et al., 2000;
Mansky, 2000; Mattapallil et al., 2005; Li et al., 2005). That HIV has a similar
effect in humans was suggested by demonstration ofmarked CD4 lymphocyte loss in
jejunal biopsies from two subjects with PHI (Guadalupe et al., 2003), and confirmed
in two papers published together in September last year (Mehandru et al., 2004;
Brenchley et al., 2004b). Mehandru et al., (2004), studied colonic biopsies from 27
HIV infected subjects (13 with PHI) and 10 uninfected controls. The proportion of
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mucosal mononuclear cells expressing CD4 and CCR5 was significantly reduced in
primary HIV infection, and immunohistochemistry of biopsy sections demonstrated
that while the inductive lymphoid sites (comprising the B cell follicle and
surrounding T cell zone) contained normal numbers of CD4 lymphocytes,
approximately 2/3 of these cells were lost in effector sites (lamina propria). In a
recent review of T cell dynamics Douek argues that these early events leave a
profound and long-lasting impact on the immune system that may set the stage for
the subsequent progressive immunodeficiency (Douek et al., 2003).
1.6.1.2 Chronic infection
In contrast to the rapid depletion of activated antigen experienced CD4 lymphocytes
in the acute phase, during the chronic phase peripheral blood CD4 lymphocyte
counts drop very slowly. Both memory and na'ive subsets decline, but the naive
subset declines more rapidly, such that the proportion ofCD4 lymphocytes that are
nai've drops from 50% in healthy subjects to approximately 25% in subjects with
AIDS. The profound deficiency of CD4 lymphocytes in GI tissue in primary
infection is maintained into chronic infection, with a trend towards ongoing decline
(Mehandru et al., 2004; Brenchley et al., 2004b).
Total CD8 lymphocyte numbers remain stable until late stages of disease, but this
stability masks changes in CD8 lymphocyte subsets. If antigen naive and
experienced, cells are considered separately then a steady decline in the naive subset
is observed which parallels the decline in naive CD4 lymphocytes (
Figure 1-5) (Roederer et al., 1995). HIV infection ofCD8 lymphocytes may
contribute to this decline, but as discussed in section 1.6.6 the relationship between
infection and depletion is complex.
1.6.2 T lymphocyte redistribution
The movement of T cells between blood, lymphoid and extralymphoid compartments
is controlled by the interaction of an array of cellular adhesion molecules and homing
receptors, and their counterparts on endothelial surfaces. Immune activation of T
lymphocytes classically causes downregulation of lymph node homing molecules
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such as CD62L and CD27, and an increase in tissue homing molecules, resulting in
redistribution of cells away from the lymphoreticular system and into the tissues.
Given that only 2% of total body CD4 lymphocytes reside in the circulation, small
shifts in homing to lymph node or tissues can lead to large changes in the circulating
population (Trepel, 1974; Zhang et al., 1998). HIV infection results in prolonged
immune activation (described in section 1.6.3) and it was soon recognised that much
of the CD4 lymphocyte decline observed in acute and chronic HIV infection was due
to cell redistribution rather than loss (Bucy et al., 1999). The extent of the
redistribution was revealed by studies examining immune reconstitution following
HAART. The early rapid rise in the antigen experienced CD4 lymphocyte
population was attributed to resolution of the HIV induced redistribution, with the
slower rise in the nai've population attributed to regeneration (Parker et al., 1998). A
recent study ofT cell dynamics in multiple tissues biopsied from SIV infected
macaques demonstrated that population shifts play little part in the massive loss of
CD4 lymphocytes seen in acute infection (Mattapallil et al., 2005).
1.6.3 T lymphocyte activation.
HIV infection results not only in activation of responding lymphocytes as would be
expected for any acute viral infection, but also profound generalised immune
activation which extends into the chronic phase. In acute infection this generalised
activation is evidenced by increased expression of activation and proliferation
markers including CD38 and Ki67 not only on HIV specific, but also EBV, CMV
and influenza specific CD8 lymphocytes (Trepel, 1974; Doisne et al., 2004).
Evidence of continuing generalised activation into the chronic phase of disease is
provided by increased expression of activation markers including CD25, HLA-DR,
CD38 and Ki-67 on ap-and y8-T lymphocytes from blood and lymph nodes
(Norazmi et al., 1995; Peakman et al., 1995; Benito et al., 1997; Brenchley et al.,
2004b). There is also increased turnover of both CD4 and CD8 lymphocytes
(Sachsenberg et al., 1998; Hazenberg et al., 2000b), polyclonal activation of B
lymphocytes, and in SIV infection, increased proliferation of B lymphocytes and NK
cells (Mohri et al., 1998).
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1.6.4 T lymphocyte turnover
An early estimate ofT lymphocyte turnover in HIV was published in Nature in 1995
(Wei et al., 1995; Ho et al., 1995). The authors used rates of CD4 lymphocyte
recovery post HAART to postulate that, in subjects with asymptomatic chronic
infection, CD4 lymphocyte turnover was grossly elevated, with an estimated 5% of
the total CD4 lymphocyte population (1 - 2 x 109 cells) dying and being replaced on
a daily basis. The authors estimated that this represented a 78 fold increase on normal
CD4 lymphocyte turnover. This hypothesis spawned a plethora of studies, (reviewed
in (Johnson, 2000), assessing the effect ofHIV on CD4 lymphocyte turnover.
Conflicting results were reported, largely because 'turnover' is not an exact concept
but an amalgam of production, destruction and life span, and its rate was inferred
using a number of inexact correlates. Thus the observation that telomere lengths of
CD4 lymphocytes in HIV infected persons remained stable over time suggested no
increase in turnover (Wolthers et al., 1996), but this conclusion was contradicted by
studies ofKi67 expression (Sachsenberg et al., 1998), and by bromodeoxyuridine
(BrdU) labelling in SIV infected macaques (Mohri et al., 1998). Development of H-
glucose labelling allowed direct measurement of cell proliferation and destruction
rates in healthy human volunteers and was a huge step forward for the field.
Following the publication of two studies using this technique it is generally agreed
that HIV infection leads to a moderate increase in turnover, with a 3 - 6 fold increase
in fractional CD4 lymphocyte proliferation and destruction rates (Hellerstein et al.,
1999; Mohri et al., 2001).
1.6.5 Lymph node architecture
HIV disease leads to progressive destruction of lymph node architecture. (Schacker
et al., 2002). The degree of destruction has been shown to correlate with the extent
of effector T lymphocyte infiltration of the lymph node, and is thought to be immune
mediated (Brenchley et al., 2004b).
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1.6.6 Cause of T cell depletion
It is tempting to speculate that HIV infection of CD8 lymphocytes may cause the
depletion in naive CD8 lymphocyte numbers. However, as elaborated in this section,
the relationship between HIV infection of CD4 lymphocytes and CD4 lymphopaenia
is still hotly debated, so any ideas regarding the causality of CD8 lymphocyte
depletion must be viewed in the light of this ongoing debate.
It has been proposed that the massive loss of antigen experienced CD4+ lymphocytes
in primary HIV or SIV infection is caused by infection of large numbers of activated
cells (activated through recent interaction with gut associated microbes) followed by
viral cytopathicity or CD8 mediated killing (Veazey et al., 1998; Veazey et al., 2000;
Veazey & Lackner, 2003; Mattapallil et al., 2005). This hypothesis is supported by
the very high numbers of productively infected CD4 lymphocytes within the gut
(Mattapallil et al., 2005), together with in vitro demonstrations ofHIV cytopathicity,
and CD8 directed lysis ofHIV infected cells. However, detailed
immunohistochemical studies of SIV and HIV infected GI tissue have shown that the
areas ofmaximum infection are the inductive lymphoid tissue while the maximal
CD4 cell loss occurs in the effector tissue of the lamina propria (Mehandru et al.,
2004; Li et al., 2005), leading authors to suggest that cell loss is largely bystander
cell death. In keeping with this proposal Li et al., (2005), found peak levels of
infection could only account for 20% of the total CD4 lymphocyte depletion. In
addition markers of apoptosis as well as expression of Fas and Fas-ligand were
increased in the effector but not the inductive tissue, and this expression correlated in
time with the peak destruction of CD4 lymphocytes.
The cause of the T lymphocyte loss during chronic infection is clearly more
complicated as the subsets in sharpest decline (ie naive CD4 and CD8 lymphocytes)
are not major targets for productive infection with CCR5 tropic virus. The main
theories regarding the cause of depletion are reviewed below.
1.6.6.1 Accelerated destruction.
The first theory to address the cause of chronic CD4 lymphocyte decline was the 'tap
and drain' or 'accelerated destruction' model introduced by Ho and Wei (Wei et al.,
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1995; Ho et al., 1995), This theory contains two basic premises, first that the
increased CD4 lymphocyte turnover is driven by excess destruction mediated by
viral cytotoxicity or CTL killing of infected cells with the increased proliferation
being a homeostatic response to lymphopaenia, and second that the progressive CD4
lymphocyte decline is caused by exhaustion of the regenerative capacity of the
immune system in the face of prolonged high turnover.
Since the theory was proposed the degree of T lymphocyte turnover has been revised
downwards, but the two basic premises of the theory retain support (Mohri et al.,
2001). HIV infected CD4 lymphocytes, while present at a very low frequency in
blood (1/1000 - 1/10,000 PBMCs) (Simmonds et al., 1990; Chun et al., 1997) are
detected at higher levels in lymph node (Pantaleo et al., 1993) and GI tissue (Mohri
et al., 2001; Anton et al., 2003; Mehandru et al., 2004), and it remains conceivable
that the observed level of increased turnover may be driven by HIV induced
destruction.
However, viral cytotoxicity and CTL killing preferentially effect antigen experienced
cells, while the cell population in rapid decline is the nai've subset. Ho et al., (1995),
did not clearly delineate the proposed mechanism linking these two events, but
possibilities include homeostatic movement of cells from the naive compartment
(Picker et al., 2004). Clearly in subjects carrying a CXCR4 tropic virus naive
lymphocytes may be depleted by direct infection (Blaak et al., 2000). The question
of CD8 lymphocyte depletion is not addressed by proponents of this theory, but viral
cytotoxicity and CTL mediated killing could lead to increased turnover ofHIV
infected CD8 lymphocytes.
1.6.6.2 Immune activation
Others argue that the increased lymphocyte turnover is fuelled by generalised
immune activation which causes lymphocyte proliferation, naturally followed by
death through activation induced cell death (AICD) (Hazenberg et al., 2000a;
Hazenberg et al., 2000b; Grossman et al., 2002). To investigate this issue, Kovacs et
al., (2001), used BrdU labelling in HIV infected people. They found that HAART
reduces the fraction ofproliferating CD4 lymphocytes but not their half life
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suggesting that proliferation rather than premature destruction is the driving force
behind increased turnover.
Proponents of the immune activation theory postulate that activation not only causes
increased cell turnover, but also leads to the decline in CD4 lymphocyte count and
disease pregression. This link is supportive by correlative evidence, by animal
model studies and by studies of IL-2 therapy. Thus, markers of immune activation
correlate more strongly with CD4 lymphocyte decline than does viral load (Sousa et
al., 2002), and are predictive of disease progression. Also, in its natural hosts (Sooty
Mangabeys and African Green Monkeys) SIV replicates to high copy number and is
cytopathic to infected cells, but causes no increased cell turnover and no
immunodeficiency (Chakrabarti et al., 2000; Broussard et al., 2001). In contrast, in
Macaques the viraemia excites high levels immune activation, increased cell turnover
and a progressive lymphopaenia (Kaur et al., 1998). Finally, IL-2 induced CD4
lymphocyte expansion in HIV infected subjects is associated with decreased Ki67
expression and decreased turnover (Sereti et al., 2004).
The chronic immune activation ofHIV affects both CD4 and CD8 lymphocytes (see
section 1.6.3) but to date the mechanism by which activation could cause naive CD4
and CD8 lymphocyte decline has not been demonstrated. Possibilities include:
sustained activation of naive lymphocytes which then enter the memory pool;
induction of an anergic state in which lymphocytes become less sensitive to signals
promoting regenerative proliferation resulting in reduced steady state numbers of
resting cells (Grossman et al., 2002); or disruption of T cell regeneration by collagen
deposition in lymph tissue (Brenchley et al., 2004b).
1.6.6.3 Regenerative failure.
The third major theory of CD4 lymphocyte decline, known as the regenerative failure
model, proposes that HIV induced failure of production rather than increased
destruction is paramount. It was championed by Hellerstein and McCune following
a cross sectional study in which the absolute production rate of CD4 lymphocytes per
ml of blood was not significantly different in HIV infected compared to uninfected
subjects (despite significant lymphopaenia), but was increased 3 fold in subjects
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following 12 weeks ofHAART treatment. (Hellerstein et al., 1999; McCune et al.,
2000). Supportive findings include a link between speed of progression and
measures of thymic potential (Touloumi & Hatzakis, 2000; Teixeira et al., 2001), but
attempts to show a direct link between CD4 lymphocyte decline and reduced thymic
output have been compromised by methodological issues (Hazenberg et al., 2000a).
Against this theory, Hellerstein and McCune's findings regarding the effect of
HAART were contradicted by two longitudinal studies (Mohri et al., 2001)(Kovacs
et al., 2001), both ofwhich found that treatment causes a definite reduction in CD4
lymphocyte proliferation.
Of interest, in the SIV infected macaques, animals that progressed rapidly to disease
had both marked acute phase loss ofmemory CD4 lymphocytes, and a progressive
failure of proliferation of the remaining memory cells. In contrast, animals that
progressed slowly were able to maintain the residual memory CD4 lymphocyte
population by ongoing proliferation (Picker et al., 2004). The cause of the failure of
proliferation was not addressed, but this finding does suggest that while accelerated
destruction in the acute phase is paramount, failure ofproduction may be critical in
disease progression.
1.6.7 T lymphocyte function
In addition to the decline in numbers ofCD4 and CD8 lymphocytes in HIV infected
persons, there is evidence that those that remain do not function optimally. Studies
comparing LTNP versus rapid progressors suggest that T lymphocyte function may
be crucial in curbing disease progression, (Migueles et al., 2002). Again, it is easy to
assume that abnormalities in CD8 lymphocyte function may be due to HIV infection
of CD8 lymphocytes, but, as was seen for the decline in lymphocyte numbers, the
lessons from CD4 lymphocytes indicate that direct infection is only one ofmany
possible causes of dysfunction. In this section an overview of the methods used to
measure lymphocyte function is given, highlighting aspects of relevance to HIV.
This is followed by a brief review ofHIV induced dysfunction of CD4 lymphocytes,
and then CD8 lymphocytes are considered in more detail. The proposed mechanisms
behind the defects are also presented.
40
1.6.7.1 Measuring T lymphocyte function.
The contribution of T lymphocyte dysfunction to HIV induced immunodeficiency
has been tested ex vivo using a variety of approaches which involve measuring the
response of the cell to a stimulus (Allen & Watkins, 2001). The methods are often
technically demanding and poorly standardised and have produced a myriad of
conflicting results in the field ofHIV immunopathology. Importantly the vast
majority of investigations have been performed on lymphocytes isolated from blood,
while the effector functions are largely delivered in peripheral tissue or lymph nodes.
Many of the older methods require culture for up to a week and thus could under¬
estimate the function of cells from HIV infected subjects which are prone to
apoptosis in culture. Teasing out the true cause of the responses observed and
relating these back to in vivo function is challenging. The main assays used and the
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i) Number of precursors available capable of proliferating
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of cells secreting one
or many cytokines in
response to a stimulus.
Number of cells present able to secrete cytokine in
response to the given stimulus.
Table 1-2. Evaluating T-cell responses, (a) These assays can be performed at limiting dilution
allowing estimation of the proportion of cells that have the given attribute.
1.6.7.2 CD4 lymphocyte function in HIV infection
A number of studies in the 1980s demonstrated that CD4 lymphocyte function, as
measured by proliferative response, IL-2 production or CD4 lymphocyte dependent
B lymphocyte function, was reduced in HIV infected subjects (Lane et al., 1983;
Miedema et al., 1988; Clerici et al., 1989; Weimer et al., 1989; Shearer & Clerici,
1991). Loss of function was observed in CD4 lymphocytes derived from blood and
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lymph node (Jobe et al., 1999). These deficiencies were initially reported in subjects
with AIDS, and were assumed to be caused by a profound loss of CD4 lymphocyte
numbers, but it soon became apparent that some functions were defective in earlier
stages of disease when CD4 lymphocyte numbers were only slightly reduced. In a
classic experiment Clerici et al.compared proliferation and IL-2 production of
stimulated peripheral blood lymphocytes in 96 HIV infected subjects with 70
controls. There was a clear loss of both proliferation and IL-2 production in the HIV
infected group which was present at the asymptomatic stage of disease and became
more profound over time. Thus 84% of asymptomatic HIV infected subjects lacked
response to recall antigens (tetanus toxoid and influenza), 30% lacked response to
recall antigens and HLA alloantigens and 14% did not respond to recall antigen,
alloantigen or mitogen (PHA). In subjects with more progressive disease none of the
22 subjects responded to recall antigens, 36% responded to alloantigen and 64% had
no response to any of the stimuli (Clerici et al., 1989). Other investigators have not
found proliferative defects (Gurley et al., 1989). The range of proliferative responses
reported may be due to the smaller sample size of some later studies (Gurley et al.,
1989), or may reflect the different intensities of stimulus used by different
investigators, as the loss of proliferation can be overcome by strong stimulation
(Meyaard et al., 1994a).
Significant loss ofproliferative response can occur early in the course ofHIV
infection. In subjects tested within three months of seroconversion the majority had
no detectable response to Candida or tetanus, and had decreased response to PHA.
These responses recovered to some extent in the next 12 months but did not return to
the levels seen in uninfected controls (Musey et al., 1999).
Where proliferative defects are observed, they are generally reversed with effective
antiretroviral therapy. Thus (Angel et al., 1998), found the majority of treated
subjects recovered their proliferative response to mitogen (PHA) and in a separate
trial proliferation to recall antigen also improved (Kelleher et al., 1996).
Measurement of antigen specific CD4 lymphocyte function using intracellular
cytokine staining has produced a very different picture. Rather than the expected
progressive loss of function, HIV infected subjects demonstrated a largely intact
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response with the fraction of CD4 lymphocytes responding to CMV being enhanced,
while that responding to mumps was decreased (Waldrop et al., 1997; Pitcher et al.,
1999). These findings led the authors to suggest that the early loss of antigen
experienced cells, and the increased lymphocyte turnover generates an environment
in which lymphocytes responding to frequently encountered antigen out compete
memory lymphocytes generated during past events. This would explain the
preserved immune control of opportunistic infection until late stages of disease.
A number of investigators found that the antigen specific CD4 lymphocyte response
in HIV infected subjects was dominated by secretion of IFN-y and TNF-a, with little
secretion of IL-2 or IL-4 (Waldrop et al., 1997; Sieg et al., 2001). As proliferation
requires IL-2, this cytokine pattern may explain the conflict between these results
and those measuring response in terms ofproliferation. Alternatively the length of in
vitro culture required for the different methodologies may be instrumental (see
section 1.6.7.1. T lymphocytes from HIV infected subjects are known to be prone to
apoptosis in vitro, and the 5 -6 day culture used in proliferation assays may have
resulted in the death ofmany of the effector cells. In contrast, the intracellular
cytokine staining protocol requires only a 6 hour stimulation.
1.6.7.3 Mechanism of decreased CD4 lymphocyte function.
A number ofmechanisms could contribute to the decline in CD4 lymphocyte
function, including subset imbalance, toxic effects of the virus and its proteins,
changes in the cytokine environment and defective antigen presentation.
Direct cytotoxic effect. The cytotoxic effects ofHIV on infected CD4 lymphocytes
are described in section 1.3.4. While these effects often result in cell death, they can
also impair function in CD4 lymphocytes that are infected but not killed. Given the
low frequency of infection ofCD4 lymphocytes, especially during the asymptomatic
stages, these mechanisms alone could not account for all the loss of function
observed. However they may be of particular relevance to the loss ofHIV specific
CD4 lymphocyte function, as these cells are preferentially infected (Douek et al.,
2002).
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CD4 lymphocyte subset imbalance. Van Noelson et al., (1990), demonstrated
selective loss of activated memory (CD4+CD29+) as opposed to nai've CD4
lymphocytes in asymptomatic HIV infected subjects with normal CD4 lymphocyte
counts. The authors noted that many of the functional abnormalities observed early
in infection, including lack of response to recall antigen, to anti-CD3 or anti-CD2
monoclonal antibodies, and lack of helper activity could all be explained by this
subset imbalance. Subsequent more detailed phenotypic analyses have confirmed the
loss ofmemory cells, now thought to result largely from massive loss of CCR5
expressing (largely activated memory) CD4 lymphocytes during primary infection.
(Schnittman et al., 1990; Veazey et al., 1998; Veazey et al., 2000; Veazey &
Lackner, 2003; Mattapallil et al., 2005). Of relevance decreased frequencies of
alloreactive precursor cells, and decreased proliferative responses per alloreactive
cell, have been demonstrated in both CD45RA+ and CD45RO+ T lymphocyte
populations. This was interpreted to indicate loss of function within the nai've and
memory subsets, indicating that subset imbalance alone is unlikely to account for all
the dysfunction observed (Meyaard et al., 1994a).
Effect ofcirculating viralproteins. Viral envelope proteins are secreted from
infected cells (Tas et al., 1988) and have been noted to have immunosuppressive
effects on T lymphocytes (Chanh et al., 1988; Diamond et al., 1988; Gurley et al.,
1989; Oyaizu et al., 1990; Quintana et al., 2005). This effect is thought to be
mediated through interactions with cell surface receptors causing dysfunction of
activation pathways (Rosenstein et al., 1990), and alteration of cytokine secretion
(Oyaizu et al., 1990). Toxic effects such as induction of cell fusion and membrane
defects could also be important (gpl20) (Lifson et al., 1986a; Miller et al., 1993). In
addition Gag can affect intracellular function through binding to cyclophillins
(Luban et al., 1993) while Tat has been shown to reduce the proliferative response of
CD4 lymphocytes to recall antigens (Seth et al., 2000).
Cytokines. The cytokine milieu is central to the fine balance of immune function, and
there is increasing evidence that HIV causes disturbance of both cytokine production
and the response to cytokines (reviewed in (Kedzierska & Crowe, 2001). For
example, HIV infection ofmacrophages in vitro leads to increased secretion of
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TNFa, a cytokine that can be toxic to T cells (Merrill et al., 1989), and in SIV or
SHIV infected macaques CD4 lymphocytes are deficient in cytokine expression
(McKay et al., 2003). In addition, PBMCs from HIV infected subjects are deficient
in IL-12 production, a cytokine important for T cell proliferation and IFN-y
production (Marshall et al., 1999). Inappropriate cytokine secretion may also induce
the shift from a ThI to a Th2 type immune response, an event which is thought to be
crucial for progression to AIDS (Clerici & Shearer, 1997), and could contribute to
the generation of T lymphocyte anergy.
Defective antigen presentation and anergy. Dendritic cells are responsible for
transporting antigen to lymph nodes and activating nai've T lymphocytes. HIV is
known to bind strongly to DC-SIGN (Geijtenbeek et al., 2000), a cell surface
molecule involved in the activation process. This could result in antigen being
presented to the TCR in the absence of costimulation, causing naive T cells to
become anergized rather than activated. Similarly restimulation of antigen
experienced T cells by macrophages may be compromised by HIV induced
downregulation ofMHC class II and the costimulatory molecules CD80 and CD86
(Clerici et al., 1991; Dudhane et al., 1996). Anergy could also be induced by low
affinity TCR interactions caused by the presentation of subtly mutated epitopes or
downregulation of TCR expression (Trimble & Lieberman, 1998). Anergic cells
compete with naive cells for antigen and are thus powerful inhibitors of a specific T
lymphocyte response. HIV induction of anergy is an attractive hypothesis explaining
many of the features of CD4 and CD8 lymphocyte function (Maier et al., 1998), but
direct evidence is lacking.
1.6.7.4 CD8 lymphocyte function in HIV infection.
Of interest to this thesis is whether HIV infected individuals have compromised CD8
lymphocyte function, which could be caused by direct infection of CD8
lymphocytes. Numerous studies have investigated anti-HIV specific CD8
lymphocyte responses but as these may be subverted by HIV immune evasion they
do not reflect global CD8 lymphocyte function, and I will therefore focus on studies
assessing general CD8 lymphocyte abilities, or CD8 lymphocyte responses to non-
HIV pathogens.
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Cytotoxic function. A number of investigators in the early years ofHIV research
noted decreased CTL responses in patients with AIDS. Thus in 1982, prior to the
isolation ofHIV, a paper was presented describing depressed anti-CMV CTL
responses in subjects with AIDS (Frederick et al., 1982), a finding replicated in a
number of further studies (Rook et al., 1983; Epstein et al., 1985). Subsequently it
was demonstrated that allogeneic CTL responses were also depressed, being present
in only 4 of 19 subjects with AIDS or AIDS related complex (Sharma & Gupta,
1985). The lack ofproliferative responses to alloantigen and mitogen demonstrated
by Clerici et al., (1989),(described in section 1.6.7.2), further support a profound loss
of function of CD8 lymphocytes in the late stages ofHIV disease.
The effector CTL response to CD3 stimulation in AIDS has been controversial, with
some investigators finding loss of response (Gamberg et al., 1999) while others
found the response was maintained (Pantaleo et al., 1990). The reason for these
conflicting results is unclear, both Pantaleo and Gamberg used P815 mastocytoma
cell lines as targets so there should not have been differential expression of pro
apoptotic receptors.
Antigen stimulated IFN-y production was also found to be defective in PBMC from
subjects with AIDS. As IFN-y can be produced both by CD4 and CD8 lymphocytes,
the very low levels of production observed in advanced disease suggested
dysfunction of both cell types (Murray et al., 1988).
Once serological testing for HIV became available investigators were better
equipped to study the asymptomatic phase of disease. Shearer et al., (1986),
assessed CTL activity ofPBLs from asymptomatic and symptomatic HIV infected
donors against influenza infected autologous targets and allogenic targets. PBLs
were cultured for seven days with either influenza A or allogeneic cells, then the
CTL response was tested by a 6 hour chromium release assay. Of 40 HTLV-III
(later renamed HIV, see section 1.1) seronegative high risk individuals (largely
homosexual men) all showed positive CTL responses to influenza and alloantigen, of
14 asymptomatic seropositive subjects 8 had strong responses to both stimuli but 6
responded only to alloantigen, while of 25 subjects with advanced disease, 2
responded to both stimuli, 11 responded to alloantigen only and 10 responded to
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neither. Longitudinal study of a single subject confirmed progressive loss of
response over time first to influenza then to alloantigen. In keeping with previous
observations (Rook et al., 1983), co-culture with IL-2 could rescue the anti-influenza
response, and in healthy subjects with a good response to both antigens, the anti
influenza response but not the anti-alloantigen response could be abrogated by
depletion of CD4 lymphocytes. The authors conclude that HTLV-III infection
results in progressive defects in CTL function that are initially consistent with lack of
CD4 lymphocyte help, but in later stages are indicative of a more profound failure
(Shearer et al., 1986).
Precursor CTL function. A number of studies confirmed deterioration ofCTL
function with disease progression, and demonstrated that the CTL function can be
recovered by various stimuli (Gruters et al., 1990; Lewis et al., 1994; Gamberg et al.,
1999). Thus Gruters et al., (1990), demonstrated that CTL response to immobilized
CD3 was normal in asymptomatic HIV infected subjects, but decreased in subjects
with ARC or AIDS, and that function was almost wholly recovered by CD28
costimulation or addition of IL-2. Again, Gamberg et al., (1999), demonstrated
complete loss of the CD3 induced CTL response in freshly isolated PBMCs from 10
of 11 subjects with AIDS, but normal responses when PBMCs were first stimulated
in an IL-2 containing medium.
Proliferation. Abnormalities in CD8 lymphocyte proliferation in HIV infected
subjects have also been noted, including impaired response to CD3 stimulation in
asymptomatics (Miedema et al., 1988), and reduced response to IL-2 in subjects with
high viral loads (Kryworuchko et al., 2004). Use of a cell free CD3 stimulation
methodology confirmed that the defect was in the responding T cells, not antigen
presenting cells.
Anti-EBV CD8 lymphocytes. The relationship between HIV infection and EBV
specific CD8 lymphocyte function has been extensively researched and has benefited
from a number of longitudinal studies using prospectively cryopreserved PBMCs
from untreated HIV infected subjects enrolled in the Amsterdam cohort.
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A study in the 1980s indicated loss of anti-EBV CTL activity in HIV infected
subjects. The level of activity correlated with CD4 lymphocyte count, and in early
disease the defect could be reversed with IL-2 (Blumberg et al., 1987). Subsequent
studies have shown that numbers of functional anti-EBV precursor CTLs, are
generally well preserved in HIV infected subjects, but drop in subjects developing
EBV related tumors. Thus, in a cross sectional study using limiting dilution analysis
with chromium release cytotoxicity assays, (a method which quantifies a subset of
antigen specific CTL precursors that are able to proliferate and remain cytotoxic after
prolonged stimulation), Carmichael et al., (1993), found no difference in frequency
of anti-EBV CTL precursors between HIV infected subjects, (including 5 with
AIDS), and uninfected controls. In a detailed longitudinal study, (Kersten et al.,
1997). used similar methodology to show that anti-EBV CTL precursor frequencies
remained stable over 5 to 8 years of follow up both in two long term non-progressors
and two subjects who progressed slowly to opportunistic infection. In contrast,
significant decline in EBV CTL precursor frequency was noted in two subjects who
progressed rapidly to AIDS and in two subjects who developed EBV related tumors.
In the subjects who developed EBV associated tumors the decline in anti-EBV CTL
precursor frequencies preceded a rise in EBV load, suggesting that poor CD8
function plays a role in the loss of control of this virus. Two subsequent studies from
the same group used tetramers to quantify circulating EBV specific CD8
lymphocytes, and found numbers to be normal throughout the course ofHIV
infection.
While numbers ofEBV specific cells appear stable in HIV infection, there is
increasing evidence that their function may be progressively compromised. In a
cross sectional study of IFN-y secretion in response to EBV peptides, the intensity of
the response, as measured by enzyme linked immunospot (elispot) assay, correlated
with CD4 lymphocyte count (suggesting deterioration in function with advancing
HIV disease). In six subjects responses were assessed longitudinally, IFN-y
secretion was maintained over time in two subjects with stable CD4 lymphocyte
counts and in two patients with declining CD4 lymphocyte counts. In the remaining
two subjects the intensity of response declined with disease progression (Dalod et al.,
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1999). A subsequent longitudinal study of 11 HIV infected subjects used the same
assay to assess the relationship between anti-EBV CD8 lymphocyte function and the
development ofEBV related tumors. PBMCs isolated from HIV infected subjects
within a few years of seroconversion showed decreased EBV specific IFN-y
secretion compared to PBMCs from uninfected controls. In HIV infected subjects
that progressed to EBV associated tumors the IFN-y production further deteriorated
while in the remaining subjects there was no change in function with time (Van
Baarle et al., 2001).
Maturation ofEBV specific CD8 lymphocytesin HIV infection has been assessed in
terms of CD27 and perforin expression. Jansen et al., 2004, found that as disease
progressed EBV specific CD8 lymphocytes became more differentiated with a higher
proportion expressing perforin and displaying the CD27- effector phenotype.
Interestingly this progressive differentiation is absent in HIV infected subjects who
progress to EBV associated tumors (Van Baarle et al., 2002a).
Anti-HBV CD8 lymphocytefunction. In a clear case controlled study (Lascar et al.,
2005), determined the effect ofHIV infection on the CD8 lymphocyte anti hepatitis
B virus (HBV) response in individuals who had recovered from HBV infection. The
proportion of CD8 lymphocytes able to secrete IFN-y in response to various hepatitis
B virus peptides was assessed by intracellular staining in 16 HIV infected subjects at
various stages of disease progression, compared with 14 HIV -ve controls. There
was a marked decrease in response in the HIV infected compared to the control
group, with only one of 16 HIV infected subjects having a detectable response
compared to 9 of 14 controls. In two of four subjects studied longitudinally anti HBV
responses recovered with reconstitution of CD4 lymphocytes following introduction
ofHAART.
Reconstitution with HAART. In addition to assessment ofCD8 lymphocyte response
during the natural history of disease there has been extensive investigation of
recovery of immune function with therapy. (Hsieh et al., 2000; Havlir et al., 2000).
A longitudinal study of the effect ofHAART on EBV specific CD8 lymphocytes
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demonstrated significant recovery of IFN-y production that shadowed the rise in CD4
lymphocyte count (Kostense et al., 2002a). Recovery of immune function is
particularly important where the clinical question ofwithdrawal of long term
prophylactic medication is raised, and large scale clinical trials have demonstrated
that immune recovery sufficient to allow discontinuation of prophylaxis does occur
(Ledergerber et al., 2001). In some cases recovery ofCTL response can be excessive,
leading to immune restoration disease, (reviewed in (French et al., 2004).
Interestingly HIV specific CMV responses as measured by IFN-y elispot assay
increased initially with HAART but then declined. The decline could not be
explained in terms of viral load or T cell counts. (Keane et al., 2004).
Conclusion. Taken together, the above studies demonstrate that CD8 lymphocyte
effector function deteriorates progressively during the course ofHIV infection
despite maintenance of normal numbers of antigen specific cells. Early in infection
antigen specific IFN-y production declines, while CTL function is largely
maintained. As disease progresses IFN-y production declines further, and circulating
or effector CTL function is lost, while general precursor CTL function is maintained.
Changes in CTL function with disease progression appear to vary for different
pathogens and between different subjects. Thus EBV specific precursor CTL
function is maintained in the majority of subjects into the advanced stages of disease,
but in a subset ofpatients EBV specific CD8 lymphocytes lose the ability to mature
to effector status, precursor CTL function and IFN-y production is lost and the
patients suffer increasing EBV loads and EBV related malignancy. CD8
lymphocytes specific for other pathogens appear to behave differently, thus the vast
majority of subjects with AIDS have no detectable precursor CTL response to
influenza, and the CTL response to TB appears to deteriorate even earlier, during
asymptomatic disease. Elucidation of the mechanisms behind these varying
responses is one of the major current challenges in HIV research
1.6.7.5 Mechanism of CD8 lymphocytes dysfunction in HIV infection
CD4 lymphocyte help. It is likely that the lack of CD4 lymphocyte help is a major
reason behind poor CTL function in HIV (Kalams & Walker, 1998; Altfeld &
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Rosenberg, 2000). CD4 lymphocytes secrete IL-2 which is vital for CD8
lymphocyte survival, and play an integral part in the activation of naive CD8
lymphocytes. Thus in the CD4 lymphocyte depleted mouse, CD8 lymphocytes
remain but do not function (Cardin et al., 1996). The importance of CD4 lymphocyte
help is supported by the recovery of CTL response in vitro by the addition of IL-2,
and by the correlation between CD8 lymphocyte function and CD4 lymphocyte
count (Dalod et al., 1996; Kostense et al., 2002a), but diminished production of IL-2
or other cytokines important in CD4 lymphocyte help has not been detected (Kaech
et al., 2002). While lack ofCD4 lymphocyte help cannot directly explain the loss of
CD4 lymphocyte independent functions such as the CTL response to alloantigen, it is
possible that prolonged lack of CD4 lymphocyte help could contribute to lack of
CD8 lymphocyte maturation or cause a state of anergy resulting in global
hyporesponsiveness.
Direct and indirect cytotoxicity. Both direct and indirect cytotoxicity ofHIV,
described in section 1.3.4, are of relevance to CD8 lymphocyte function. Direct
toxicity has been reported in HIV infection of CD8bllglltCD4dim lymphocytes in vitro.
Toxic effects included downmodulation of cell surface CD4 and CD8 expression,
deregulation of IFN-y and FASligand expression and decreased effector function
(Kitchen et al., 2004; Stove et al., 2005). In addition CD4 independent HIV variants
isolated from HIV infected subjects showed significant cytopathic effects on infected
CD8 lymphocytes including syncytia formation (Zerhouni et al., 2004). Some of the
toxic effects of secreted viral proteins have been shown to affect CD8 as well as CD4
lymphocytes, for example vpr induces apoptosis ofCD8 lymphocytes (Okada et al.,
1998).
Subset imbalance. It is likely that a number of abnormalities reported in
unfractionated PBMC or CD8 lymphocyte populations from HIV infected subjects
will reflect differences in the relative proportions of cells at different stages of
maturation. Lewis et al., 1994, found that HIV infected subjects have a significant
expansion of the terminally differentiated CD57+ subset of CD8 lymphocytes. They
demonstrated that these cells have markedly reduced proliferation in comparison to
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their CD57- counterparts, regardless ofHIV status. They therefore argue that the
increased contribution of this subset to the overall population may explain the
observed decreased proliferation of unfractionated CD8 lymphocyte populations.
Dysmaturation. While there is an overall expansion of effector cells in HIV infected
subjects compared to healthy controls, within populations of antigen specific CD8
lymphocytes there may be a failure to differentiate to effector status (as described in
section 1.6.7.4 for EBV specific CTLs). Currently it is unclear whether the lack of
mature cells is due to a block in maturation, such as could be caused by HIV
accessory proteins, or due to premature death ofmature effector cells. Premature
death could result from HIV infection of CD8 lymphocytes during activation, or
from HIV induced apoptosis which preferentially effects preterminally differentiated
cells (Mueller et al., 2001).
Anergy. While anergy has been more extensively studied in CD4 lymphocyes, the
defects in antigen presentation described in section 1.6.7.3, could equally lead to the
state of reduced responsiveness observed in CD8 lymphocytes (reviewed in
(Lieberman et al., 2001). In addition, downregulation of cell surface CD8 expression
could impair CD8 lymphocyte activation (Stove et al., 2005).
Impaired signaling. (Kryworuchko et al., 2004), showed that CD8 lymphocytes
isolated from HIV infected subjects with high viral loads had impaired proliferative
response to IL-2. The impaired proliferation was found to correlate with impaired
activation of Jak-3, part of the Jak/stat signaling cascade. The mechanism by which
HIV exerts this effect is unknown.
Natural killer cell inhibitory receptors. Natural killer cell inhibitory receptors
(NKRs) are upregulated on CD8 lymphocytes in HIV infected subjects (Galiani et
al., 1999; De Maria et al., 2000). These receptors are known to inhibit cytotoxicity
and IFN-y production (Huard & Karlsson, 2000) and in HIV infected donor samples
blocking NKR with specific antibodies augmented HIV specific cytotoxicity
(Demaria et al., 1997).
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1.6.8 Summary of section 1.6
PHI is characterized by massive HIV infection ofmemory CD4 lymphocytes within
mucosae, lymph nodes and blood, associated with extensive apoptosis of effector
CD4 lymphocytes such that these are effectively wiped out from mucosal sites.
During the asymptomatic phase of chronic infection there is a steady decline in the
numbers of both memory and nai've CD4 lymphocytes, with naive cells declining
more rapidly, and a decline in nai've CD8 lymphocytes. The cause of this decline is
unclear but is likely to involve ongoing high turnover of antigen experienced CD4
and CD8 lymphocytes due to infection, immune activation or HIV induced apoptosis,
together with difficulty in regeneration due to thymic involution and loss of lymph
node architecture.
The extent to which the function of the remaining T lymphocytes is impaired in
asymptomatic disease is unclear. Certainly there are deficiencies in proliferation and
cytotoxic responses to some pathogens in vitro, while a number of secretory
functions are maintained. The lack ofproliferation and killing may be due to true
impaired function in vivo or intolerance of culture conditions. Likely causes of
impaired CD8 lymphocyte function include lack ofCD4 lymphocyte help due to
decreased numbers of effector CD4 lymphocytes, inhibitory effects of circulating
HIV proteins, abnormal antigen presentation and changes in the cytokine
environment. As disease progresses the lack of responses become incontroversial.
1.7 Importance of CD8 lymphocytes in controlling HIV
infection
There is considerable evidence that CD8 lymphocytes are vital in the control ofHIV
replication both in primary and chronic HIV infection. HIV specific CD8
lymphocytes become detectable early during acute HIV infection and remain
throughout the chronic phase (Moss et al., 1995; Ogg et al., 1998). In vitro these
lymphocytes are able to kill HIV infected cells (though as discussed earlier this may
require addition of IL-2 or overnight culture) (Yang et al., 1996; Mueller et al.,
2001), and to inhibit HIV replication through an unidentified factor, CD8+ cell
antiviral factor (CAF) (Walker et al., 1986). Evidence that CD8 lymphocytes are
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active against HIV in vivo is provided by the appearance of CTL escape mutants
during acute and chronic infection (Borrow et al., 1997).
Both correlative data and animal experiments indicate that CTL activity slows
disease progression. Thus certain HLA-1 types (eg. HLA-B35), as well as
homozygosity at the HLA-1 loci, are associated with rapid progression, while others
(HLA B27 and HLA B57) are protective (Kaslow et al., 1996b). In primary
infection, the appearance of anti HIV CTLs is temporally associated with control of
viral replication (Koup et al., 1994), and increased diversity of the primary CTL
response correlates with slow disease progression (Pantaleo et al., 1997). In chronic
infection, while the data is split, there does not appear to be a significant link
between disease progression and the size or diversity of the cytotoxic response
(Harrer et al., 1996; Migueles & Connors, 2001), but slow progression has been
found to correlate with enhanced CD8 lymphocyte proliferative responses (Migueles
et al., 2002).
Direct experimental evidence comes from SIV infected rhesus monkeys where
deletion of the CTL response with anti CD8 antibodies causes failure of viral control
both in acute and chronic infection (Schmitz et al., 1999; Jin et al., 1999). Finally,
rhesus monkeys that are vaccinated to induce a CTL response and are then infected
with SIV or SHIV have a more benign course than unvaccinated animals (Seth et al.,
2000).
1.8 Failure of the anti-HIV T lymphocyte response.
Despite evidence of significant T lymphocyte pressure, the early anti-HIV response
fails and HIV continues to replicate, with an estimated 10 billion HIV virions
produced daily in asymptomatic untreated individuals (Wei et al., 1995; Ho et al.,
1995). The degree to which the anti-HIV CTL response is ineffectual was
demonstrated by the superinfection of a subject, despite the presence ofCTL
responses against 8 epitopes present in the superinfecting virus (Altfeld et al., 2002).
The cause of the anti-HIV CTL failure has been extensively reviewed (McMichael &
Rowland-Jones, 2001; Lieberman et al., 2001; Piguet & Trono, 2001; Petrovas et al.,
2004), and is due to a combination of viral strategies to avoid recognition such as
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mutation and down-modulation of cellular MHC expression, and defects in T
lymphocyte function. Here the viral strategies for immune evasion are introduced,
then the evidence for HIV specific T lymphocyte dysfunction is considered.
1.8.1 HIV immune evasion
Failure ofCD8 lymphocytes to control HIV replication in vivo can be partly
explained by viral strategies to avoid CTL recognition, (reviewed in (Altman &
Feinberg, 2004). Thus the lack of fidelity of the viral reverse transcriptase and the
viral tolerence for sequence change results in production ofmillions of new HIV
variants each day. In the SIV model there is clear evidence of the rapid emergence
of CTL escape mutants, associated with a decreased CTL viral control (Schmitz et
al., 1999), and similar findings have been reported for HIV. In addition HIV avoids
recognition by downmodulation ofMHC class I on infected cells, a strategy it shares
with a number of other viruses. This downregulation is mediated by the HIV protein
nefwhich diverts MHC I molecules away from the cell surface into the trans-Golgi
network (Schwartz et al., 1996).
1.8.2 Anti-HIV CD4 Lymphocyte response
There is good evidence that HIV specific CD4 lymphocytes are present in the
majority ofHIV infected subjects during the asymptomatic phase of infection. They
are able to secrete cytokines (Pitcher et al., 1999; Mathew et al., 1999) but do not
proliferate in vitro (Musey et al., 1999; Rosenberg et al., 1999). McNeil et al., 2001,
demonstrated that proliferation ofHIV specific CD4 lymphocytes is actively
inhibited by high levels ofHIV viraemia, and can be rescued in vitro by CD28
costimulation. A similar pattern of diminished proliferative response during
viraemia is seen in HBV (Boni et al., 1998), measles (Whittle et al., 1978), CMV
(Carney & Hirsch, 1981) and dengue infection (Mathew et al., 1999), and may
reflect an anergic response to persisting high levels of antigen. Alternatively the lack
of proliferation in vitro may reflect intolerance of culture conditions.
56
1.8.3 Anti-HIV CD8 lymphocyte response
1.8.3.1 Size and breadth of response
The acute anti HIV CTL response is large involving up to 10% of circulating CD8
lymphocytes (Koup et al., 1994; Borrow et al., 1994), dropping to 1 - 2% during
chronic infecton (Altman et al., 1996). Despite the identification ofmore than 180
optimal CTL epitopes spread throughout the HIV protein, the CTL response is often
restricted to a few dominant epitopes (Lieberman et al., 1997), a pattern that is also
seen for other viral infections (Callan et al., 1996). This narrow focus may promote
immune escape, and assessment ofCTL responses in a large cohort of 148 subjects
showed that the breadth of response (ie the number ofHIV epitopes which elicited a
CTL response) was correlated with immune control ofHIV replication and disease
progression. In a related issue, it has been suggested that the large CD8 lymphocyte
clonal expansions which occur in primary HIV infection could lead to clonal deletion
as described in lymphocytic choriomeningitis virus (LCMV) infection of mice,
resulting in restriction of the TCR repertoire (Moskophidis et al., 1993). However
other studies have found normal TCR diversity in chronic HIV disease, and where
diversity has appeared restricted, reconstitution of a more diverse repertoire occurs
following antiviral treatment (Boyer et al., 1993; Gamberg et al., 1999). Thus while
the breadth of response is clearly important, the determinants of a broad or narrow
response remain obscure.
1.8.3.2 Function of anti-HIV CD8 lymphocytes
The function ofHIV specific CD8 lymphocytes has been assessed by comparison
with CD8 lymphocytes specific to other antigens, and by comparison of function in
rapid progressors against that in non-progressors. Interpretation of the significance
of observations requires care. Differences noted using the former strategy may
reflect defective function, or, as discussed later, may reflect a normal response
tailored to a given pathogen. Differences in CD8 lymphocyte function noted
between progressors and non-progressors may be causative, or could be the
consequence of a less virulent viral strain or lower viraemia.
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In the asymptomatic phase ofHIV infection there is good evidence that HIV specific
CD8 lymphocytes differ from CD8 lymphocytes specific for other chronic viral
infections in terms ofmaturation, perforin expression and susceptibility to apoptosis.
Some investigators also report defective cytotoxic function. The maturation ofHIV
specific CD8 lymphocytes appears to be truncated such that the majority ofHIV
specific CD8 lymphocytes have a CD45RO+CD27+CD28- phenotype classic of
memory function with relatively few expressing the CD45RO+CD27-CD28-
phenotype indicative of full differentiation to effector status (Ogg et al., 1999; Roos
et al., 2000; Appay et al., 2000). Similar findings were reported by Champagne et
al., 2001, using CD45RA and CCR7 as alternative markers of effector and memory
phenotype, and by Mueller et al., 2001, using CD45RA and CD62L. The cause of
the skewed maturation is unknown, but possibilities include rapid loss of terminally
differentiated cells (potentially caused by apoptosis), lack of CD4 lymphocyte help,
or high dose antigen induced tolerance.
HIV specific CD8 lymphocytes have also been noted to be perforin deficient (Appay
et al., 2000), and this deficiency has been linked to an immature phenotype. Others
find no difference in perforin expression between CMV-, EBV- or HIV specific CD8
lymphocytes, and suggest that low perforin expression is the norm in chronic viral
infections (Zhang et al., 2003). Lymphoid tissue from subjects with primary HIV
disease display a relative lack ofperforin when compared to primary EBV infection,
suggesting that the lack ofperforin is not a response to chronic disease, but is a
response to something intrinsic to HIV itself (Andersson et al., 2002).
The significance of the immature phenotype and lack ofperforin expression is hotly
debated. Some suggest it represents a failing of the immune system which
contributes to loss of control ofHIV replication (Van Baarle et al., 2002b). Perforin
is a vital component in the cytotoxic granules used to lyse target cells, so decreased
perforin expression would logically lead to decreased effector function. In support,
(Appay et al., 2000), found that the lack ofmaturity was linked to defective cytolysis
ofHIV infected targets in a direct 4 hour chromium release assay. As discussed
below, others refute that HIV specific CD8 lymphocytes have deficient cytotoxic
function. Interestingly, in HIV infected subjects who lose control of EBV
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replication, EBV specific CD8 lymphocytes also display an immature phenotype
(Van Baarle et al., 2002c, see section 1.6.7.4).
Others argue that CD8 lymphocytes in asymptomatic HIV infection are essentially
'fully functional' and the immature phenotype reflects an appropriate immune
response to HIV (Appay & Rowland-Jones, 2002; Gamadia et al., 2002; Zhang et al.,
2003). Preserved function ofHIV specific CD8 lymphocytes is supported by studies
showing normal ability to secrete antiviral cytokines such as IFN-y, TNF-a and
macrophage inflammatory protein-ip (MIP-ip) (Dalod et al., 1999; Appay et al.,
2000), and by studies demonstrating the anti-HIV immune pressure applied by CD8
lymphocytes in vivo which continues throughout the asymptomatic stage ofHIV
disease (Kelleher et al., 2001).
An increased susceptibility to apoptosis was noted by Mueller et al., 2001, who
found HIV specific CD8 lymphocytes to be 3 times more sensitive to Fas-induced
apoptosis when compared to CMV specific CD8 lymphocytes from the same donors.
This increased sensitivity was most marked in the preterminally differentiated
(memory) cells, leading the authors to suggest that the lack of fully differentiated
CD8 lymphocytes is a result of increased apoptosis just prior to terminal
differentiation.
Some investigators report that the cytotoxic function ofHIV specific CD8
lymphocytes is abnormal (Shankar et al., 2000; Appay et al., 2000) while others have
found no such defect (Mueller et al., 2001). It has been suggested that the
experiments showing normal cytotoxic function were confounded by use of
overnight culture, or culture in IL-2 containing media prior to the cytotoxicity assays,
both ofwhich could mask a functional deficit (Walker et al., 1987; Trimble &
Lieberman, 1998; Lieberman et al., 2001). However, this does not explain the
observation of normal cytotoxicity in freshly isolated cells (Mueller et al., 2001).
Mueller et al., 2001, argue that the discrepant findings may reflect the different
targets used. Thus, in the studies showing impaired cytotoxicity EBV transformed B
cells were used as targets, and, as these cells express Fas-L they are likely to induce
apoptosis in the HIV specific CTLs and underestimate their cytotoxic ability.
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Numerous studies have been performed comparing CD8 lymphocyte function in
LTNP against that in rapid progressors in an attempt to elucidate correlates of non-
progression (Kostense et al., 2001; Migueles et al., 2002; Van Baarle et al., 2002a).
Results have often been contradictory, for example some investigators found HIV
specific CD8 lymphocyte of non-progressors to be more differentiated (Van Baarle et
al., 2002a), and have better IFN-y responses to antigenic stimuli than those of rapid
progressors (Kostense et al., 2001), while others have found no difference in terms of
IFN-y secretion (Migueles et al., 2002) or differentiation (Appay & Rowland-Jones,
2002). One recent report in which the non-progressor group had maintained
undetectable serum viral loads over at least 5 years of untreated infection, found no
difference between the two groups in the number or diversity ofHIV specific CD8
lymphocytes and their response to autologous HIV infected CD4 lymphocytes was
similar in terms of activation and IFN-y secretion, but proliferation and perforin
expression was much more marked in the LTNPs (Migueles et al., 2002).
Inefficient trafficking ofHIV specific CD8 lymphocytes to lymph tissue, where the
majority of infected cells are sited, has also been proposed as a factor in their failure
to control HIV replication (Chen et al., 2001). Inefficient trafficking to lymph nodes
is not unexpected as priming classically leads to downregulation of lymph node
homing receptors.
While there is controversy regarding the function of CD8 lymphocytes in the
asymptomatic stage of chronic infection, it is generally agreed that in advanced
stages HIV specific CD8 function is impaired as evidenced by reduced cytolytic
activity (Pantaleo et al., 1990) impaired cytokine production (Kostense et al., 2002b)
and reduced CD3^ expression (Trimble & Lieberman, 1998).
As noted in section 1.6.7.4 lack ofCD4 help is a likely cause of generalized CD8
lymphocyte dysfunction in HIV disease. Of relevance to anti-HIV CD8 lymphocyte
function, the CD4 lymphocyte help required for primary CD 8 lymphocyte activation
is exclusively provided by a CD4 lymphocyte of the same specificity, so primary
activation of an HIV specific CD8 lymphocyte often requires the participation of an
HIV specific CD4 lymphocyte. Thus, the early deterioration of the anti-HIV CD4
lymphocyte response (described in section 1.6.7.2) could contribute to the failure of
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the anti-HIV CTL response in asymptomatic disease. A role for CD4 lymphocytes is
supported by the recovery of the anti-HIV CTL response in vitro by addition of IL-2,
and by the correlation between the strength of the anti-HIV CD4 lymphocyte
response and control of viraemia (Rosenberg et al., 1997).
1.8.3.3 Summary of section 1.8
In summary, an anti-HIV T lymphocyte response is initiated early in infection but is
unable to control infection due immune evasion strategies and massive loss of the
CD4 lymphocyte effector arm. After a few weeks of viraemia the function ofHIV
specific lymphocytes declines. Thus in asymptomatic disease HIV specific CD4
lymphocytes are able to secrete IFN-y but are deficient in proliferation, while anti-
HIV CD8 lymphocytes do not mature to effector status and may have reduced
cytotoxicity. These abnormalities occur at an earlier stage than similar
abnormalities in T lymphocytes specific for other antigens, and therefore must be
caused by mechanisms acting preferentially on the HIV-specific cells. Likely
mechanisms include HIV infection, which occurs more readily in HIV-specific CD4
lymphocytes, anergy induced by the very high levels of antigen, or antigen
processing defects. In addition, the proximity of HIV-specific T lymphocytes to
infected cells during activation and effector functions may lead to increased risk
from the cytotoxic effects of secreted HIV proteins.
1.9 HIV Reservoirs.
The persistence ofHIV is largely due to its ability to establish non-cytopathic
infection of long-lived cells that are relatively hidden from immune surveillance, a
topic extensively reviewed by Pierson et al., (Pierson et al., 2000). Populations of
these cells form viral reservoirs that are unaffected by antiviral therapy, allowing
recurrence of infection after years of combination therapy. In addition these
reservoirs can harbor virus generated at any time during the history of infection of an
individual, including virus with drug resistant mutations which may have developed
during therapeutic regimens that have since been superceded. This historical record
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means that patients tend to have only a single opportunity with any given antiviral
regimen, limiting the choices available once regimens need to be altered. This topic
is of particular interest as at least some HIV infected CD8 lymphocytes are likely to
be longlived and therefore to contribute to these reservoirs.
The existence of viral reservoirs was revealed by analysis of the decay dynamics of
plasma viral load after initiation of combination antiviral therapy. Using methods for
viral load measurement sensitive to 50 copies per ml, two distinct phases were
observed with half lives of 1-2 days and 14 days, corresponding to virus production
by activated CD4 lymphocytes and macrophages (Perelson et al., 1997).
Extrapolation of the second stage lead to the prediction that three years of antiviral
therapy would be sufficient to eradicate the virus. This has proved not to be the case
and two further phases of decay have been reported. Phase three has a half life of 6
months and is thought to reflect virus produced by resting (Gi) T cells and possibly
dendritic cells. The forth phase has a half life of 43 months, and is due to infection
of quiescent (Go) T cells (Chun et al., 1995; Finzi et al., 1999). This quiescent
lymphocyte reservoir was demonstrated by viral production following ex vivo
activation of lymphocytes isolated from HIV infected individuals on HAART (Wong
et al., 1997; Finzi et al., 1997). Thus there is no longer an expectation that HIV can
be eradicated by current antiviral therapy alone, and a thorough understanding of the
dynamics of the various long-lived cell types infected has become paramount.
The mechanism of infection of quiescent cells is intriguing as activated CD4
lymphocytes do not generally revert to a quiescent state (Stevenson, 2003) and truly
quiescent (Go) lymphocytes are refractory to infection (Zack et al., 1990). Recent
evidence indicates that subtle stimulatory signals, which can be produced by HIV
infected macrophages in a nef dependent manner, may move Go lymphocytes into Gi
without inducing full activation (Swingler et al., 2003). Such cells are permissive to
infection, and may revert back to a truly quiescent state.
Macrophages also serve as an important reservoir for HIV, with a number of factors
enhancing the longevity of infected cells. Firstly, non-dividing macrophages are
permissive to HIV infection (Weinberg et al., 1991). Retroviruses usually require
cell division to allow cDNA to enter the nucleus, but HIV nuclear targeting signals
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guide the reverse transcription complex through nuclear pores thus allowing
infection in the absence of cell division (Bukrinsky et ah, 1993). Secondly,
macrophages are relatively resistant to the cytopathic effects ofHIV. Finally the
assembly ofHIV virions in vesicles rather than on the plasma membrane renders the
macrophages less visible to HIV specifc CTLs (Orenstein et ah, 1988).
The CNS is also a potentially important reservoir as it is an immunologically
privileged site and penetration of antiretrovirals such as protease inhibitors is
suboptimal (Hughes et ah, 1997b). HIV enters the CNS soon after seroconversion
(Davis et ah, 1992; Bell et ah, 1993), and infection ofmacrophages and microglial
cells in the CNS have been demonstrated (Takahashi et ah, 1996; Hughes et ah,
1997a). Whether these cells act as a source of virus to reseed the general circulation
after therapy is not known.
1.10 Evidence of HIV infection of CD8 lymphocytes.
It is well established that CD8 lymphocytes are susceptible to HIV infection in vitro
(Flamand et ah, 1998; Yang et ah, 1998; Kitchen et ah, 1998; Zhang et ah, 2001;
Zloza et ah, 2003); (De Maria et ah, 1991) and an increasing number of investigators
have demonstrated HIV infection of CD8 lymphocytes ex vivo (Semenzato et ah,
1995; Livingstone et ah, 1996; Flamand et ah, 1998; Semenzato et ah, 1998;
McBreen et ah, 2001; Imlach et ah, 2001; Brenchley et ah, 2004a).
Infection of CD8 lymphocytes in vitro was first reported in the 1980s, initially in
HTLV-1 transformed CD8 lymphocyte clones, and then in cultured PBMCs isolated
from HIV infected subjects. Efficient infection of CD8 lymphocytes required co-
culture with HIV infected CD4 lymphocytes and resulted in productive infection (De
Maria et ah, 1991). More recently a number of investigators have demonstrated HIV
infection of activated CD8 lymphocytes without the presence ofCD4 lymphocytes.
These studies have shown unequivocally that HIV can enter CD8 lymphocytes, and
that these cells can support viral replication, but the question as to whether this
occurs to any significant degree in HIV infected people has remained controversial
(Agostini & Semenzato, 2002).
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In the mid 1990s two papers reported low frequencies ofHIV infection of CD8
lymphocytes in humans (Semenzato et al., 1995; Livingstone et al., 1996), and a
third paper described significantly higher levels of CD8 lymphocyte infection in SIV
infected macaques (Dean et al., 1996). Semenzato et al. (1995) demonstrated HIV
provirus in CD8 lymphocytes isolated from the lung ofHIV infected subjects, with
infection rates ranging from 70 to 3960 proviral copies per 106 CD8 lymphocytes.
Livingstone et al., (1996) reported slightly lower frequencies of infection in CD8
lymphocytes isolated from blood (ranging from less than 1 to 400 proviral copies per
106 CD8 lymphocytes). Subsequently these findings were repeated by a number of
investigators (Flamand et al., 1997; Semenzato et al., 1998; McBreen et al., 2001;
Imlach et al., 2001; Potter et al., 2003; Brenchley et al., 2004a), all reporting low
frequencies of infection in blood derived CD8 lymphocytes. All these investigators
used a similar methodology involving isolation of highly purified CD8 lymphocyte
populations from HIV infected donors, extraction ofDNA then quantification ofHIV
provirus per cell by PCR. Other investigators have been unable to detect HIV
infection ofCD8 lymphocytes recovered in vivo (Levy, 1994) and critics have argued
that the provirus observed could be explained by CD4 lymphocyte or free virion
contamination of the isolated CD8 lymphocyte populations (Levy, 1994; Agostini &
Semenzato, 2002; Brenchley et al., 2004a).
HIV RNA has been reported in CD8 lymphocytes from lung and blood, suggesting
productive infection of these cells. The first report, published in 1995, was based on
data from a single patient. HIV RNA was demonstrated by RT-PCR in CD8
lymphocytes isolated from lung of an HIV infected subject. The proviral load was
162 copies per 105 CD8 lymphocytes, and HIV RNA was detected in 104 cell
equivalents of extracted RNA, suggesting that at least 1 in 16 HIV infected CD8
lymphocytes were productively infected. The purity is quoted as >99% CD8
lymphocytes with 'virtually no detectable residual CD4 lymphocytes', and given that
CD4 lymphocytes represented only 1% of the cells in the unfractionated broncho-
alveolar lavage, it is unlikely that this finding is due to contamination (Semenzato et
al., 1995). These findings were subsequently confirmed in four additional subjects
(Semenzato et al., 1998). A separate study, presented in poster format at the 9th
Conference on Retroviruses and Opportunistic Infections, demonstrated HIV RNA in
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blood derived CD8 lymphocytes from all of 20 HIV infected subjects investigated
using ultrasensitive fluorescence in situ hybridisation. This work has not been
formally published (Rubbert et al., 2005).
1.11 Mechanism of HIV infection of CD8 lymphocytes
Both CD4 dependent and independent mechanisms have been proposed to explain
HIV entry into CD8 lymphocytes.
1.11.1 CD4 dependent mechanisms
CD8 lymphocytes express CD4 and become vulnerable to CD4 dependent HIV entry
at two stages in their life cycle, firstly during intrathymic development, and secondly
following antigen specific activation. These two opportunities for infection ofCD8
lymphocytes are considered in detail in section 4.1. Infection of CD8 lymphocytes
with either HTLV-1 or HHV-6 induces cell surface CD4 expression providing a
further opportunity for HIV infection in co-infected individuals (Lusso et al., 1991;
Macchi et al., 1993). Seroprevalence for HTLV-1 is increasing worldwide, reaching
30% in some IVDU populations (de Araujo et al., 1994; Brites et al., 1997;
Guimaraes et al., 2001). Seroprevalence for HHV-6 is almost universal in most
populations, but lymphocytes are infected at low frequency and HHV-6 was not
found in HIV infected CD8 lymphocytes isolated from lung (Semenzato et al., 1995).
Thus, while co-infection does not account for all the CD8 lymphocyte infection
observed in vivo it may play an important role in selected populations, and increased
CD8 lymphocyte infection could explain the accelerated disease progression
observed in HTLV-1 / HIV co-infected individuals (Schechter et al., 1994; Brites et
al., 1998; Brites et al., 2001).
1.11.2 CD4 independent mechanisms.
HIV can also infect CD8 lymphocytes via CD4 independent mechanisms including
coreceptor mediated infection, trans-mediated infection and CD8 dependent or novel
mechanisms.
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In vitro interactions between gpl20 and the coreceptors CXCR4 and CCR5 can
initiate viral entry in the absence ofCD4 binding (Hesselgesser et al., 1997;
Dumonceaux et al., 1998; Bandres et al., 1998). While these interactions occur
relatively frequently for SIV (Potempa et al., 1997; Edinger et al., 1997) and HIV-2
(Endres et al., 1996; Potempa et al., 1997; Reeves & Schulz, 1997), it is generally
considered that they are too inefficient to play a major role in HIV-1 (Meireles-de-
Souza & Shattock, 2005).
7ra«.s-mediated infection occurs where neighbouring cells, one expressing CD4, and
the other expressing CCR5 or CXCR4, cooperate to permit virus cell fusion. This
mechanism allows infection ofCD8 lymphocytes when co-cultured with CD4
expressing cells and is dependent on direct cell contact (De Maria et al., 1991; Speck
et al., 1999). A similar mechanism may be responsible for infection ofHIV specific
effector CD8 lymphocytes on interaction with HIV infected target cells (De Maria et
al., 1994), but no preferential infection ofHIV specific CD8 lymphocytes has been
demonstrated in vivo (Brenchley et al., 2004a).
Co-infection with HTLV-1 may lead to HIV infection of CD8 lymphocytes through
the production ofprogeny virus with altered cell fusion requirements. HIV able to
infect CD8 lymphocytes in a CD4 independent manner were generated by this
method in vitro, but whether this occurs to a significant degree in vivo is unknown
(Lusso et al., 1990).
Two HIV variants have been isolated that infect CD8 lymphocytes through
attachment to the CD8 molecule (Saha et al., 2001). These variants were isolated
from immortalized HIV infected CD8+CD4" T cells isolated from a single AIDS
patient, and were shown to infect highly purified CD8+ PBLs and a cell line
engineered to express CD8. Infection was blocked by anti CD8 antibodies and
surprisingly did not require either of the co-receptors CXCR4 or CCR5. These
variants showed novel sequence variations in the env gene, and these changes were
thought to be responsible for their unusual tropism.
Subsequently the same group isolated CD4 independent viruses from 7 of 12
randomly selected HIV infected subjects, leading the authors to suggest that these
variants commonly circulate at low frequency within the HIV quasispecies.
66
Infection of CD8+ cells by these variants was not inhibited by either anti CD4 or anti
CD8 antibody, and some of the variants were able to infect cell lines negative for all
common HIV co-receptors suggesting a novel mechanism for cell entry (Zerhouni et
al., 2004). All the subjects from whom CD4 independent virus was isolated were
infected with X4 or R5X4 viruses that usually appear late in HIV-1 disease, the
authors therefore speculate that CD4 independent variants may evolve with disease
progression. The CD4 independent variants had changes in the variable loops or
transmembrane portion of the env gene when compared to CD4 tropic virus from the
same subjects, but no consensus sequence for CD4 independence was found.
1.11.3 Phylogenetic data.
Phylogenetic relationships between virus isolated from CD8 lymphocytes and that
isolated from other cell types or from plasma could provide insights into the
mechanism of viral entry, the contribution of the infected cell type to the circulating
viral pool and the longevity of the infected cells. For example, if the usual mode of
entry to CD8 lymphocytes was through novel receptor use, one would expect
variation in the env gene that would make CD8 tropic viruses cluster separately from
the virus isolated from CD4 expressing cells. Distinct clusters could also be
explained by distinct lifespans of the cell populations studied.
McBreen et al., (2001), assessed the phylogenetic relationships between V3
hypervariable region sequences amplified by PCR and cloning from CD8
lymphocytes and CD4 lymphocytes. Of the six subjects studied CD8 lymphocyte
sequences were monophyletic in a single patient. In this patient plasma sequences
grouped with CD4 derived sequences and contained a positively charged amino acid
at residues 306 and 320, a genotype indicative ofCXCR4 virus, while the CD8
lymphocyte derived sequences displayed the CCR5 virus genotype. This suggests
that, in this patient, either the HIV infected CD8 lymphocytes were longlived, having
been infected at a time prior to the R5 to X4 switch, or that CD 8 lymphocytes were
more easily infected by R5 varients. In four other patients there was partial
separation ofCD4 and CD8 sequences with the last patient showing random mixing.
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In a separate study Potter et al., (2003), assessed drug resistance mutations in
provirus amplified from various cell types isolated from 10 HIV infected patients
receiving HAART. Overall the prevalence of resistance mutations was higher in
HIV infecting CD4 lymphocytes and monocytes than it was in HIV from CD8
lymphocytes, though there was marked heterogeneity between individual patients.
Thus, in five subjects virus from CD8 lymphocytes had fewer drug resistance
mutations than CD4 lymphocyte or monocyte derived virus, while the remainder
showed no difference. Relationships between CD8 lymphocyte derived and plasma
derived virus were also assessed in 4 subjects, and again considerable inter-patient
variability was noted. In two patients CD8 lymphocyte sequences were closely
related to plasma sequences (suggesting either recent infection of the CD8
lymphocytes or productive infection ofCD8 lymphocytes), but in the other two the
plasma and CD8 lymphocyte derived sequences were segregated.
The interpretation of the phylogenetic data presented in these two papers is difficult
due to inter-patient variability. The variability is likely to reflect different dynamics
of infection of the different populations observed. Alternatively, some of the mixing
ofCD8 lymphocyte sequences into those derived from CD4 lymphocytes may have
been due to contamination of CD8 lymphocyte cell populations with CD4
lymphocytes, and the appearance of distinct populations could have been secondary
to cloning induced artefact.
1.11.4 Summary of HIV infection of CD8 lymphocytes
CD8 lymphocytes are susceptible to HIV infection under various culture conditions,
and a number of investigators have found low frequency infection ex vivo. The
mechanism of infection in vivo remains unclear, with conflicting data from the
studies published to date.
1.12 Scope of thesis.
As discussed in section 1.10, there is now considerable evidence that HIV commonly
infects CD8 lymphocytes in vivo, but general acceptance of this concept has been
inhibited by concerns regarding the purity of the CD8 lymphocyte populations
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studied. These concerns are addressed in chapter three, through development of a
method for isolation and verification ofhighly purified populations of CD8
lymphocyte subsets. This process necessitated cell fixing and therefore a method for
DNA extraction from fixed tissue was also developed. Finally in this chapter a
method for real-time PCR quantification ofHIV provirus is described, this proved to
be unsuitable for sole use with samples where the frequency of infection was low but
was useful as an initial step prior to limiting dilution analysis.
In chapter four the extent ofHIV infection ofCD8 lymphocyte populations isolated
from the blood of 20 HIV infected subjects is addressed. To determine the likely
route of infection, CD8 lymphocyte populations were subdivided on the basis of
differentiation phenotype or CD4 co-expression. The data presented confirms the
presence ofHIV infection ofCD8 lymphocytes ex vivo and demonstrates high levels
of infection in CD8bnghtCD4dim lymphocytes. This suggests that infection occurs
following upregulation ofCD4 expression during activation rather than during
intrathymic development.
Given the potential role of CD8bnghtCD4d"TI lymphocytes in HIV immunopathology, a
clear understanding of their natural history and function is important. Current
concepts are almost wholly derived from in vitro experiments, therefore in chapter 5
the differentiation and activation status of CD8bnghtCD4d,m lymphocytes ex vivo is
addressed. To determine whether HIV infection had any impact on their numbers,
differentiation or activation status, data is presented both for HIV infected subjects
and healthy controls. Finally, in chapter 6, the relevance ofHIV infection of CD8
lymphocytes to HIV immunopathology is discussed.
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Chapter 2: General Methods.
2.1 Isolation of lymphocyte populations.
Highly purified populations of CD4 lymphocytes and CD8 lymphocytes subsets
were isolated from all donated blood samples. As each sample contained insufficient
CD8 lymphocytes to assess HIV infection of all the cell subsets of interest, the
samples were divided into two groups. CD8 lymphocytes from group 1 samples were
isolated on the basis ofCD4 expression yielding populations of CD8bnghtCD4dim and
CD8bnghtCD4" lymphocytes, and those from group 2 were isolated on the basis of
differentiation phenotype yielding antigen nai've, antigen experienced, memory and
effector subsets. y8-T lymphocytes were also isolated from ten subjects and
monocytes from three. The populations were isolated using a three step protocol first
PBMC isolation, then immunomagnetic enrichment of lymphocyte populations, and
finally fluorescent activated cell sorting. The overall strategy is shown in fig 2.1.
2.1.1 General notes on lymphocyte isolation.
In order to minimize cell metabolism, cells were maintained at 4°C unless otherwise
stated. To pellet cells the cell suspension was centrifuged at 250g for a maximum of
ten minutes. When resuspending cells or mixing cells with reagents this was done by
gentle pipetting up and down. To wash cells, the cells were pelleted, the supernatant
removed either by pouring off or using a Pasteur pipette, the cells were resuspended
in the wash buffer, then re-pelleted, the wash buffer removed and the cells
resuspended as required. Cells were counted at various stages in the process using a
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Figure 2-1. Schematic diagram ofprotocol for isolation of cell populations of interest. PBMC =
peripheral blood mononuclear cells, MACS = immunomagnetic cell sorting, FACS = fluorescent
activated cell sorting.
2.1.2 Isolation of PBMCs by density centrifugation.
Blood samples were taken into tubes containing ethylenediaminetetraacetic acid
(EDTA, Sarstedt, Leicester, UK). Within 6 hours of sample donation, the blood was
diluted 1:1 with phosphate buffered saline without calcium or magnesium (PBS,
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Invitrogen, Paisley, UK), and 15ml of diluted blood was layered over 10ml of
Histopaque in 25ml universal tubes (Sterilin, Staffordshire, UK) at room temperature
(Sigma Diagnostics, St. Louis, USA). The tubes were centrifuged at 400g for
30mins with no brake in a Heraeus Christ centrifuge. The PBMCs were then
removed from the interface using a Pasteur pipette, combined into a single universal
tube, and washed twice in PBS. Total cells were counted then either stored overnight
at 4°C in 3mls of 10% autologous serum in automax buffer (AMB, see section 2.8),
or taken directly to immunomagnetic enrichment.
2.1.3 Immunomagnetic enrichment of T lymphocyte populations.
All immunomagnetic selection was performed using MACS reagents (Miltenyi
Biotec Ltd (UK), Bisley, UK) and an autoMACS machine (Miltenyi Biotec Ltd.).
Up to three steps were employed depending on the CD8 lymphocyte subsets to be
isolated.
Step 1. Immunomagnetic depletion ofyS-Tlymphocytes. PBMCs were pelleted and
resuspended in 40pl AMB per 107 total cells. MACS yS-hapten antibody (Miltenyi
Biotec) was then added (10pl per 107 total cells), mixed, then incubated for 10
minutes. Cells were then washed in 20ml AMB, pelleted and resuspended in 90ml
AMB per 107 total cells. MACS anti hapten FITC microbeads (Miltenyi Biotec) were
added (10pl per 107 total cells), mixed, then incubated for 15 minutes. Cells were
washed in 20ml AMB, resuspended in 1ml AMB and separated using program
POSSEL on an autoMACS (Miltenyi Biotec). The cells obtained in each fraction
were then counted, and the negative (unlabelled) fraction, depleted of y5-T
lymphocytes, was taken forward for CD8 lymphocyte isolation.
Step 2. Immunomagnetic enrichment ofCD8 lymphocytes. The appropriate cells
were pelleted and resuspended in 80pl AMB per 107 total cells. MACS CD8
microbeads (Miltenyi Biotec) were added (20pl per 107 total cells), mixed, then
incubated for 10 minutes. Cells were washed in 20ml AMB, resuspended in 1ml
AMB and separated using program POSSEL on an autoMACS (Miltenyi Biotec).
The cells obtained in each fraction were then counted, and the positive (labelled)
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fraction, enriched for CD8 expressing cells, was saved for FACS. The negative
fraction was taken forward to step 3.
Step 3. Immunomagnetic enrichment ofCD3 lymphocytes. The appropriate cells
were pelleted and resuspended in 80pl AMB per 107 total cells. MACS CD4
microbeads (Miltenyi Biotec) were added (20pl per 107 total cells), mixed, then
incubated for 10 minutes. Cells were washed in 20ml AMB, resuspended in 1ml
AMB and separated using program POSSEL on an autoMACS (Miltenyi Biotec).
The cells obtained in each fraction were then counted, and the positive (labelled)
fraction, enriched for CD3 expressing cells, was used for isolation ofCD4
lymphocytes and the negative fraction was used for isolation ofmonocytes.
2.1.4 Fluorescent Activated Cell Sorting.
Immunomagnetically enriched cells were stained with a combination of fluorescence
conjugated monoclonal antibodies (Table 2-1) and sorted using a Vantage flow sorter
(Becton Dickenson, Crawley, UK) to generate highly pure populations ofCD8
lymphocytes, CD4 lymphocytes, y8-T lymphoytes and monocytes (Figure 2-1). The
sorter was calibrated daily using calibrite beads (Becton Dickenson), and was
operated by a trained technician.
The phenotypes used to define the populations of interest are given (Table 2-2). To
ensure that the population of CD8bnghtCD4d'm lymphocytes did not contain CD4
lymphocytes expressing CD8, the anti CD8 monoclonal employed was directed
against the (3 chain of the CD8 molecule which is only present on true CD8
lymphocytes (Norment & Littman, 1988; Shiue et al., 1988; Hori et al., 1991).
Gates were drawn by eye for clear discrete populations, lymphocyte and monocyte
forward and side scatter, nai've CD8 lymphocytes (CD27hlghCD45RAhlgh), and
CD8b"shtCD4dim lymphocytes. The latter was positioned to maximise inclusion of all
CD8bllght cells with any CD4 expression and to avoid any CD4b,lghtCD8" cells. Gates
for the memory and effector CD8 lymphocytes were positioned with the aid of
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isotype controls. The position of gates for CD4 lymphocytes and CD8 lymphocyte
subpopulations of a typical sample are shown, (Figure 2-2).
Cells were sorted into 3.5ml FACS tubes (Becton Dickinson), or 1.5ml microtubes
(Eppendorf) depending on the number of cells expected. To avoid the electrically
charged droplets sticking to the inside of the tubes, the inner surface was coated with
sterile media (RPMI, invitrogen) prior to collection.
Cell population stained Populations to be isolated
Fluorescent conjugated
monoclonal antibodies
Cells enriched for y5-T lymphocytes y5-T lymphocytes y5-TCR PE
Cells enriched for CD8 expression



























Cells enriched for CD3 expression CD4 lymphocytes
CD3 PE
CD4 Cy-chrome™
Cells not expressing CD3 or CD8 Monocytes
CD14-PE
CD3 cychrome
Table 2-1. Monoclonal antibody combinations used for FACS. The combination used for CD8
lymphocytes in group A was changed after the first five patients to allow exclusion of dead cells by
costaining with tubulin PC7, and to avoid artefactual events mimicking CD4+ve cells (see section
4.3.1.2 , Figure 4-1). CD4 APC was subsequently dropped in favour of CD4 FITC due to better
performance in the Vantage flow sorter. Details of clone and manufacturer given in table 2.3.
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Lymphocyte subset Phenotype
CD4 lymphocyte CD4+ CD3+
Naive CD8 lymphocyte CD8P+ CD45RAhigh CD27hiBh
Antigen experienced CD8 lymphocyte All CD8p+ lymphocytes not falling into the naive population.
Memory CD8 lymphocyte CD8P+ CD45RAlow CD27+
Effector CD8 lymphocyte CD8P+ CD45RA+ CD27"
CD8 lymphocyte expressing CD4 CD8phi6hCD4+
CD8 lymphocyte not expressing CD4 CD8P+ CD4~
y8-T lymphoytes y8-TCR+
Monocytes CD14+CD3-
Table 2-2. Phenotypes used to define cell populations isolated by FACS. All populations were







R1 and R2 CD8(SbrightCD4dim
(CD8 lymphocyte expressing CD4)
R1 and R3 CD8P+CD4-
(CD8 lymphocytes not expressing CD4)
Gate Population phenotvpe
R1 and R2 CD8(3+CD45RAhighCD27high
and R3 (naive CD8 lymphocyte)

















Figure 2-2. Flow activated cell sorting ofCD4 lymphocytes and CD8 lymphocyte subsets.
Phenotypes and gates used for fluorescent activated flow sorting of CD4 and CD8 lymphocytes are
shown: CD8 lymphocytes sorted on the basis ofCD4 expression (A), CD8 lymphocytes sorted on the
basis of differentiation phenotype (B and C), and CD4 lymphocytes (D). Sorting on the basis of
differentiation phenotype was performed in two stages, first enriched CD8 lymphocytes were sorted
into antigen naive and antigen experienced subsets (B), a portion of the antigen experienced subset
was retained for HIV DNA analysis and the remainder was further sorted into memory and effector
subtypes (C). (fsc = forward scatter, ssc = side scatter).
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2.2 Staining cells for fluorescent activated cell sorting and
flow cytometry.
FACS was used to isolate lymphocyte populations used to determine proviral load
(chapter 4), and flow cytometry was used to determine the phenotype of
CD8bnghtCD4d'm lymphocytes (chapters 5 and 6). Staining the relevant cell
populations for these processes was performed according to the following protocol.
Fluorescent conjugated monoclonal antibodies were diluted to working
concentrations in PBS (table 2.3). For FACS, enriched cell populations were
pelleted and resuspended in lOOpl AMB per 107 cells, then incubated for 30 minutes
at 4°C with lOpl of the appropriate fluorescent conjugated monoclonal antibodies per
107 cells (Table 2-1). For flow cytometry, approximately 2 x 106 cells were
resuspended in 50pl AMB, and incubated for 30 minutes at 4°C with 5pl of the
appropriate fluorescent conjugated monoclonal antibodies, (Table 2-1). Cell were
then washed in 2mls PBS, (this wash step was repeated for any tubulin stained cells),
pelleted and resuspended in 0.75% w/v paraformaldehyde (Sigma Diagnostics) in
PBS, then incubated at 4°C for an hour. They were then washed twice in PBS and
stored in PBS for a maximum of four days prior to flow sorting. For each
experiment PBMCs were also stained with single monoclonal antibodies for use in
setting flow cytometer compensation. At all times exposure of fluorescent
conjugated monoclonal antibodies to light was minimised.
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Fluorescent conjugated mouse
anti human monoclonal antibody
Clone Isotype Company Working Dilution
CD3 PE UCHT1 IgGl,K BD Biosciences 1/5
CD3 Cy-Chrome™ UCHT1 IgCl,K BD Biosciences 1/5
CD4 Cy-Chrome™ RPA-T4 IgGl.K BD Biosciences 1/5
CD4APC RPA-T4 IgGl.K BD Biosciences 1/10
CD4 Alexa Fluor® 488 289-14120 IgGl Molecular Probes 1/5
CD8P PE 2ST8.5H7 IgGl.K Coulter Immunotech 2/5
CD8a FITC RPA-T8 IgGl Pharmingen 2/5
CD 14 PE M5E2 IgGl BD pharmingen 1/5
CD27 FITC M-T271 IgGl.K BD Biosciences 2/5
CD38 FITC HIT2 IgGl.K BD pharmingen 1/5
CD45RA Cy-Chrome™ HI 100 IgG2b,K Pharmingen 1/5
CD45RO FITC UCHL1 IgGl Dacko 1/5
CD69 FITC FN50 IgGl,K PharmingenInternational 1/5
y5-TCR PE Bl.l IgGl.K PharmingenInternational 1/5
Tubulin PC7 TBIA337.3 IgGl Beckman Coulter 1/5
Isotype FITC IgGl Dacko 1/2
Isotype Cy-Chrome IgGl BD Biosciences 1/5
Isotype APC IgGl BD Biosciences 1/10
Table 2-3. Fluorescent conjugated monoclonal antibodies used for FACS and flow cytometry.
Cy-Chrome™ is a registered trademark ofBecton, Dickinson and Company. Alexa Fluor® 488 is a
registered trademark ofMolecular Probes.
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2.3 Flow cytometry.
Flow cytometry was used to assess purity of FACS isolated cell populations, and to
assess the activation and differentiation phenotype of CD8bnghtCD4dim lymphocytes.
It was performed on a FACScalibur flow cytometer (Becton Dickenson) which was
equipped with a 488nm argon laser and a 635nm diode laser and could measure up to
four fluorescent colors, as well as fsc and ssc. It was calibrated weekly by a trained
technician using calibrite beads (Becton Dickenson). Samples were acquired at
approximately 1000 events per second with a threshold of 52 on the forward scatter
parameter. Data was viewed and analysed using CellQuest software (BD
biosciences).
2.4 Nucleic acid extraction.
DNA was isolated from the cell subsets using phenol chloroform extraction and
ethanol precipitation. A negative control sample ofPBMCs from a known HIV-ve
subject was included in each experiment. Cells in FACS tubes were transferred into
1.5ml microtubes, with a maximum of 1.5xl06 cells per tube. Cells were pelleted by
centrifugation at 250g for 2 minutes, the supernatant was removed and the cells were
resuspended in 500pl lysis buffer (section 2.8), mixed briefly and incubated at 37°
overnight. The lysed cells were then vigorously shaken for 15 minutes with 250pl
chloroform (BDH Laboratory supplies, Poole) and 250pl water saturated with phenol
(Rathburn Biochemicals Ltd, Walkerburn, UK), then centrifuged at 13,000 rpm for
10 minutes at room temperature (Haraeus benchtop centrifuge). The aqueous (upper)
layer was transferred into a fresh 1.5ml microtube containing 500pl chloroform,
mixed vigorously for 5 minutes then centrifuged at 13,000 rpm for 5 minutes at room
temperature. The aqueous (upper) layer was removed and placed in a fresh 1.5 ml
microtube (Maximum Recovery Microtube, Axygen Scientific Inc, CA 94587,
USA), and 3M sodium acetate (pH 5.2, Sigma) and 100% ethanol were added at a
ratio of 10:1:20 aqueous layer: sodium acetate: ethanol. The DNA was left to
precipitate for at least 4 hours at -20°C.
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The precipitated DNA was pelleted by centrifugation at 13000rpm for 15 minutes at
4°C and the supernatant removed, the pellet was washed in 70% (v/v) ethanol in
water, centrifuged again (13000rpm for 5 minutes) and all supernatant carefully
removed with a fine end pipette before leaving the pellet to air dry at room
temperature. The pellet was then dissolved in 30 to lOOpl DNA storage buffer
(section 2.8) by incubating at 60°C for two hours and mixing by pipetting up and
down, and stored at 4°C for immediate or next day use, or frozen at -20°C for longer
term storage.
2.5 HIV provirus quantification.
HIV proviral LTR copies were quantified per pg DNA using real-time PCR and the
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Figure 2-3 Position of primers and probes used for the real-time and limiting dilution nested
PCRs shown against the HIV LTR. PBS = primer binding site.
2.5.1 Spectrophotometry
DNA was diluted 1/5 with DNA storage buffer then absorbance at 260nm
wavelength was measured (corrected for absorption at 320V) using a GeneQuant II
spectrophotometer, (Amersham Biosciences, Cambridge, UK). DNA concentration
was calculated using the formula: C = A260/ 0.02, where C = concentration in pg/ml,
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and A260 = absorbance at 260nm wavelength. The A260/A280 ratio was also checked to
assess DNA purity.
Some samples contained insufficient DNA to allow spectrophotometry. In these
cases the DNA concentration was estimated using the following equation:
c = ny; where c = concentration in pg/ml, n = the number of cells counted into the
tube during FACS, and y = the mean fractional yield (extracted DNA / expected
DNA) for the other samples within the same extraction run.
2.5.2 Real-time PCR.
The real-time PCR was performed using a nested approach with a conventional
primary reaction and a real-time secondary and was performed with external
standards. Each run included two reactions for each DNA sample, one undiluted
(containing up to 150pg/ml DNA) and one diluted 1/3 with nuclease free water. Four
external standards containing 5, 50, 500 and 5000 template copies, a negative control
containing DNA extracted from known HIV negative PBMCs, and a negative control
containing water instead ofDNA were also included. The standards were DNA
extracted from an HIV infected cell line diluted in DNA extracted from HIV negative
PBMCs, standardized against HIV DNA of known concentration (provided by the
EU Programme EVA/MRC Centralised facility for AIDS Reagents, NIBSC,
Hertfordshire, UK, Grant number QLK2-CT-1999-00609 and GP828102, donated by
J Bootman).
The primary reaction employed primers 'A1352': GRAACCCACTGCTTAAsscTCAA (sense)
and 'ASOl': AAGCCGAGYCCTGCGTCGAGAG (antisense) (5' base positions 506 and 686 of
the HXB2 genome, (
Figure 2-3). The reaction was carried out in a 20pl volume mixture containing 2pl
of lOxPCR buffer (50mMKCl, lOmM Tris-HCl pH 9.0, Triton X-100 and 1.5mM
MgCk), 5pM each of dGTP, dATP, dTTP and dCTP, 0.1 pi sense and antisense
primers (both at 10 OD), 0.4 units of Taq DNA polymerase (Promega Corporation,
2800 Woods Hollow Road, Madison, USA),18pl with filtered water (Milli-Q filter,
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Millipore Coorporation, Bedford , USA) and 2pl DNA. The reaction was carried out
on a Techne thermocycler (Techne LTD, Duxford, Cambridge, UK), and ran for 18
cycles using the following thermocycling parameters: 94°C for 18 s, 55°C for 21 s,
and 72°C for 1 min 30 s, followed by a final extension step of 72°C for 6 min.
The secondary reaction used primers 'A1354': CTCAATAAAGCTTGCCTTGAG (sense) and
'pan LTR OAS': TGTTCGGGCGCCACTGCTAGAGA (antisense) (5' base positions 524 and
626 of the HXB2 genome, obtained from Oswell, Southampton, UK) and hybridisation probes
LCRed705-ACTCTGGTARCTAGAGATCCCTCAGA-phosphate (acceptor probe) and
AAGTAGTGTGTGCCCGTCTGTTGT-fluorescin (donor probe) (Tib Molbiol, Berlin,
Germany;
Figure 2-3). The reaction was carried out in 20p containing 2.4pl ofMgCL 25mM
(Roche) (final Mg2+ concentration of 4mM), 2pl of Light Cycler DNA Master
Hybridisation Probes (Roche, Mannheim, Germany), 0.4pM acceptor probe, 0.2pM
donor probe, approximately 0.5pi sense and antisense primers at optical density of
10, 11.6pl PCR grade water (Roche) and 2pl of primary PCR product. The
thermocycling was performed on a Light Cycler (Roche) using the following
parameters: an initial 6 minute denaturation at 95°C, followed by 40 cycles of 95°C
for 10 seconds, 55°C for 10 seconds and 72°C for 10 seconds, acquiring at the
annealing stage.
For each reaction Roche Light Cycler software was used to calculate the crossing
point using the Second Derivative Maximum method, a standard curve was drawn
and the HIV LTR copies in each reaction calculated. The mean LTR copies per pg
DNA was then calculated for each cell population from results obtained for the
undiluted and diluted reactions.
This method was sensitive to a single copy as assessed against NIBSC HIV-1 DNA
standards (provided by the EU Programme EVA/MRC Centralised facility for AIDS
Reagents, NIBSC, UK, Grant number QLK2-CT-1999-00609 and GP828102,
donated by J Bootman) and a single reaction was sensitive to infection frequencies of
40 proviral copies per million cells (see section 3.3.2.2).
82
2.5.3 Limiting dilution PCR.
Limiting dilution PCR was then performed to confirm the estimated proviral load
using published Pan-LTR primers and thermocycling conditions (Imlach et al.,
2001). Pan-LTR primers were 5'-GRAACCCACTGCTTAAsscTCAA-3' (outer,
sense), 5'-TGTTCGGGCGCCACTGCTAGAGA-3' (outer, antisense), 5'-
CTCAATAAAGCTTGCCTTGAG-3' (inner, sense), and 5'-
GAGGGATCTCTAGNYAWAGAGT-3'(inner, antisense) (5' base positions
506, 626, 524, and 578 in the HXB2 genome, respectively; fig 2.2). Both primary and
secondary reactions were carried out on a Techne Genius thermocycler (Techne
LTD), using the following parameters: 94°C for 18 s, 55°C for 21 s, and 72°C for
1 min 30 s for 30 cycles followed by a final extension step of 72°C for 6 min.
Ten replicate reactions were performed at the DNA concentration expected to
contain 0.5 copies per reaction. Further dilutions were performed if necessary to
produce replicates containing both positive and negative results. Ten replicate
reactions using the negative control DNA were included in each run. One reaction
for each sample was spiked with 5 template copies to ensure that negative results
were not due to the presence of inhibitors.
PCR amplicons were loaded onto a gel (2% wt/vol agarose (Seakem® LE agarose,
Bioproducts, Maine, USA) in TAE buffer) containing 0.5 pg of ethidium
bromide/ml. The gel was run at 150 V for 30min and DNA visualized under UV
light.
The number of LTR copies per pg DNA was then estimated from The Poisson
Distribution using the program QUALITY (Rodrigo et al., 1997). This assumed that
the two LTRs of each provirus would segregate sperately which was only likely to
occur where proviral DNA was sheared, and therefore provided a conservative
estimate of LTR concentration. Standard errors were estimated using the same
software according to the equation:
SE(c) = Jywhere c = LTR copy number, and/"(c) is 2nd derivative of chi2 at
c.
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For samples where only a single positive replicate was generated due to limited
availability of proviral DNA, no standard error is provided. Viral load per million
cells was then estimated assuming two copies of LTR per provirus, and 6.6 pg DNA
per million cells.
2.5.4 Calculation of attributable proviral load.
For each CD8 lymphocyte subset, the HIV DNA load attributable to contamination
was calculated from the cell population purity data and the CD4 lymphocyte DNA
load. Both 'best estimate' and 'worst case scenario' purity data are used, see section
4.3.1.2. The HIV DNA load attributable to contamination was then subtracted from
the observed HIV DNA load in the CDS lymphocyte subset to give the HIV DNA
load attributable to CD8 lymphocytes. All HIV DNA loads given in the results
section for CD8 lymphocyte subsets are attributable to the CD8 lymphocytes.
2.6 Laboratory layout.
The project involved determining HIV proviral load in cell populations by PCR. In
order to ensure that samples did not become contaminated with PCR product, the
experiments were performed in three separate laboratories, one for cell preparation, a
second for extraction ofDNA and primary PCR setup, and a third for secondary PCR
setup.
2.7 Solutions and Buffers.
Automacs running buffer (AMB): 10% (w/v) bovine serum albumin (Sigma) plus
2mM EDTA in PBS without calcium or magnesium.
Automacs wash buffer : 2mM EDTA in PBS without calcium or magnesium.
Lysis buffer: 0.1M NaCl, 5mM tris pH 8, ImM EDTA, 0.5% SDS, recombinant
proteinase K, PCR grade 2mg/ml (Roche Diagnostics Ltd., Lewes, United Kingdom).
DNA storage buffer lOmM Tris HC1, 0.5mM EDTA (AE buffer from QIAamp
DNA mini Kit, QIAGEN Ltd, Crawley, UK).
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TAE: 40mM tris base (BDH laboratory supplies, Poole, England), 50mM EDTA, pH
8 (Fisher Scientific UK Ltd, Loughborough), 19mM glacial acetic acid (Sigma).
Complete medium: RPMI 1640 (Gibco, Paisley, UK), 2mmol/L glutanamine
(Gibco), lOOpg/ml penicillin (Gibco), and 100 IU/ml streptomycin (Gibco).
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Chapter 3: Development of Methods
This project required the isolation ofhighly purified cell populations from limited
blood samples, the extraction of nucleic acid from fixed cells and quantification of
HIV proviral DNA from cell populations with infection frequencies as low as 10
copies per million cells. These requirements led to development of new cell isolation
protocols, refinement of parameters for cell fixation, optimisation of phenol
chloroform DNA extraction for nucleic acid recovery from fixed cells, and
development of a real-time PCR for quantification ofHIV provirus. For each
method the rationale behind the protocol chosen is presented, and the experiments
used to optimise and standardise the methodology are described.
3.1 Isolation of lymphocyte subsets
One of the major aims of this thesis was to determine the route ofHIV infection of
CD8 lymphocytes in vivo. The two most likely routes were thought to be intrathymic
infection of CD8 lymphocyte precursors, or infection following CD4 upregulation
during activation ofmature CD8 lymphocytes. The strategy used to differentiate
between these two possibilities was to determine the relative levels ofHIV infection
of CD8 lymphocyte subsets. Two approaches were developed. In the first, CD8
lymphocytes were divided into antigen naive and antigen experienced subsets, with
the expectation that intrathymic infection would generate HIV infected naive cells,
some ofwhich might mature to antigen experienced status, while infection on
activation would generate only HIV infected antigen experienced cells. The second
approach divided cells into CD8b"gbtCD4dim lymphocytes and CD8bllghtCD4"
lymphocytes, with the expectation that infection on activation would lead to
preferential infection of the former population.
To counter the possibility that HIV provirus found in CD8 lymphocyte populations
could originate in contaminating CD4 lymphocytes, it was important that all CD8
lymphocyte populations were highly purified. The target level of CD4 lymphocyte
contamination was less than 0.2%. Assuming a CD4 lymphocyte proviral load of
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1000 copies / million cells, this level of contamination would generate two proviral
copies per million CD8 lymphocytes isolated.
To allow detection of low frequency infection, the average yield of the CD8
lymphocyte subsets from a 50ml blood sample needed to be at least 1.5x10° cells and
cells needed to be in a condition to allow optimal DNA extraction.
The techniques available with the potential to isolate the populations of interest with
sufficient yield and purity were immunomagnetic cell sorting or fluorescent activated
cell sorting (FACS). Both methods require that the populations of interest be defined
in terms of the expression of cell markers. In immunomagnetic sorting these markers
are used to label the cells of interest with a ferrous bead, the cells are then passed
through a column that is placed in a magnetic field such that the labeled cells are
retained within the column and the unlabelled cells pass through. The magnetic field
can then be removed and the labeled cells eluted. Sequential rounds of negative
selection (where the population of interest is unlabelled) and positive selection
(where the population of interest is labeled) can be used to allow selection of a cell
subset defined by multiple parameters. Beads are also available that can be
enzymatically removed from the cell after sorting allowing sequential positive
selection, but purity is reduced for second or subsequent isolations. The number of
selection steps is also limited by unavoidable loss of cells at each step, by the
deterioration in cell quality with handling and by the time available. Very high purity
can be achieved by repeated selection for the same label, but the gain in purity is
balanced by loss of yield. Ferrous beads for immunomagnetic sorting are marketed
directly conjugated to monoclonal antibodies, or two step staining methods can be
used. An automated system for placing columns in and out of the magnetic field, and
washing through the cell populations was available (autoMACS, Miltenyi biotec),
which could be used within a negative pressure hood allowing isolation of infectious
material.
For fluorescent activated cell sorting the phenotypic markers used to define the
population of interest are labelled with fluorescent dyes and the labeled cells are
processed through the flow sorter. The flow sorter generates a fine jet of droplets,
with each droplet containing no more than a single cell. The fluorescent labels
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attached to any single cell are then detected through a system of lasers and detectors
which are commonly able to process three or four colours and can be set up to detect
many more. In addition to fluorescent markers, cell size and shape are assessed in
terms of light scatter. Forward scatter increases with increasing cell size, and side
scatter with increasing irregularity of the cell shape or surface. The fluorescence and
scatter parameters of each cell are then displayed digitally, and the operator can
select the specific characteristics of the population to be isolated. Thus populations
can be defined by degree of staining and by shape characteristics of live cells
allowing much more refined population definition than is possible using
immunomagnetic technique. Drops containing a cell with the specified
characteristics are then electrically charged and deflected into a collection tube. The
flow sorter available was not biocontained and therefore cells had to be fixed prior to
sorting.
3.1.1 Isolation of antigen naive and antigen experienced CD8 lymphocytes.
The use of phenotypic markers to define differentiation stages ofCD8 lymphocytes
has been a topic ofmuch debate (Hamann et al., 1999b), but the combination of
CD45RA or CD45RO and either CD27, CD28, CD62L or CD1 la has been shown to
define a population of CD8 lymphocytes ofwhich 85% are naive as defined by a
further three phenotypic markers (De Rosa et al., 2001). CD27 and CD45RA have
also been demonstrated to define populations with distinct cytokine profiles and a
differentiation pathway from CD27+CD45RA+ (antigen nai've) to CD27+CD45RAT
(memory) then CD27~CD45RA"f (effector) has been proposed (Hamann et al., 1997;
Kern et al., 1999; Hamann et al., 1999a). It was therefore decided to aim to isolate
nai've CD8 lymphocytes defined by CD45 isotype plus a second naive marker.
In animal models, antigen experienced CD8 lymphocytes can revert to a naive
phenotype (Bell & Sparshott, 1990). While there is no direct evidence of this
occuring in humans, there is a theoretical possibility that HIV infected
phenotypically nai've CD8 lymphocytes could have acquired infection on activation
rather than within the thymus. More stringent evidence for export of intrathymically
infected cells would be demonstration ofHIV provirus in cells recently exported
88
from the thymus. It has been proposed that these cells, known as recent thymic
emigrants (RTE) can be identified by the expression ofCD 103 in addition to other
nai've cell markers (McFarland et al., 2000). The possibility of isolating RTE was
therefore also considered.
3.1.1.1 Immunomagnetic method.
As cell fixing compromises DNA extraction, an immunomagnetic method was
initially preferred, and a five step cell sorting strategy was drawn up which could be
adapted to allow sorting of either nai've or RTE CD8 lymphocytes (Figure 3-1). The
T cell isolation step was required to remove NK cells which can express CD8 and
would otherwise be selected into the CD8 lymphocyte population. The MACS T cell
isolation kit (Miltenyi Biotech) isolates y8- as well as aP-T lymphocytes. y8-T
lymphocytes have been shown to carry relatively high levels ofHIV provirus ranging
from 10 - 500 copies per million cells and would therefore represent a contamination
issue if they were present in the CD8 lymphocyte population (Imlach et al., 2003).
To determine the likely levels of contamination ofMACS sorted CD8 lymphocyte
populations with y8-T lymphocytes in HIV infected subjects, the proportion of y8-T
lymphocytes expressing CD8 was assessed. PBMCs were isolated from three HIV
infected subjects, stained with the following fluorescent conjugated monoclonal
antibodies: y5-TCR PE, CD8a-FITC and CD3-CyChrome (table 2.3), and assessed
by flow cytometry (section 2.3). y8-T lymphocytes expressing CD8 were found to
account for 0.37%, 0.89% and 6.6% of the total CD8+ve lymphocytes in the three
subjects. Assuming an HIV proviral load within y8-T lymphocytes of 10 -500 copies
/ million cells (Imlach et al., 2003), y5-T lymphocytes could thus generate up to 33
HIV copies / million CD8+ve lymphocytes. This level was considered unacceptable
and the isolation strategy was revised to include a y8-T lymphocyte isolation step.
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Figure 3-1. Schematic representation of the sequential immunomagnetic selection steps
required to isolate naive and antigen experienced CD8 lymphocytes and CD4 lymphocytes from
blood. Target populations are shown in bold boxes, a) Recent thymic emigrant CD8 lymphocytes
should be defined as CD8+CD45RO+CD62L+CD103+, this protocol would not select for CD62L
thus this population would be enriched in RTE rather than a pure RTE population. MACS reagents
are produced by Miltenyi Biotec.
In view of the possibility of reversion of antigen experienced cells to a nai've
phenotype, the feasibility of isolating RTEs was then assessed. Using the strategy for
RTE isolation given (Figure 3-1), cell subsets were isolated from a single subject. In
the final selection step, cells were labeled with a FITC conjugated anti-CD103
monoclonal antibody, and then indirectly labeled with anti-FITC MACS beads,
(Miltenyi Biotec). Although a relatively pure naive CD8 population was isolated
following negative selection for CD45RO (as measured by CD45RO and CD62L
expression), the selection for CD 103 was poor resulting in a cell population where
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only 13% were CD103+ve. In addition the prevalence of CD8+CD45RO-
CD62L+CD103+ cells was determined in one HIV+ve subject by flow cytometry,
and found to be very low at 0.02% of all lymphocytes. It was therefore decided that
isolation of these cells from HIV infected subjects was unlikely to be successful, and
isolation ofnaive CD8 lymphocytes was prefered.
The first naive lymphocyte marker to be assessed in addition to CD45RO was CD27,
chosen as directly conjugated anti-CD27 MACs beads (Miltenyi Biotec) were
available. CD27 is a recognised marker of naive cells, but only cells expressing high
levels ofCD27 are true naive, with those expressing intermediate levels having
characteristics of antigen experienced cells (Kern et al., 1999). Using PBMCs from
tliree HIV infected subjects it was found that between 12% and 32% of
CD8+CD45RO-CD27+ cells were CD27 intermediate, and it was thus decided that
CD27 would not be a suitable 2nd marker for immunomagnetic selection of naive
cells.
Before investigating alternative naive markers, the feasibility of the 5 step process in
terms of yield and purity were assessed. The individual steps up to step 4 were
optimised, and the method was tested using PBMCs from a single 50ml blood
sample. Purity of the CD45RO-ve CD8 lymphocyte population was assessed by
flow cytometry, and did not quite achieve the 0.2% CD4 lymphocyte contamination
standard desired (Table 3-1).
Cell type (phenotype in parenthesis) Percentage of isolated CD8+CD45RO-
population.
CD8 lymphocytes






(Lymphocyte fsc and ssc , CD4+, CD3+)
Table 3-1. Purity of immunomagnetically isolated CD8+CD45RO- population. Fsc = forward
scatter, ssc = side scatter.
CD ytes nU. J /o
91
Typical cell losses during the procedure were 20% of cells at each +ve selection step
and 30% at each -ve selection step, giving projected cumulative losses over a five
step process of 78%. The number of nai've CD8 lymphocytes present in four HIV +ve
subjects was assessed and ranged from 3.9xl04 - 1.4xl05 cells per ml of blood. With
78% losses this would lead to isolation of between 4.3x105 and 1.5xl06 naive CD8
lymphocytes per 50ml sample, barely sufficient for both purity checks and proviral
load estimation.
3.1.1.2 Two stage method of immunomagnetc enrichment followed by FACS.
Given the problems outlined above, the alternative strategy of FACS was
investigated, and the concerns regarding proviral quantification from fixed tissue
were approached by optimising the fixation and DNA extraction methods (section
3.2). A FACSVantage flow sorter was available (Becton Dickenson) equipped to sort
two retained populations and a waste population based on forward scatter, side
scatter, and three fluorescent markers.
The initial strategy, tested using blood donated by an HIV infected subject, was to
isolate PBMCs from blood by density centrifugation, then split the PBMCs into two
aliquots, one for isolation of antigen naive and antigen experienced CD8
lymphocytes and the other for CD4 lymphocyte isolation. The phenotypes and gates
used to define these populations are the same as those used in the final protocol
(2.1.4). The two PBMC aliquots were stained with appropriate fluorescent
conjugated monoclonal antibodies (Table 3-2).
Population to be isolated Monoclonal antibodies
CD27 FITC




CD4 lymphocytes CD3 PE
CD4 Cy-chrome
Table 3-2. Fluorescent conjugated monoclonal antibodies used to stain PBMC for FACS. See
table 2.3 for clones and manufacturers of the antibodies.
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The purity of the na'ive and antigen experienced CD8 lymphocytes was assessed on a
facscalibur flow cytometer that was able to detect the fluorochrome APC (allowing
assessment of contamination with CD4 lymphocytes) in addition to the three
fluorochromes used for sorting (section 2.3). The yields of na'ive and experienced
CD8 lymphocytes were adequate at 7.7x105 and 2xl06 respectively, but the CD4
contamination level of the naive subset was too high at 0.41%.
Contamination of cell populations isolated by FACS with cells from outside the
selection gate is usually due to the presence of the unwanted cell in the droplet
immediately following a desired cell. In this situation the unwanted droplet is often
deflected along with the correct droplet. The easiest way to avoid this is to sort the
cells in a more dilute suspension such that the possibility of two consecutive droplets
containing cells is diminished, but this can lead to very long sorting times with cost
implications. An alternative approach is to pre-enrich for the desired population, and
this approach was taken by introduction of an immunomagnetic CD8 lymphocyte
enrichment step prior to the FACS. This also had the beneficial effect of increasing
the yield of CD8 and CD4 lymphocytes. The strategy proved successful in fulfilling
all five of the initial requirements and no further refinements were made. The
method is given in full in section 2.1 and yield and purity data are presented in
section 4.3.1.
3.1.2 Isolation of CD8br'9htCD4dim lymphocytes and CD8br'shtCD4- lymphocytes.
3.1.2.1 Immunomagnetic method.
CD8b"shtCD4d'm lymphocytes and CD8bnglltCD4" lymphocytes could be isolated by
immunomagnetic selection through use of a negative selection for T cells, followed
by positive selection for CD8 and then positive selection for CD4 (Figure 3-2). This
strategy has a number of problems. Firstly, it would result in selection of all
CD8+CD4+ lymphocytes, including CD4bnghtCD8dirn (thought to originate from CD4
lymphocytes) as well as CD8b"ghtCD4dim, and second all CD4 lymphocytes
contaminating the CD8 lymphocyte population would be selected into the
CD8+CD4+ population.
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To assess whether CD4bnghtCD8dim lymphocytes were likely to result in significant
contamination of the CD8brightCD4dim population, the relative numbers of
CD4brightCD8dim and CD8brightCD4dim lymphocytes was checked in three healthy
subjects. One subject demonstrated a substantial population of CD4bnghtCD8dim
lymphocytes, sufficient to cause a major purity issue for immunomagnetic isolation
(Figure 3-3).
Figure 3-2. Schematic diagram of an immunomagnetic approach for isolation of




Figure 3-3. Relative prevalence of CD8brightCD4dim and CD4brightCD8dim lymphocytes. Dot plot
of PBMCs from a healthy subject, gated on lymphocyte forward and side scatter characteristics and
stained for CD4 and CD8. In this subject there are more CD4bnshtCD8d'm lymphocytes (Rl) than
CD8brightCD4dim lymphocytes (R2).
The likely extent of CD4 lymphocyte contamination of an immunomagnetically
isolated CD8+CD4+ lymphocyte population was calculated from published results.
Previous levels of CD4 contamination ofCD8 lymphocyte populations isolated using
MACS beads were 0.2 - 0.5% (McBreen et al., 2001; Imlach et al., 2001). Given
that CD8b"shtCD4dim lymphocytes usually represent 0.4 - 3.4% of CD8 lymphocytes
in HIV infected subjects (Zloza et al., 2003), co-localisation of the CD8bnghtCD4dim
lymphocytes and the contaminating CD4 lymphocytes would result in a population
comprising 5 - 55% CD4 lymphocytes. This level of CD4 lymphocyte
contamination would be unacceptable.
3.1.2.2 Two stage method of immunomagnetc enrichment followed by FACS.
In view of the problems inherent in immunomagnetic isolation of CD8b"ghtCD4d,m
lymphocytes outlined above, the same two stage approach described for separation of
nai've and experienced CD8 lymphocytes (immunomagnetc enrichment followed by
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FACS, 3.1.1.2) was adopted for isolation of CD8bnghtCD4d,rn and CD8b"ghtCD4~
lymphocytes.
Flow cytometry is notorious for detection of small populations of double positive
cells that are an artefact of the staining or detection process.
(http://www.cyto.purdue.edu/hmarchiv/2001/2463.htm)(Ekong et al., 1993;
Nicholson et al., 1994). Such populations may be caused by non-specific staining,
increased autofluorescence, coincidence error or cell clumping.
To ensure the CD8bnghtCD4dim events were not simply CD8 lymphocytes with
increased non-specific staining, the non-specific staining properties of the APC- and
Cychrome- conjugated anti-human CD4 monoclonal antibodies were mimicked
using appropriate isotype controls (Table 2-3). Very little non-specific staining was
seen, and a clear increase in staining was observed when the anti-CD4 monoclonal
antibodies were used.
Dead cells can auto-fluoresce and bind non-specifically to monoclonal antibodies.
The vast majority of dead cells were excluded from the sorted populations by gating
on forward and side scatter characteristics of live lymphocytes. For four of the HIV
infected subjects, the population to be sorted into CD8pbnghtCD4dim and
CD8pbnghtCD4" lymphocytes was co-stained with an anti-tubulin monoclonal
antibody to further exclude dead cells. Unlike live cells, dead cells are porous to
antibody and will thus bind anti-tubulin antibody (tubulin being one of the major
components of the cytoskeleton). In these subjects the frequency of tubulin stained
cells within the CD8pbnghtCD4dim lymphocyte population (defined using a tight
lymphocyte fsc and ssc gate) was reassuringly low, although only small numbers of
events were acquired (Table 3-3).
Coincidence error occurs when two cells present in a single droplet, lie behind one
another as viewed from the fsc and ssc detectors thus mimicking a single cell. This
could result in a single CD4 lymphocyte together with a single CD 8 lymphocyte
appearing as a CD8+CD4+ event. This type of artefact was of particular concern as
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it could lead to high levels of CD4 lymphocyte contamination. The frequency of
coincidence was therefore assessed using two approaches, first using a separate
staining then mixing experiment, and second by sorting CD8b"ghtCD4dim lymphocytes
and then checking their identity by flow cytometry.





Table 3-3. Dead cells within the CD8brightCD4dim subset. The proportion of CD8brigh,CD4dim
lymphocytes staining for tubulin in four HIV infected subjects. The lymphocytes were tightly gated
by forward and side scatter characteristics.
In the first experiment PBMCs from a healthy donor were divided into aliquots and
stained either for CD8P (aliquot A) or CD4 (aliquot B) or both CD8(3 and CD4
(aliquot C). All cells were also stained for CD27 and CD45RA to mimic the
conditions used in subsequent experiments. Three samples were prepared for flow
cytometry, sample 1 contained a 1:1 mixture of aliquots A and B mixed immediately
after staining and incubated at 4° overnight, sample 2 contained a 1:1 mixture of
aliquots A and B mixed immediately prior to flow cytometry, and sample 3
contained aliquot C cells only. In the text to follow, samples 1 and 2 are referred to
as 'mixed' while sample 3 is refered to as 'co-stained'. Appropriate isotype controls
were also included. If the CD8br,ghtCD4+ population were the result of coincidence
error, it would be seen in the 'mixed' as well as the 'co-stained' sample.
The frequency of CD8br,gbtCD4+ cells in the 'mixed' samples was found to be very
low (mean 0.2% of CD8 lymphocytes, range 0.1 - 0.24), contrasting well with the
clear double positive population seen in the 'co-stained' sample (Figure 3-4A).
However, as the population of CD8bnghtCD4+ lymphocytes in the 'co-stained' sample
was also small (2.7% of CD8 lymphocytes), coincidence error could still have
accounted for 10% of the CD8bllghtCD4+ lymphocytes. Coincidence error is not the
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only explanation for the appearance of CD8bnghtCD4+ events in the 'mixed' samples,
which could be due to carry over of small amounts of unbound anti CD4 antibody
from the CD4 stained sample into the mixed sample. This explanation is supported
by the following: a) the CD8bllghtCD4+ events in the mixed sample had very low
intensity CD4 expression, and no CD8bnghtCD4bnght events were observed (Table 3-4,
Figure 3-4B); b) the number of CD8bngbtCD4+ events did not increase with increasing
speed of acquisition (Table 3-4); c) there was no increase in CD8bnghtCD4+ cells in
the sample mixed then incubated overnight (which could promote cell adhesion) than
in the sample mixed immediately prior to flow cytometry (Table 3-4).
The extent of coincidence error was also assessed by checking the purity of
CD8b"ghtCD4dim lymphocytes isolated by FACS from five HIV positive subjects.
Any cells sorted erroneously due to coincidence error would be expected to appear as
separate CD4 and CD8 lymphocytes in the purity check. The median contamination
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Figure 3-4. Role of coincidence error in generation of CD8h"8h,CD4d"11 events. The impact of
coincidence error was assessed by determining the frequency of CD8br'shtCD4 ' lymphocytes in
samples that contained a mixture of cells separately stained for CD4 or CD8 (samples 1 and 2, 'mixed
samples') compared to their frequency in samples stained for CD4 and CD8 in a single tube (sample
3, 'co-stained' sample). (A) The bar chart indicates the mean frequency of CD8br,ghtCD4+
lymphocytes from all flow cytometry acquisitions of the mixed samples (grey bar) and the 'co-
stained' sample (chequered bar). (B) Dot plot of CD4 against CD8 expression for samples 1 and 3,
(gated with a tight gate on lymphocyte forward and side scatter characteristics) showing the lack of
double stained cells in the 'mixed' compared to the 'co-stained' sample. (This subject consistently
displayed a significant CD4bnghtCD8dim population).
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Cell clumping occurs when the cell preparation does not form a single cell
suspension, but one or more cells stick together. A doublet of a CD4 lymphocyte
and a CD8 lymphocyte could present a CD8+CD4+ appearance on flow cytometry,
and if cells were well adhered this appearance could be maintained after sorting.
Such doublets are generally excluded by gating on the fsc/ssc properties of single
cells. To ensure that the CD8br'shtCD4dim population did not represent doublets
mimicking single cells, an aliquot of sorted CD8bnghtCD4dim cells were viewed under
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Sample 1 400 0.23 0.18 0.05
300 0.24 0.27 -0.03
Sample 2 450 0.10 0.03 0.07
675 0.24 0.20 0.04
Mean ofsample
1 and sample 2
data
0.20 0.17 0.03
Sample 3 450 2.73 1.11 1.62
Table 3-4. Coincidence error. The likelihood that coincidence error was the cause of the small
number of CD8br'8htCD4+ lymphocytes seen in 'mixed' samples was assessed by altering speed of
acquisition, and by quantifying the number of CD8bnBhtCD4bnshtas compared to CD8briEhtCD4dlm
events. Coincidence error would be expected to increase with increasing speed of acquisition, and to
generate CD8bnshtCD4br'eht in preference to CD8br'shtCD4dlm events. These trends were not observed
suggesting alternative explanations for the CD8bnghtCD4+ lymphocytes seen in 'mixed' samples.
In view of the data indicating that the CD8bnghtCD4d,m events apparent on flow
cytometry were not artefactual, a method of immunomagnetic enrichment followed
by FACS was used to isolate CD8brightCD4dim and CD8brightCD4" lymphocytes from
test subjects. The full protocol is given in section 2.1.
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3.2 Cell fixation and DNA extraction.
Due to aerosol generation and infection risk during FACS, cells had to be fixed prior
to sorting. All methods of fixation have some effect on DNA, and as HIV proviral
load was to be assessed in the sorted cells, it was important to develop a fixation
method that allowed maximal DNA extraction and accurate proviral load
quantification.
The standard fixation protocol used prior to cell sorting was to incubate cells for one
hour in 2% paraformaldehyde. Paraformaldehyde damages DNA by initiating
denaturation at AT rich regions creating sites for chemical interaction (Douglas &
Rogers, 1998). It can also hamper DNA extraction by cross-linking histone proteins.
The damage to DNA can be reduced by altering a number of fixation parameters
including reduction of paraformaldehyde concentration (McGhee & von Hippel,
1977), ensuring a neutral pH (Douglas & Rogers, 1998), fixing at low temperature
(Tokuda et al., 1990; Yagi et al., 1996; Noguchi et al., 1997) fixing in the presence
ofEDTA (Yagi et al., 1996), and reducing the duration of fixation. Alternatively use
of alcoholic fixatives such as 100% ethanol or methanol have good nucleic acid
preservation properties (Noguchi et al., 1997). The approach taken first was to
optimise the paraformaldehyde fixation parameters, and if this failed then alternative
fixatives were to be trialed.
3.2.1.1 Duration of fixation.
PBMCs from an HIV infected subject were fixed in 2% paraformaldehyde for either
10 or 20 minutes. DNA from duplicate samples of the fixed cells and unfixed
controls was then extracted and HIV proviral load quantified using the LightCycler
real-time PCR assay described in 2.5.2. Both 10 and 20 minutes fixation lead to a
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Figure 3-5. Effect of duration of fixation on proviral load detection. HIV proviral load detected
in lxlO6 PBMCs isolated from an HIV infected subject and fixed in 2% paraformaldehyde for 0, 10 or
20 mins (duplicate samples).
3.2.1.2 Concentration of paraformaldehyde.
To determine whether use of a less concentrated paraformaldehyde solution would
allow improved DNA recovery, DNA was extracted from HIV infected C8166 cells
fixed for 1 hour in varying concentrations of paraformaldehyde. HIV provirus was
then quantified from a lxlO"5 dilution of the extracted DNA using real-time PCR.
(The infection of the C8166 cells and the DNA extraction was performed by Dr.
Imlach). No provirus was detected in cells fixed in 2% or 1.75% praformaldehyde,
while concentrations up to 0.5% had no detrimental effect (Figure 3-6).
102
Paraformaldehyde concentration (%)
Figure 3-6. Effect of paraformaldehyde concentration on ability to detect HIV provirus. HIV
infected C8166 cells were fixed in various concentrations of paraformaldehyde, DNA was extracted
and HIV proviral load quantified by real-time PCR.
3.2.1.3 Phenol chloroform DNA extraction method for paraformaldehyde fixed
cells.
The standard phenol chloroform based DNA extraction methods consists of a lysis
step followed by DNA extraction and ethanol precipitation. It was expected that the
cell fixation process would compromise the ability of the lysis step to fully separate
the DNA from the protein component, and therefore the standard lysis method was
compared against two enhanced methods. Stored PBMCs isolated from a HIV
infected subject were thawed, washed, resuspended in 1 X PBS, filtered to ensure a
single cell suspension and divided into 24 aliquots each containing lxlO6 cells. Six
aliquots were fixed with either 0%, 0.75%, 1% or 1.25% paraformaldehyde and
DNA was extracted in duplicate using three protocols: 'standard lysis', 'hot lysis' or
'extended lysis'. All methods involved lysis with SDS and proteinase K. In the hot
lysis method a PBS based lysis buffer was used and cells were heated to 100°C for
10 minutes prior to a 12 hour incubation at 56°C, in the standard and extended
protocols the lysis buffer was TNE based with no high temperature step and the
methods differed only in the length of the lysis period (standard = 2 hours, extended
= 12 hours).
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It was found that separation of the aqueous and organic layers was much easier in the
hot lysis than in the other two methods due to decreased viscosity of the aqueous
layer. The amount ofDNA extracted using each method was measured by 260nm
wavelength light absorption (corrected for absorption at 320X.) using a GeneQuant II
spectrophotometer. Combining all samples the extended lysis protocol was
significantly superior to the other two (Figure 3-7A) and this superiority was evident
for all paraformaldehyde concentrations tested (Figure 3-7B).
The ratio of the light absorbance at wavelength 260nm to that at 280nm gives a
measure of the DNA purity, with a ratio of 1.8 being optimum and lower levels
indicating significant protein contamination. None of the extraction methods
demonstrated ratios suggestive of protein contamination even at the higher
paraformaldehyde concentrations. The higher ratios seen for the standard lysis
conditions may reflect increased RNA retention or phenol contamination, (Figure
3-7C).
HIV proviral load per pg DNA extracted using the 'hot' and 'extended' lysis
conditions was quantified using real-time PCR (fig 3.2.3.D). Neither method showed
overall superiority, though the 'hot' method did appear to give more consistent
results. It is possible that this superior consistency could be due to the easier
separation of aqueous and organic layers due to denaturing and shearing ofDNA
during the 100°C incubation.
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Figure 3-7. Comparison of lysis conditions for extraction of DNA from fixed cells. PBMCs were
fixed in 0.75%, 1.0% or 1.5% paraformaldehyde or left unfixed, and DNA extracted using one of
three different lysis conditions followed by phenol chloroform extraction and ethanol precipitation.
The amount ofDNA extracted was measured by spectrophotometry. Overall DNA extraction
efficiency was significantly greater using extended lysis conditions (A), this was evident across all
paraformaldehyde concentrations used (B); DNA purity was high as measured by the ratio of
absorbance at 260A.:280 X (C). There was no consistent difference between the hot and extended lysis
conditions in the number ofHIV proviral copies detected per pg DNA (D).
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Finally, given that cell numbers available for some of the CD8 lymphocyte
subpopulations were expected to be low, the DNA yield using the extended and hot
methods was compared at low cell numbers. PBMC samples containing either
2.1xl05 cells or 1.4 x 106 cells (the lower cell number was included to mimic the
conditions expected for CD8 lymphocyte subsets) were fixed in 0.75%
paraformaldehyde for an hour then DNA was extracted using either 'hot' or
'extended' lysis conditions. Again the DNA yield was consistently higher in the
'extended' as compared to the 'hot' protocol, (Figure 3-8). Extraction failed in one




















Figure 3-8. Effect of lysis conditions on DNA yield from small populations of cells. DNA yield
was superior using 'extended' as compared to 'hot' lysis conditions when extracting from high or low
numbers of cells.
3.2.1.4 Infectivity of HIV infected cells fixed with 0.75% paraformaldehyde.
To ensure that the fixation with 0.75% paraformaldehyde for an hour at 4°C was
adequate to render HIV infected cells non-infectious (and safe to sort on the flow
sorter), the infectivity of an HIV infected T cell line, fixed using the above
parameters was tested. This work was performed by Dr. S. Imlach, (Laboratory of
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Clinical and Molecular Virology, University ofEdinburgh) and demonstrated that the
fixation protocol was sufficient.
3.3 Quantification of HIV provirus.
Quantification ofHIV proviral load in cell subsets has traditionally been performed
by limiting dilution PCR (Simmonds et al., 1990). In this method a nested PCR
sensitive to a single HIV proviral copy is performed on serial dilutions ofDNA
extracted from the cell population of interest. Multiple replicates are performed at
the dilution expected to contain just less than a single copy (on average) per reaction,
and the true average number of copies per reaction is calculated from the number of
positive and negative replicates using an equation derived from the Poisson
Distribution. This method is very sensitive (its sensitivity being limited only by the
amount ofDNA available), but is very labour intensive. With the aim of increasing
time efficiency a real-time PCR quantification method was developed. The HIV
LTR was chosen as the target sequence as it is highly conserved between different
HIV subtypes. This was a priority as many of the HIV infected subjects available for
recruitment to the study had acquired the virus outside the UK and inclusion of
subjects with non-subtype B virus in the study population was likely. The real-time
PCR reaction was performed on a Roche Light Cycler (Roche) using hybridization
probes and external standards. Initial primers, probes and reaction conditions were
based on those developed for detection ofHIV RNA in pooled plasma (Cleland et
al, 2001).
3.3.1 Quantification of HIV provirus using real-time PCR.
3.3.1.1 Sensitivity.
Using two dilution series the relative sensitivity of a single round real-time PCR was
compared with a nested approach using a standard primary reaction and a real-time
secondary reaction. The first dilution series used DNA extracted from an HIV
infected cell line, while the second used cloned HIV proviral DNA. Both series were
diluted in DNA extracted from HIV negative PBMC at a concentration of 600pg/ml
(1,2pg DNA per PCR, DNA concentration of 60pg/ml in PCR reaction). DNA
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extracted from PBMCs was used as the diluent instead ofwater or carrier DNA to
approximate the conditions when testing proviral load in cell subsets isolated from
HIV infected subjects. The high DNA concentration was chosen as it would allow
the proviral load of approximately 5x10s cells to be determined in one reaction,
though as a result of experiments assessing inhibiton of PCR (3.3.1.2), the
concentration ofDNA in standards was subsequently reduced to lOOpg/ml. Using
both dilution series the nested approach was shown to be 1 log more sensitive than
the single round.
To determine the actual sensitivity (in terms of number of provirus copies in a
reaction required for detection) a standard series of known proviral copy
concentration was generated by diluting a known amount ofHIV proviral clone
(measured by spectrophotometry). The LTR concentration in the standard was also
assessed using limiting dilution, which demonstrated that lxl O"10 dilution of the







Figure 3-9. Quantification of LTR copies in standard using limiting dilution PCR. The LTR
concentration in the 10"'° dilution of the standard (full length HIV clone diluted in DNA extracted
from HIV negative PBMCs) was determined by limiting dilution. Nine out of twenty replicates were
positive indicating an LTR concentration of 0.6 copies per 2pi.
The proviral concentration of the standards was also checked by limiting dilution
using primers against HIV gag (Simmonds et al., 1990), and results correlated well
with those obtained using LTR primers. The accuracy of the gag limiting dilution
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method was confirmed against a standard series ofHIV proviral DNA at known
concentration (provided by the EU Programme EVA/MRC Centralised facility for
AIDS Reagents, NIBSC, Hertfordshire, UK, Grant number QLK2-CT-1999-00609
and GP828102, donated by J Bootman). The NIBSC standard lacked the LTR and
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Figure 3-10. Sensitivity of real-time PCR for LTR. The sensitivity of the nested real-time PGR
protocol was tested using in house standards generated by serial dilution of a full length HIV clone
diluted in DNA extracted from HIV negative PBMCs at a concentration of 1OOpg/ml. The nested
real-time PCR protocol was positive in 3/5 replicate reactions containing an average of0.6 LTR
copies each (as assessed by limiting dilution, Figure 3-9).
The sensitivity of the 18 cycle conventional primary and real-time secondary PCR
was then tested and was found to be approximately five copies, which was
considered insufficient for the purpose. To improve sensitivity, the probes were
altered to optimise binding to M group virus, a 'hot start' real-time reaction was
used, and the amount of carrier DNA in the dilution series was reduced to lOOpg/ml.
Following these changes the protocol was consistently sensitive to a single LTR copy
(Figure 3-10). Full details of the final protocol, probes and primer sequences is
given in section 2.5.2.
600 LTR copies per reaction
60 LTR copies per reaction
6 LTR copies per reaction
0.6 LTR copies per reaction
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3.3.1.2 Determining the optimum DNA concentration for proviral load
quantification.
As the expected number ofproviral copies in the cell populations of interest was very
low, ranging from less than 1 to 1000 copies per million cells (Livingstone et al.,
1996; McBreen et al., 2001), the real-time PCR assay was required to assess DNA
extracted from a large number of cells (up to 106). Too high a concentration ofDNA
in each PCR leads to inhibition, while use of a low concentration would necessitate
multiple replicate reactions with cost implications. To determine the maximum
DNA concentration tolerated without compromising the reaction efficiency, dilution
series ofHIV provirus were made up in DNA extracted from HIV negative PBMCs
at concentrations of 150, 300 and 900 pg/ml; giving final DNA concentrations in the
PCR reaction mix of 15, 30 and 90pg/ml respectively. The crossing points (the
number of real-time PCR cycles required to generate a given amount of template) for
the 15pg/ml DNA and 30pg/ml DNA reactions were almost identical, but those for







Figure 3-11. Effect of DNA concentration on LTR quantification. LTR was quantified from
standard solutions containing 50, 100 and 500 LTR copies, using the nested PCR protocol described
(section 2.5.2). The DNA concentration in the primary reaction was either 15 pg/'ml (blue triangles),
30 pg/ml (red squares) or 90pg/ml (green diamonds). The crossing point is the number of real-time
PCR cycles required to generate a given amount of template. The higher crossing points seen for
reactions containing 90pg/ml DNA indicate inhibition.
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The amplification efficiency of the real-time PCR was not lower in the 900pg/ml
samples suggesting that the inhibition occurred during the primary reaction, this is
not surprising given that the non-template DNA concentration is higher at this stage.
In view of these findings a DNA concentration of up to 150pg/ml was used in test
samples. As 2pl DNA was used in each reaction this allowed interrogation of 0.3pg
DNA per reaction (equivalent to approximately 5xl04 cells), allowing infection
frequencies as low as 40 copies per million cells to be reliably detected in a single
reaction.
3.3.1.3 Standard Curve.
In order to quantify the starting concentration of target DNA using real-time PCR,
the amplification efficiency must be constant throughout the exponential phase of the
reaction, and must be constant between individual reactions performed in a single
run. If both of these criteria are met, a plot of crossing point against logarithm of
sample concentration (termed the standard curve) will generate a straight line. To
test this DNA extracted from an HIV infected cell line was serially diluted in DNA
extracted from HIV negative PBMCs at 100pg/ml. The standard curve generated
had a linear regression coefficient of 1.00, and a standard mean error of 0.028
(Figure 3-12A). To ensure that these results were maintained for template prepared
under the conditions of a test sample, the standard curve was also assessed using
DNA extracted from CD4 lymphocytes isolated from an HIV infected subject using
the standard protocol employed for the test samples. In this experiment the
regression coefficient and error were not as good (r2=-0.97, mean squared error =
0.22, Figure 3-12B). However, the calculated starting copy number was always
within a factor of two of the true starting copy number (Figure 3-12B), and therefore
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Figure 3-12. Standard curves for LTR real-time PCR. Standard curves for a serial dilution of
DNA extracted from HIV infected cell line (A), and for a serial dilution ofDNA extracted from CD4
lymphocytes isolated from an HIV infected subject (B). The actual number of LTR copies in each
reaction, and the calculated estimates are given (B).
3.3.1.4 External standards.
The number of LTR copies in test samples were quantified against in house standards
consisting of a serial dilution of a full length HIV clone diluted in DNA extracted
from HIV -ve PBMCs at a concentration of 100p.g/ml. Four dilutions, ranging from
10 LTR copies per reaction to 5000 LTR copies per reaction, were included in each
test run. Use of external standards to quantify test samples is only valid if the
amplification efficiency of the standards and test samples are closely matched.
Amplification efficiency describes the fold amplification of target DNA per PCR
cycle, and a value close to two is expected. Use of the HIV LTR as the target
sequence in the standard, and dilution of standards in DNA extracted from PBMCs


















The amplification efficiency of the standards and two test samples was determined
by performing the nested real-time PCR on dilution series of the standards and of the
two test samples. Amplification efficiency was calculated using the equation:
E = 10~' pe where E = amplification efficiency, slope = the slope of the linear
regression line through the data points on a plot of crossing point against logarithm
of sample concentration.
The two test samples used were: i) a sample ofDNA extracted from an HIV infected
cell line, ii) DNA extracted from paraformaldehyde fixed CD4 lymphocytes isolated
from an HIV infected subject (this sample was treated in exactly the same way as test
samples used in the main study). The amplification efficiencies were 1.81 for the
standard, 1.85 for the HIV infected CTL line and 1.84 for the cells isolated from the
HIV infected subject. These amplification efficiencies differ by less than 0.05 and
thus the standards were considered suitable.
3.3.1.5 Reliability at low copy numbers.
As the expected proviral loads in the test samples were low, it was important to
ensure that the nested real-time PCR protocol remained reliable at low starting target
copy numbers. To assess this a dilution series of the external standards was run with
the five copy and ten copy reactions performed in triplicate. As expected deviation
from the standard curve did increase with lower starting copy numbers, however the





















































Figure 3-13. Use of LTR real-time PCR for quantification of low copy numbers. The reliability
of the nested real-time PCR protocol at quantifying template at low copy number was assessed using
triplicate reactions of 5 and 10 starting LTR copies. Deviation from the standard curve is seen at these
low copy numbers (A), but estimated copy numbers remain within a factor of 2 of the actual copy
numbers (B).
3.3.1.6 Ongoing quality control.
During the course of data collection, the amplification efficiency of six test samples
was monitored by inclusion of two dilutions of the test sample in the quantification
reaction. This monitoring demonstrated that in one of the samples there was a
marked difference in the proviral loads estimated from the two dilutions suggesting
either a pipetting error or marked failure of one of the amplification reactions, and in
another sample more provirus was detected in the diluted than the neat sample
making amplification efficiency impossible to assess. In the remaining four samples
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the amplification efficiency of the test samples tended to be lower than that of the
standards (mean of tests = 1.76, mean of standards = 1.96). This difference was
sufficient to cause underestimation of the proviral load in the test sample by 1 log
over 22 cycles (10 proviral copies were generally detected after approx 22 cycles).
The under-estimation of the proviral load caused by the lower amplification
efficiency is more marked for lower starting copy numbers, and thus this bias would
tend to decrease the estimated viral load in CD8 populations as compared to CD4
populations. This could thus lead to underestimation, but not overestimation of the
proviral load attributable to CD8 lymphocytes. In view of this observed difference in
the amplification efficiency, and the relatively frequent occurrence of clearly
erroneous results, it was decided to confirm all proviral loads using limiting dilution.
3.3.2 Quan tification ofHIVprovirus by limiting dilution PCR.
Limiting dilution PCR ofHIV LTR has been previously used to quantify HIV
proviral load (McBreen et al., 2001; Imlach et cil., 2001), and the method (described
in section 2.5.3) was not modified for this project. Sensitivity to a single copy was
confirmed using a standard dilution series (3.3.1.1). The reproducibility of the
protocol for DNA extraction and limiting dilution LTR quantification was tested on
five replicate samples of paraformaldehyde fixed PBMCs from an HIV infected
subject, and was found to be good with the calculated proviral load ranging from 13
-50 proviral copies per million cells. The correlation between the original real-time
PCR estimate and the final result provided by limiting dilution was rs = 0.86, p<0.01
(Figure 3-14).
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Figure 3-14. Correlation between the real-time PCR estimate and limiting dilution estimate of
proviral load. rs = Spearmans rank correlation coefficient.
3.4 Conclusion
Immunomagnetic methods alone were found to be inadequate in terms of both yield
and purity for isolation ofCD8 lymphocyte subsets, and therefore a two stage
process of immunomagnetic enrichment followed by FACS was developed. This
process allowed isolation of naive, memory, effector, CD8bnglnCD4d,m and
CD8+CD4- populations with high purity. The use of FACS necessitated cell fixation
and conditions for fixing cells and subsequent DNA extraction were optimized.
Fixation with 0.75% paraformaldehyde for one hour coupled with a DNA extraction
method with an extended period of cell lysis allowed extraction of over 75% of the
expected DNA. A real-time PCR method was developed to quantify HIV LTR
copies. Using a nested approach infection frequencies down to 40 proviral copies
per million cells could be detected in a single reaction, and quantification was
accurate to within a factor of two. Ongoing monitoring of the method revealed some
inconsistent results and thus all LTR copy number estimates were confirmed at
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limiting dilution. There was a good correlation between the real-time and limiting
dilution estimates.
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Chapter 4: HIV infection of CD8 lymphocytes.
4.1 Introduction
As discussed in section 1.10, HIV infection of CD8 lymphocytes has been repeatedly
demonstrated in vitro and, while HIV provirus has been detected in CD8 lymphocyte
populations isolated from both the blood and lung ofHIV infected subjects, some
commentators argue that this provirus may have originated in contaminating CD4
lymphocytes.
Likely mechanisms for HIV entry into CD8 lymphocytes include CD4 dependent and
CD4 independent routes, as introduced in section 1.11. The routes thought most
likely to generate the majority of circulating HIV infected CD8 lymphocytes are
export of intrathymically infected cells, or infection during CD4 upregulation on
activation of the mature CD8 lymphocyte.
It is well known that mature T lymphocytes develop from thymocytes which pass
through a stage ofCD4 and CD8 co-expression, and that these double positive
thymocytes then completely downregulate either CD4 or CD8 to become single
positive CD8 'cytotoxic' or CD4 'helper' lymphocytes. Double positive thymocytes
show marked susceptibility to productive infection by both R5 and X4 tropic HIV in
vitro, and infected cells can then mature into CD3hlghCD8+ thymoctes (De Rossi et
al., 1990; Stanley et al., 1993; Su et al., 1995). The mechanism of infection is likely
to be through classic CD4 mediated viral entry as CD3hlghCD8+ thymocytes are
resistant to infection (Lee et al., 1997).
Thymic atrophy is a common consequence ofHIV disease in both adults and
children (Grody et al., 1985; Joshi et al., 1986), and HIV infected cells have been
demonstrated by in situ hybridisation in thymic tissue removed from HIV infected
individuals (Burke et al., 1995; Haynes et al., 1999). These infected cells are most
likely to include thymocytes, an interpretation supported by the isolation of an HIV
variant with higher than normal replicative capacity in thymic cell lines (Calabro et
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al., 1995), but definitive co-localisation ofHIV and thymocyte markers is lacking. In
the thy/hu mouse HIV infected thymocytes can be exported into the circulation
(Brooks et al., 2001), but whether the thymus is the source of the circulating CD8
infected lymphocytes observed in HIV infected individuals remains unclear.
As described in section 1.5.3, in vitro stimulation of CD8 lymphocytes leads to
upregulation ofCD4 and generation of cells with a CD8bnghtCD4d,m phenotype.
These CD8br,ghtCD4dim lymphocytes are susceptible to productive HIV infection, and
this infection is CD4 dependent (Flamand et al., 1998; Kitchen et al., 1998; Zhang et
al., 2001; Zloza et al., 2003).
Two studies have investigated the likely source ofHIV infected CD8 lymphocytes
circulating in vivo, by assessment of the relative frequency ofHIV infection of CD8
lymphocyte subpopulations isolated from HIV infected subjects. In the first study a
higher frequency ofHIV infected cells was found in antigen nai've than antigen
experienced cells, supporting a thymic source (McBreen et al., 2001). However
CD45RA expression was used as the sole marker of naive status, and it was
subsequent discovered that this molecule is expressed on effector as well as naive
CD8 lymphocytes (Hamann et al., 1997). In the second study CD8 lymphocytes
were divided on the basis of CD4 co-expression. Frequency of infection was much
greater in CD8+CD4+ than CD8+CD4~ lymphocytes, suggesting direct infection of
this circulating double positive population rather than intrathymic infection (Imlach
et al., 2001). Subpopulations were isolated by immunomagnetic technology
therefore it was not possible to differentiate CD8bllghtCD4dim from CD4bnghtCD8dim
lymphocytes. More recently Brenchley et al., (2004a) demonstrated that HIV
proviral load in CD8+CD4dim lymphocytes was 5 to 100 times that found in memory
CD8 lymphocytes not expressing CD4.
To confirm HIV infection ofCD8 lymphocytes in vivo, and demonstrate that
observed provirus does not originate from contaminating cells, HIV provirus was
quantified from highly purified CD8 lymphocyte populations. To investigate the
mechanism of infection, HIV proviral load was assessed in CD8 lymphocyte subsets
isolated from the blood of 20 HIV infected subjects. The rationale behind the subsets
isolated is given in section 3.1.
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Primary HIV infection (PHI) can be defined as the period between HIV infection of a
subject and the establishment of the viral load set point. Events during this period
have a major influence on the course of disease, with poor viraemic control being
prognostic of rapid progression (Lyles et al., 2000). CD8 lymphocytes are vital in
the control of initial viraemia (Koup et al., 1994; Musey et al., 1997) and thus any
compromise of CD8 lymphocyte function at this stage could have a profound effect
on prognosis. To investigate whether significant infection of CD8 lymphocytes
occurs in PHI, the level ofHIV infection of CD8bllghtCD4dim lymphocytes was
determined in a single subject during PHI.
4.2 Subjects and Samples
Nineteen subjects with chronic HIV infection, and one with PHI, attending health
care services in Scotland were recruited with each subject giving informed consent
for participation in the study in accordance with Lothian Regional Ethics Committee
(LREC2001/4/25). The only inclusion criteria for recruitment was HIV infection.
Exclusion criteria included anaemia (Hb <100 g/L) or involvement in a clinical trial.
Data collected for each subject included age, most recent CD4 count and viral load,
and antiretroviral treatment history. The CD4 count was determined in the Western
General Hospital haematology laboratory by flow cytometry using MultiTEST IMK
Kits and TruCOUNT tubes (Becton Dickenson). Viral load was determined in the
Regional Virus Laboratory, Edinburgh Royal Infirmary, using a quantitive PCR
(Roche), with sensitivity to 50 copies/ml blood. The clinician attending the subject
was asked to indicate whether the subject had any intercurrent infection on the day
that blood was drawn for the study.
The subjects had a mean age of 37, and were at various stages of disease progression
from asymptomatic through to AIDS. Three subjects were long term non-
progressors (defined as subjects who had maintained a CD4 count above 300 without
antiretroviral therapy despite over 10 years of infection), and thirteen were receiving
combination antiretroviral therapy at the time of sampling (Table 4-1).
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A 30 - 50ml blood sample was drawn from each subject. As each sample contained
insufficient CD8 lymphocytes to assess HIV infection of all the cell subsets of
interest, the samples were divided into two groups. CD8 lymphocytes from group 1
samples were divided on the basis of CD4 expression (N=9), and those from group 2
on the basis ofdifferentiation phenotype (N=l 1). One subject (subject 19) donated a
blood sample on two occasions and is therefore included in both groups. Subjects
were selected to ensure a range of disease stages from asymptomatic to advanced
AIDS were represented in each group.
The subject with primary HIV infection presented with a typical HIV seroconversion
illness consisting of fever, rash and lymphadenopathy approximately four weeks
after HIV exposure through unprotected heterosexual intercourse. Primary HIV
infection was confirmed by two weakly reactive HIV antibody tests with a negative
western blot (4th generation HIV combo assay, Abbott Diagnostics; 4th generation
Vidas Duo assay, BioMerieux; and New LAV Blot 1, BioRad). HIVp24 antigen was
positive (Vidas p24 antigen assay, BioMerieux) and could be neutralised with
specific antiserum. The initial HIV viral load was 3.5xl06 RNA copies/ml serum
(Roche Cobas Monitor HIV RNA assay, Roche Diagnostics) rising to 6.3 xlO6 a
week later, then dropping to 2xl04 after one month without therapeutic intervention.















Recent or ongoing acute
infection Age
1 1 2 75,000 No Pulmonary tuberculosis 47
2 2 17 750,000 Yes Pyrexia of unknown origin 29
3 2 39 309 Yes None 36
4 2 51 23,100 No Pneumonia 43
5 1 66 75,000 Yes
Clinical diagnosis of PML, JC
virus not isolated
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6 1 117 75,000 Yes None 43
7 1 123 330,000 Yes Oral candidiasis 31
8 2 296 470 Yes None 32
9 2 328 <50 Yes 33
10 2 334 <50 No None 43
11 1 339 14,900 Yes None 34
12* 2 364 304 No None 37
13 1 385 153 Yes None 37
14 1 393 403 Yes None 40
15* 1 396 862 No Cellulitis 37
16 2 509 <50 Yes None 54
17 2 531 <50 Yes Small bowel overgrowth 38
18* 2 647 13400 No None 38
19A 2 824 1900 Yes None 40
19B 1 887 <50 Yes None 41
20 1 630 3,500,000 No None 34
Table 4-1. Subject characteristics. Subjects ordered in ascending CD4 lymphocyte count except
subject 20 who presented with primary HIV infection, a: subjects indicated by * are long term non-
progressors. b: CD8 lymphocytes from samples in study group 1 were subdivided on the basis of CD4
expression, those in study group 2 were subdivided by differentiation phenotype. c: Yes indicates
subject was prescribed at least three antiretrovirals at the time the sample was taken.
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4.3 Results.
The results are presented in two sections. In section 4.3.1 the characteristics of the
isolated lymphocyte populations in terms of cell numbers and purity are provided.
The purity data is important as it is used to demonstrate that the HIV detected in the
CD8 lymphocyte populations originated in the CD8 lymphocytes not contaminating
cells. The overall CD8 lymphocyte proviral load and the distribution ofprovirus
within the CD8 lymphocyte subsets are presented in section 4.3.2.
4.3.1 Isolated CD8 lymphocyte populations.
CD8 lymphocytes were isolated using a two step protocol involving initial
immunomagnetic enrichment followed by FACS (Figure 2-1, see section 2.1 for
details of protocols and section 3.1 for development of cell isolation methods). CD8
lymphocytes from group 1 samples were divided into those expressing CD4
(CD8brightCD4dim) and those not expressing CD4 (CD8brightCD4"). CD8 lymphocytes
from group 2 samples were divided into antigen nai've (CD45RA+CD27high) and
antigen experienced (all non-antigen naive CD8 lymphocytes), and in 7 samples the
antigen experienced population was further subdivided into memory (CD45RA-
CD27+) and effector (CD45RA+CD27-) subsets.
4.3.1.1 Size of CD8 lymphocyte populations isolated.
The number of cells isolated in each CD8 lymphocyte subset had a bearing on the
availability of cells for purity assessment and HIV provirus detection. A minimum
of 106 total CD8 lymphocytes was isolated from each subject, sufficient to quantify
HIV proviral loads down to approximately 10 copies per million CD8 lymphocytes
(lower proviral loads could be detected but could not be confidently ascribed to CD8
lymphocytes, see section 4.4.1.2). Cell numbers isolated in each CD8 lymphocyte
subset varied widely (Table 4-2), dropping to a mean of 7.0xl04 for CD8b"ghtCD4dim
lymphocytes. The low cell numbers available in this subset meant that levels ofHIV
infection of less than 100 copies permillion cells were unlikely to be detected.
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Cells isolated per subject
CD8 lymphocyte subset
Mean Minimum Maximum
All CD8 lymphocytes 7.1xl06 l.OxlO6 1.6xl07
CD8brightCD4dim lymphocytes 7xl04 8xl03 3xl05
CD8briBh,CD4" lymphocytes 5.6x10s 1.0x10s 1.4xl07
Naive CD8 lymphocytes l.lxlO6 3xl05 3xl06
Antigen experienced CD8 lymphocytes 6.8xl06 l.lxlO6 1.4xl07
Memory CD8 lymphocytes l.lxlO6 1.7x10s 2.4x106
Effector CD8 lymphocytes l.OxlO6 6xl04 l.SxlO6
Table 4-2. CD8 lymphocyte subset yield. The mean and range of the number of cells isolated in
each CD8 lymphocyte subset across the 20 samples from subjects with chronic HIV infection.
4.3.1.2 Purity of isolated CD8 lymphocyte subsets.
Assessment of the level of contamination ofCD8 lymphocyte subsets with other
potentially HIV infected cells was vital for calculation of the CD8 lymphocyte
proviral load. Thus, isolated CD8 lymphocyte subpopulations were assessed by flow
cytometry to determine the level of contamination with: a) CD4 lymphocytes, b) any
non-CD8 lymphocyte cell, and c) CD8 lymphocytes of the incorrect subtype. The
number of cells acquired in each purity assessment varied according to the number of
cells available (Table 4-). Unless otherwise stated the values given are ungated, ie.
all events acquired by the flow cytometer are included in the analysis. This is the
most stringent measure of purity. For some indices 'gated' values are given in which
events likely to represent non-cellular events such as bubbles, or cell debris are
excluded from the analysis (Figure 4-1). While less stringent, these values are likely
to more closely represent the actual purity of the isolated cells.
a) CD4 lymphocyte contamination, defined as the percentage of the total analysed
events that displayed a CD8P-CD4+ phenotype, was determined for all CD8
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lymphocyte populations where cell numbers allowed, and was found to be low with
an overall median level of 0.10% (Table 4-). Gated and ungated data are provided
for group 2 samples. For group 1 samples only gated data are provided, this is due to
the high number of non-cellular events which displayed the same fluorescence as
CD8J3-CD4+ cells (Figure 4-1). The ungated values for group 2 and gated values for
group 1 were then used to calculate the 'best estimate' proviral load attributable to
















































Figure 4-1. Background events influencing CD8bngh'CD4dim purity assessment. (A) Background
events acquired on running FACS acquisition fluid for 1 minute. The fsc against ssc plot shows that
few background events fall within the lymphocyte gate. The PE against CyChrome plot shows that
17.14% ofbackground events mimic CD4 lymphocytes (CyChrome+PE"). (B) CD8bn6htCD4d,m
lymphocytes purity check (data from sample 14). i) ungated analysis: the CD4+CD8P" quadrant
includes both true contaminating CD4 lymphocytes and background events, giving a falsely high level
of CD4 lymphocyte contamination, ii) gated on live lymphocytyes (Rl): a more accurate level of CD4
lymphocyte contamination is apparent. (This subject shows the highest level ofCD4 lymphocyte
contamination seen in this study, accounting for 43 proviral copies per million CD8br'BhtCD4'i"11
lymphocytes). Almost half the isolated CD8br'shtCD4dim population appears to have a CD4-ve
phenotype, this is due to fluorochrome bleaching during the sorting process.
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b) As HIV infection of CD4 lymphocytes is known to down-regulate surface CD4
expression, it could be argued that defining CD4 lymphocytes as cells expressing
CD4 could underestimate the true level of CD4 lymphocyte contamination. To allow
for this possibility, and provide a 'worst case' measure of contamination, the overall
level of contamination of CD8 lymphocyte populations with non-CD8 lymphocytes
was measured. This value, defined as the percentage of total analysed events with a
CD8P-ve phenotype, was also found to be low, with an overall median for all CD8
lymphocyte subsets of 0.97% (0.34% gated) (Table 4-) . Gates defining CD8P
expression were set using the presort sample (Figure 4-2).
c) Finally, to assess whether HIV provirus found in less commonly infected CD8
lymphocyte subsets could be attributed to contamination with cells from the more
commonly infected subset, the level of contamination of CD8+CD4- lymphocytes
with CD8b"ghtCD4dim lymphocytes and of nai've CD8 lymphocytes with antigen
experienced CD8 lymphocytes was estimated. For the purpose of this assessment all
cells with low expression of either CD45RA or CD27 were defined as antigen
experienced, with gates set on the pre-sort sample (Figure 4-2). Levels of
contamination were higher than noted for CD4 lymphocyte contamination (Table 4-),
and the implication of these results in the interpretation of provirus observed in
CD8+CD4- lymphocytes and naive CD8 lymphocytes are discussed in section
4.4.1.1.
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A) Pre-sort sample (PBMCs enriched for CD8 expression).
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Figure 4-2. Method of gating for assessment of contamination of naive CD8 lymphocytes with
non-CD8 lymphocytes and experienced CD8 lymphocytes. A) Gates for isolation of naive CD8
lymphocytes were set using the pre-sort sample, typical positions are shown. B) Gates for purity
assessment: i) A wide fsc ssc gate was used to generate gated and ungated purity data so as to include
all events representing lymphocytes in the gated population, ii) The gate R2 set on the presort sample
was used to assess contamination with CD8[3-ve cells, iii) The gate R3 used to define naive cells was
not appropriate for purity assessment due to fluorochrome bleaching, therefore contaminating CD8
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Gated Gated No gate Gated No gate Gated No gate Gated
<5x10'" 0.9 0.07
<9x10 0.42 0.17
0.1 0.56 1.59 0.6 4.87 1.21
0.01 na 1.52 0.16 na na
11 0.17 0.20 0.9 0.18 5.02 0.2
13 0.01 na 1.24 0.64 na 1.44 1.06
14 0.13 2.44 0.76 0.52 7.42 2.99 0.37 0.24
15 0.3 na 1.52 0.9 na na
19B <0.11 <0.74 1.15 0.69 0.11 0.11
20 (PHI) 0.3 na na na 0.9
Mean 1.1 0.4 4.3 1.1 0.6 0.5
Median 0.1 0.3 1.15 0.52 4.94 0.7 0.4 0.2
Table 4-3A. The purity of CD8 lymphocyte subsets, group 1 samples. Purity was assessed by flow
cytometry on a sample taken from the isolated population. CD4 lymphocytes were defined as all
CD4+CD8- events. Non-CD8 lymphocytes were defined as all CD8P-ve events. Gated data was
restricted to events with forward and side light scatter properties of live cells, a: data only given for
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Table 4-3B. The purity of CD8 lymphocyte subsets, group 2 samples. Purity was assessed by flow
cytometry on a sample taken from the isolated population. CD4 lymphocytes were defined as all
CD4+CD8- events. Non-CD8 lymphocytes were defined as all CD8P-ve events. Gated data was
restricted to events with forward and side light scatter properties of live cells, na = not available.
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4.3.2 HIVproviral load in CD8 lymphocytes.
The HIV proviral load in each lymphocyte population isolated was determined by
DNA extraction followed by quantative PCR for HIV LTR (method given in section
2.5). A 'best estimate' HIV proviral load attributable to each CD8 lymphocyte
population was determined by subtracting the provirus attributable to measured CD4
lymphocyte contamination (2.5.4). Ungated values of CD4 lymphocyte
contamination were used for group 2 samples and gated values for group 1 samples
(section 4.3.1.2). In addition a 'worst case scenario' HIV proviral load was
calculated by assuming that all non-CD8 lymphocytes in the isolated populations had
the same proviral load as CD4 lymphocytes. Gated values for non-CD8 lymphocyte
contamination were used.
4.3.2.1 HIV proviral loads in CD8 lymphocytes in chronic HIV infection
HIV infection of CD8 lymphocytes was demonstrated in 16 out of 19 subjects using
the 'best estimate' method (Table 4-4, Figure 4-3). In 12 of these 16 subjects the
HIV proviral load attributable to CD8 lymphocytes was more than ten times that
attributable to contaminating CD4 lymphocytes (Figure 4-4). The level of infection
was low (median 7 HIV DNA copies per million CD8 lymphocytes, range
undetectable - 218; Figure 4-3), and was significantly lower than that in CD4
lymphocytes from the same subjects (median 1176 HIV DNA copies / million cells,
range 8 to 12756, P<0.001, Wilcoxon Signed Rank Test; Figure 4-3A). No
significant correlation was found between HIV DNA loads in CD4 and CD8
lymphocytes, (Spearmans correlation coefficient 0.3, p>0.1).
Using the 'worst case scenario' contamination data HIV infection ofCD8
lymphocytes was demonstrated in 13 out of 19 subjects, with 7 of these having over
10 times more provirus attributable to CD8 lymphocytes than contaminating cells
(Table 4-4).
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Figure 4-3. Distribution of HIV proviral loads in lymphocyte subsets. 'Best estimate'
attributable proviral loads are shown. Black diamonds indicate detectable proviral load. Grey
diamonds indicate samples where no virus was detected, (the value given is half the lower limit of
detection which varies with the number of cells available for analysis). P values shown are calculated
using the Wilcoxon Signed Ranks Test. (A) Proviral loads for CD4 and CD8 lymphocytes from all
samples (group A and group B). Subject 19 was sampled twice and data points from this subject are
indicated with *. (B) Proviral loads for CD8pbnghlCD4d""and CD8p+CD4~ lymphocytes. (C) Proviral


















































































Figure 4-4. Ratio of HIV proviral load in CD8 lymphocyte populations to that attributable to
CD4 lymphocyte contamination. Where the ratio is greater than 10 it is unlikely that the viral load
attributed to CD8 lymphocytes could be an artefact of inaccuracies in the measurement of cell
population purity or proviral load. Samples where no provirus attributed to CD8 lymhocytes were
detected are given a ratio of 1. a) Where no purity data available CD4 lymphocyte contamination
assumed to be the same as for CD8bnBhtCD4" population from the same sort; b) where no purity data
available CD4 lymphocyte contamination assumed to be 2.44%, the worst level of contamination
measured in the series of test samples.
4.3.2.2 Correlation of HIV infection of CD8 lymphocytes with disease
progression.
There was an inverse correlation between CD4 lymphocyte count and 'best estimate'
CD8 lymphocyte HIV DNA load (Spearmans correlation coefficient R=-0.78,
p<0.001; Figure 4-5A), indicating a progressive increase in prevalence of infected
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CD8 lymphocytes with advancing disease. In subjects with advanced disease the
higher frequency of infected CD8 lymphocytes together with dwindling CD4
lymphocyte numbers, increased the contribution ofCD8 lymphocytes to the total
circulating HIV DNA load. Thus, in the subjects with the lowest CD4 lymphocyte
counts, CD8 lymphocytes contributed over 25% of the total circulating lymphocyte
HIV DNA load (Figure 4-5). In contrast the CD8 lymphocytes of long term non-
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Figure 4-5. Increased HIV infection of CD8 lymphocytes with disease progression. (A) The
correlation between CD8 lymphocyte HIV DNA load and CD4 count, rs = Spearman's Rank
Correlation Coefficient. Cases with undetectable proviral load were given a value of half the lower
limit of detection. (B) The relative contribution of CD4 and CD8 lymphocytes to overall circulating
HIV DNA load was calculated from CD4 and CD8 lymphocyte HIV DNA loads and CD4 and CD8
lymphocyte counts. Undetectable viral loads were given a value of zero. Long term non-progressors
shown in bold.
4.3.2.3 Mechanism ofHIV infection of CD8 lymphocytes in vivo.
In order to investigate the relative contributions of intrathymic infection versus
infection of activated cells in the generation of circulating HIV infected CD8
lymphocytes, HIV DNA was quantified in subsets of CD8 lymphocytes. CD8
lymphocytes expressing CD4 (CD8bnghtCD4dim) were found to be infected in 7 out of
9 subjects (78%) with relatively high levels of infection (median 865 DNA
copies/million cells, range undetectable - 3951; Table 4-4A, Figure 4-3),
approaching those in the CD4 lymphocytes of the same 9 subjects (Figure 4-6A).
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These high HIV proviral loads in the CD8brightCD4dim lymphocyte populations were
all greater than ten times that attributable to CD4 lymphocytes (Table 4-4A, Figure
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Figure 4-6. HIV DNA loads for each subject. Best estimate HIV DNA loads for CD4 lymphocytes
and CD8 lymphocyte subsets for each subject (subjects ordered by ascending CD4 lymphocyte count)
are given: (A) group 1 samples, (B) group 2 samples. Error bars indicate standard error (see
methods), they are absent from samples where insufficient cells were available. * indicates samples
where no virus was detected, the value given is half the lower limit of detection.
In contrast only three of nine subjects (33%) showed infection ofCD8+CD4~
lymphocytes. The level of infection was low at 7, 5 and 2 HIV DNA copies/million
cells, dropping to 4, 2 and 2 HIV DNA copies/million cells when contamination from
CD8bnghtCD4dim lymphocytes was taken into account. In all cases the proviral load
attributable to CD8+CD4~ lymphocytes was less than ten times that attributable to
CD4 contamination (Figure 4-4) and in two cases it became undetectable when
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attributable proviral load was calculated using the 'worst case scenario' approach.
The greater HIV DNA load in CD8br,ghtCD4d'm lymphocytes as compared to
CD8(3+CD4~ lymphocytes was significant (Wilcoxon Signed Ranks Test: p<0.01
where undetectable values were assigned half the lower limit of detection, and
p<0.05 where undetectable values were assigned zero).
Where CD8 lymphocyte subsets were divided on the basis of differentiation
phenotype infection levels were generally quite low (range <3-110 HIV DNA
copies/million cells, Table 4-4B. HIV DNA was detected in seven of ten antigen
experienced samples compared to three out of ten antigen naive samples, but there
was no significant difference in HIV DNA load (Wilcoxon Signed Ranks Test,
p=0.7, Figure 4-3C). The proviral load attributable to antigen experienced CD8
lymphocytes subsets was greater than ten times that attributable to contaminating
CD4 lymphocytes in three of the seven subjects (Figure 4-4), and remained
detectable in five subjects on use of the 'worst case scenario' method (Table 4-4B).
In contrast, only one naive CD8 lymphocyte sample had an attributable proviral load
greater than ten times that expected from CD4 lymphocyte plus experienced CD8
lymphocyte contamination, and, in that sample, provirus became undetectable on
calculation of attributable proviral load using the 'worst case scenario' method.
Further subdivision of the antigen experienced cells into memory or effector subsets
was performed in four of the subjects with detectable HIV DNA. Of these, three
demonstrated infection in the memory subset and one in the effector subset (Figure
4-3C), again with no significant difference in viral DNA load.
4.3.2.4 HIV infection of CD8 lymphocytes in primary HIV infection.
In the subject with PHI, the HIV DNA load in CD4 lymphocytes was 697 (SE 225)
HIV DNA copies per million CD4 lymphocytes, a level in keeping with results from
a previous series of 16 subjects with PHI (Karlsson et al., 2001). The level of
infection of CD8bnghtCD4dirn lymphocytes was similar to that of CD4 lymphocytes at
523 (SE 160) HIV DNA copies per million CD8brightCD4dim lymphocytes. No HIV










Figure 4-7. HIV DNA load in primary HIV infection. HIV DNA load attributable to CD4
lymphocytes, CD8bnBhtCD4dlrn lymphocytes and CD8+CD4- lymphocytes in a single subject with
primary HIV infection. * indicates undetectable viral DNA, and half the lower limit of detection is
given. Error bars show standard errors (see section 2.5.3).
4.4 Discussion
These results confirm that CD8 lymphocytes can be infected with HIV in subjects
with both primary and chronic HIV infection, and that frequency of infection rises
with disease progression. CD8bnghtCD4dim lymphocytes have a high HIV proviral
load similar to that found in CD4 lymphocytes, while CD8+CD4" lymphocytes have
either undetectable or very low levels of infection. HIV is more often detected in
antigen experienced than antigen nai've CD8 lymphocytes. The level of confidence
in these observations, and the interpretation of the distribution ofHIV provirus
between CD8 lymphocyte subsets are discussed here. Further consideration of the
implications of these results for HIV immunopathology are given in Chapter 6:.
4.4.1 Level of confidence in estimated HIV proviral loads in CD8 lymphocyte
populations.
Standard errors were calculated for the CD8 lymphocyte proviral loads (Table 4-),
but these simply refer to the error intrinsic to the calculation of target sequence copy
number from limiting dilution data, which is only the last step in the proviral load
estimation protocol. To assess the degree of confidence in the results presented two
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stages of the protocol must be considered: a) measurement of the purity of the CD8
lymphocyte populations, and b) quantification of the HIV LTR in the CD4 and CD 8
lymphocyte populations. As described in detail below, errors at either of these stages
could conceivably account for the provirus seen in CD8+CD4" and nai've CD8
lymphocyte populations, but not those seen in CD8bnghtCD4dim lymphocytes.
4 4.1.1 Purity.
The two step isolation protocol minimised CD4 lymphocyte contamination of the
CD8 lymphocyte populations, and measurement of the levels of CD4 lymphocyte
contamination allowed calculation of 'best estimate' proviral loads. The true level of
contamination ofCD8 lymphocyte populations with HIV infected cells could exceed
that measured through the following 6 mechanisms: i) Some CD4 lymphocytes may
fall within the CD4-ve quadrant on flow cytometry either due to downregulation of
CD4 secondary to HIV infection, or due to bleaching of the anti-CD4 conjugated
fluorochrome during the sorting procedure; ii) Some non-CD4 lymphocyte
contaminants such as monocytes and y5-T lymphocytes may carry HIV provirus; iii)
There may be contamination with HIV infected CD8 lymphocytes of a different
subtype; iv) Where gated data was used (ie for all CD8bnghtCD4dim and CD8+CD4~
lymphocyte populations), some CD4 lymphocytes may lie outside the 'live cell' gate
due to fragmentation during the sorting procedure; v) where the level of CD4
contamination could not be measured due to low cell numbers, the substitute level
used may have been inaccurate; vi) The CD4 lymphocytes contaminating the CD8
lymphocyte populations may be different from the general CD4 lymphcyte
population and therefore might have a higher HIV proviral load.
Before considering these potential influences in turn, it is worth noting that as the
proviral load in CD8b,,gbtCD4dim lymphocytes sometimes exceeded that of CD4
lymphocytes, it cannot be completely accounted for by any level of unselected CD4
lymphocyte contamination (ie. only mechanism (vi) can challenge the finding ofHIV
infection of CD8bnghtCD4dim lymphocytes). In addition, the lack of a correlation
between CD4 lymphocyte proviral load and CD8 lymphocyte proviral load argues
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against CD4 lymphocyte contamination being the source of virus attributed to CD8
lymphocytes.
i) and ii). To determine how robust the data were to the first two challenges, 'worst
case scenario' attributable proviral loads were calculated in which all non-CD8
lymphocytes were considered to carry as much HIV provirus as CD4 lymphocytes.
Using this method HIV provirus attributable to CD8 was observed in 6/9
CD8bngbtCD4dim populations, 0/9 CD8+CD4- populations, 5/10 experienced CD8
populations and 2/10 naive CD8 populations (Table 4-). To assess the contribution
of yS-T-lymphocytes and monocytes to the observed HIV provirus, proviral loads
were assessed in these cells in a subset of samples. HIV provirus was detected in y5-
T-lymphocyles in 1/10 subjects and in monocytes in 2/3 subjects, in all cases the
proviral load was less than 50 copies per million cells, considerably less than
observed in CD4 lymphocytes.
iii) Proviral load attributable to contaminating CD8bnghtCD4dim lymphocytes did not
completely account for the provirus observed in CD8+CD4~ lymphocyte populations,
but further decreased the already low proviral loads attributable to CD8+CD4"
lymphocytes. Similarly, proviral load attributable to contaminating experienced CD8
lymphocytes did not completely account for the provirus observed in naive
lymphocyte populations, though it did contribute sufficient to ensure that in all
samples, proviral load attributable to nai've CD8 lymphocytes was less than ten times
that attributed to contaminants.
iv) The use of gated purity data for CD8b"ghtCD4dim and CD8+CD4" lymphocyte
populations was necessary due to the high frequency of background events
mimicking CD4 lymphocyte contamination (Figure 4-1). While this does allow the
potential for contaminating cell fragments to be excluded from the purity
measurement, gated data has been used elsewhere (Brenchley et al., 2004a) and is
likely to provide the most accurate measurement. Reassurance that these events were
not contributing HIV DNA was provided by the lack of detectable provirus in
CD8+CD4" samples with high ungated levels CD4+CD8- contamination, ie. In
samples 6 and 7 (which had high ungated levels CD4+CD8- contamination, Table
4-), if all CD4+CD8- events lying outside the live cell gate were true CD4
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lymphocyte contaminants, then HIV proviral loads of 12 and 155 would have been
detected. When tested, these populations revealed undetectable proviral loads with
the lower limit of detection at 2 and 41 respectively.
v) CD4 lymphocyte contamination was not measured in 5/9 samples of
CD8bnghtCD4dim lymphocytes, 2/10 naive and 3/10 experienced CD8 lymphocytes.
Of these 4/5 CD8bnshtCD4dim lymphocyte populations, neither of the naive samples
and 2 of the 3 experienced samples had HIV provirus attributable to CD8
lymphocytes. The substitute level of contamination used to estimate proviral loads in
the two experienced samples were 0.2% for sample 9 (as the 75th percentile of the
contamination seen in all cell subsets) and 0.41% for sample 10 (as a level equivalent
to that of the naive population was assumed). Contamination levels of 0.9% and
1.8% respectively would have been required to negate attributable CD8 lymphocyte
provirus, compared to a median level of 0.03% and a maximum level of 0.79%
observed for this cell subset (Table 4-3B).
The substitute level used for estimation of attributable proviral load in the
CD8bnghtCD4dim lymphocytes was taken to be equivalent to that of the CD8+CD4-
lymphocytes from the same subjects. While this was considered to be the best
estimate, it can be seen that on average, the level of contamination of
CD8bllghtCD4d,m lymphocytes exceeded that of CD8+CD4- lymphocytes (Table
4-3A). Recalculation of the attributable proviral load for these four samples using
the worst observed level of contamination (ie 2.44%) negates the observation of
provirus attributable to CD8bngbtCD4dim lymphocytes in one case (sample 13), but in
all other samples the provirus observed in the CD8b"ghtCD4dim lymphocytes remains
greater than ten times that attributable to CD4 lymphocyte contamination (Figure
4-4).
vi) Selective contamination of CD8 populations with CD4 lymphocytes carrying a
higher HIV proviral load than the general CD4 lymphocyte population could have a
marked effect on the level ofprovirus attributable to CD4 lymphocyte
contamination. Such selective contamination could conceivably occur through
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contamination with dead or activated CD4 lymphocytes. Selection of dead cells was
avoided by staining with a dead cell marker and sorting only live cells. Selective
contamination with activated CD4 lymphocytes can be envisaged due to the greater
adhesive properties of activated cells which could make them more susceptible either
to non-specific staining or to formation of doublets with CD8 lymphocytes.
Arguments against this possibility include the results of the mixing experiments
(section 3.1.2.2), which show no doublet generation, and the use of isotype controls
to assess levels ofnon-specific binding.
4.4.1.2 Quantification ofHIV proviral load in lymphocyte populations.
The development and monitoring of the real-time PCR for quantification ofHIV
LTR is covered in section 3.3.1, demonstrating accuracy to within 2.0 times the true
value in serial dilutions of standard samples, and good correlation between limiting
dilution and real-time results (Figure 3-14). The spectrophotometer used to measue
DNA concentration was found to consistently read to an accuracy ofwithin 0.8 to 1.2
times the true value on a standard sample. Some of the DNA extracted from samples
had 260:280 ratios suggesting a degree of protein contamination, which could have
lead to an overestimation of the amount ofDNA in the sample. This tended to occur
more for samples with very few cells, which were generally the CD8 lymphocyte
subsets, and would lead to an underestimation of the proviral load within the sample.
Overall it is therefore reasonable to assume that where the provirus measured in the
CD8 lymphocyte population is more than 10 times that attributable to CD4
lymphocyte contamination, inaccuracies in the measurement ofproviral load are
unlikely to account for the CD8 lymphocyte provirus. Thus, this mechanism is
unlikely to account for the provirus found in CD8bnghtCD4dim or experienced CD8
lymphocytes (Figure 4-4), though it could conceivably account for most of the virus
attributed to CD8+CD4- and naive subsets.
4.4.1.3 Unintegrated HIV DNA
As described in the introduction (section 1.3.3), following reverse transcription HIV
DNA can either integrate into the host cell genome or form circular DNA structures.
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These DNA rings can be detected by PCR methods using primers binding wholly
within the LTR sequence, and therefore can be detected by the limiting dilution assay
used here. However, the outer anti-sense primer for the real-time PCR assay bind
within the gag gene, and therefore would not amplify DNA from LTR circles. The
good correlation between limiting dilution and real-time PCR estimates of proviral
load (Figure 3-14) indicates that unintegrated DNA circles do not make up a
significant proportion of the LTR detected. A similar finding was made previously
by comparing results of limiting dilution proviral load estimates using primers within
the LTR, versus primers spanning the LTR-gag junction(Imlach et al., 2001).
4.4.2 Extent of CD8 lymphocyte infection.
In keeping with previous reports, the overall frequency ofHIV infection of CD8
lymphocytes was very low (Livingstone et al., 1996; McBreen et al., 2001), and was
lower than that reported for lung derived CD8 lymphocytes (Semenzato et al., 1995;
Semenzato et al., 1998). The inverse correlation between CD8 lymphocyte proviral
load and CD4 lymphocyte count suggests increasing infection of CD8 lymphocytes
with disease progression. This could be caused by increased viraemia, increased
lymphocyte activation (Eggena et al., 2005), or the generation of variants more
suited to infection of CD8 lymphocytes (Zerhouni et al., 2004).
4.4.3 Route of CD8 lymphocyte infection.
CD4 dependent HIV infection of CD8 lymphocytes has been demonstrated during
intrathymic development (De Rossi et al., 1990; Brooks et al., 2001) and following
activation ofmature lymphocytes (Flamand et al., 1998; Kitchen et al., 1998; Zhang
et al., 2001; Imlach et al., 2001). Given that CD8 lymphocyte precursors would be
expected to lose CD4 before leaving the thymus, our observation of very low or
undetectable viral loads in CD8(3+CD4~ lymphocytes implies that this route
contributes little if anything to the circulating CD8 lymphocyte proviral load.
Similarly, export of intrathymically infected cells is thought not to be the source of
HIV infected naive CD4 lymphocytes (Brenchley et al., 2004a). In contrast, the
higher proviral loads observed in the CD8b"glltCD4dMT1 population provides
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convincing evidence of infection of this subset, suggesting that infection of CD8
lymphocytes occurs following antigen specific activation.
This distribution ofHIV provirus is in keeping with previous results in which
CD8+CD4+ cells isolated by immunomagnetic methods were found to contribute a
higher proportion to the overall proviral load than their CD4 -ve counterparts
(Imlach et al., 2001). Similarly in a recent paper, Brenchley et al., (2004a), observed
5 to 100 fold more proviral copies in CD8+CD4dul1 lymphocytes than in CD8
lymphocytes lacking CD4 expression. The results presented are not consistent with
previous reports of significant infection ofblood derived CD8 lymphocyte
populations isolated by removal of all CD4 expressing cells (McBreen et al., 2001).
Lung derived CDS lymphocytes purified by removal of CD4 expressing cells (with
CD4 lymphocyte contamination levels of 0.01%), have also demonstrated significant
levels of infection (Semenzato et al., 1995; Semenzato et al., 1998). While these
cells were isolated from a different tissue compartment, the results do suggest that
CD8+CD4- lymphocytes can be infected, unlike the results presented here. The
reason for this discrepancy is unclear, but it is possible that the need to fix the cells
reduced the sensitivity of the protocol used here in comparison to those used by
McBreen and Semenzato. This does not challenge the main finding that the
frequency of infection is clearly much greater in the CD8bnghtCD4dim than the
CD8brightCD4" population.
The distribution of provirus between CD8 lymphocytes at sequential stages of
differentiation can also provide information regarding the likely route of infection.
The use ofphenotypic markers to define differentiation stages of CD8 lymphocytes
has been a topic ofmuch debate (Hamann et al., 1999b), and is discussed in section
3.1.1. The relationship between differentiation markers and memory versus effector
function remains unclear (Appay et al., 2002a), and while the labels 'memory' and
'effector' are retained for the CD27+CD45RA~ and CD27~CD45RA+ subsets
respectively, a degree of functional overlap is likely.
Given that the results provide good evidence for HIV provirus in CD8bnghtCD4d,m but
not CD8+CD4~ lymphocytes, and the hypothesis that CD8bllghtCD4dim lymphocytes
are generated through antigen specific activation, one would expect HIV provirus to
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be detectable in antigen experienced CD8 lymphocytes but not in the antigen naive
subset. Interestingly, although provirus was more frequently detected in antigen
experienced populations, three out of eleven subjects also demonstrated provirus in
the nai've subset. While the evidence for infection of these naive subsets was not
particularly strong (being either less than ten times that expected from contaminants,
or lost on calculation of'worst case scenario' contamination, section4.4.1), it does
warrant consideration. It is possible that the observed HIV infected naive CD8
lymphocytes could be cells early in the priming process that have upregulated CD4
but have not yet lost their naive markers, or could represent naive CD8 lymphocytes
undergoing regenerative proliferation. Alternatively they could be non-activated CD8
lymphocytes which have either been infected within the thymus or through a CD4
independent route. These issues are further investigated in chapter 5.
The lack of correlation between CD4 lymphocyte proviral load and CD8 lymphocyte
proviral load suggests that, although we propose that HIV enters both cells via the
CD4 receptor, different factors influence the frequency of this event in the two cell
types. The inverse correlation between CD8 lymphocyte proviral load and CD4
lymphocyte count indicates that disease progression may be one factor that favours
CD8 lymphocyte infection. Teasing out the relative importance of the many other
host, viral and therapeutic factors that are likely to influence CD8 lymphocyte
infection would be ofmajor value in future studies.
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Chapter 5: Generation and differentiation of
CD8bnghtCD4d!m lymphocytes in vivo.
5.1 Introduction
Given that CD8br'shtCD4dim lymphocytes are targets for HIV infection, a clear
understanding of their natural history is important. Current knowledge is derived
from analysis of CD8br,ghtCD4dim lymphocytes generated in vitro (Flamand et al.,
1998; Kitchen et al., 1998; Laux et al., 2000; Sullivan et al., 2001; Kitchen et al.,
2002; Zloza et al., 2002), from investigation of CD8+CD4+ lymphocytes circulating
in vivo (Scott et al., 1983; Blue et al., 1985; Matsui et al., 1989; Sala et al., 1993;
Ortolani et al., 1993; Macchi et al., 1993; Tonutti et al., 1994; Prince et al., 1994;
Weiss et al., 1998; Mizuki et al., 1998; Bagot et al., 1998; Nascimbeni et al., 2004),
and from observations of similar cells in animals including mice, chickens, swine
and monkeys (Zuckermann & Husmann, 1996; Ober et al., 1998; Nam et al., 2000;
Hernandez et al., 2001; Nascimbeni et al., 2004).
As described in section 1.5.3, a number of investigators have now shown that
activation ofCD8 lymphocytes in vitro, results in the upregulation ofCD4 on
between 20 and 80% of cells, with response mediated through T cell receptor (TCR)
binding (Flamand et al., 1998). Nai've CD8 lymphocytes were the most responsive
(Kitchen et al., 1998), and upregulated CD4 in response to mitogens such as
staphylococcal enterotoxin B (SEB), to co-ligation with anti-CD3 and anti-CD28
monoclonal antibodies (but not anti-CD3 alone) and to co-culture with allogenic
dendritic cells.
When compared to non-responding (CD8+CD4") lymphocytes, a greater proportion
of CD8bllghtCD4dim lymphocytes expressed activation markers such as CD25, CD38
and CD95, and over 90% had the antigen experienced CD45RO+ phenotype
(Flamand et al., 1998; Sullivan et al., 2001). The upregulation of CD4 appeared to
be temporary reaching a peak around day six post stimulation, but although the
proportion of CD8 lymphocytes expressing CD4 dropped after this peak, it had not
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reached baseline by day 27, the longest published period of observation to date
(Flamand et al., 1998). It is not known whether the decrease in proportion of cells
expressing CD4 over time was due to preferential death of cells expressing CD4 or
due to downregulation of CD4 expression.
The presence ofCD8+CD4+ lymphocytes in the human circulation in vivo was first
noted in 1985 (Blue et al., 1985). Subsequently expansions ofCD8+CD4+
lymphocytes have been reported associated with viral infections (Ortolani et al.,
1993; Weiss et al., 1998), with autoimmune disease (Scott et al., 1983; Matsui et al.,
1989), with malignancy (Mizuki et al., 1998; Bagot et al., 1998)and in healthy
subjects (Sala et al., 1993; Tonutti et al., 1994; Prince et al., 1994). A number of
these reports distinguished between CD4bllghtCD8dim cells (which expressed a CDS
molecule composed of two a subunits and appeared to be ofCD4 lymphocyte
lineage) (Tonutti et al., 1994; Suni et al., 2001), and CD8brightCD4dim cells (which
expressed a CD8 molecule composed of an a and a (3 subunit and appeared to be of
CD8 lymphocyte lineage) (Tonutti et al., 1994). Ortolani et al., (1993), noted that in
a series of 51 subjects with expanded CD8+CD4+ populations, expansion of the
CD8bllghtCD4dim lymphocyte population occurred in 13 subjects all ofwhom had
acute EBV or CMV infection, while expansion ofCD4b"ghtCD8d'm lymphocytes was
more common and non-specific, occurring in healthy subjects and those with a range
of pathologies. In keeping with the in vitro data, the CD8bnghtCD4dim lymphocytes in
the expanded populations had antigen experienced activated phenotypes, with over
90% expressing the markers CD45RO and CD38. These expanded populations were
temporary, having disappeared within 2 months of recovery from the acute illness
(Ortolani et al., 1993). While both Blue and Ortlani observed a small population of
CD8+CD4+ lymphocytes in healthy individuals they were not further characterised.
More recently Nascimbeni et al., (2004), assessed phenotype, antigen specificity and
cytokine secretion profiles of CD8+CD4+ lymphocytes in healthy subjects and
subjects with HCV infection. They confirmed that these cells are generally antigen
experienced but did not find an increased activation profile. Their findings are
considered in more detail in section 5.4
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Together, the in vitro and in vivo evidence suggests that naive, and, to a lesser, extent
experienced CD8 lymphocytes upregulate CD4 after antigen specific, mitogen or
alloantigen induced activation to generate a temporary CD8b"ghtCD4dim population.
The relationship between this temporary population and the CD8b"shtCD4dim
lymphocytes circulating in healthy individuals and individuals with chronic infection
remains unclear.
In this chapter two aspects of the natural history of CD4 expression on CD8
lymphocytes are addressed. First the differentiation and activation phenotype of
circulating CD8bngbtCD4dim lymphocytes in healthy controls was determined. The
specific question of interest was whether the differentiation and activation phenotype
of CD8bllghtCD4dim lymphocytes circulating in healthy subjects supports the
hypothesis of generation through temporary CD4 upregulation following antigen
specific activation. Secondly the effect ofHIV infection on prevalence and
phenotype of CD8b"sbtCD4dim lymphocytes was assessed
The differentiation phenotype of circulating CD8bnghtCD4dim lymphocytes in healthy
subjects was determined ex vivo using the markers CD45RA and CD27. Use of these
markers is discussed in section 3.1.1. Activation was assessed in terms of cell size
and expression of CD69 and CD38. Upon activation, small resting lymphocytes
transform into larger blasts (Robbins, 1964), and an increase in cell size has been
shown to be a sensitive marker of activation (Teague et al., 1993). Blue et al.,
(1985), demonstrated that the CD8+CD4+ phenotype was associated with an
increase in cell size in mitogen stimulated T lymphocyte cultures. They also noted a
marked increase in CD4 and CD8 coexpression on large as compared to small
lymphocytes circulating in peripheral blood, but the proportion of circulating
CD8+CD4+ lymphocytes that were large was not given, and no distinction was made
between CD8brightCD4dim and CD4brightCD8dim lymphocytes.
The activation marker CD69 is a signalling molecule and is one of the earliest
surface markers to appear on activated T lymphocytes (Lopez-Cabrera et al., 1993).
Expression begins approximately 8 hours after stimulation with alloantigen, reaches
a peak within 16-24 hours and then, in the absence of ongoing stimulation,
expression is rapidly lost (Craston et al., 1997). CD69 was expressed on between 12
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and 50% of CD8bnghtCD4dim lymphocytes generated by stimulation with
staphylococcal enterotoxin B (Flamand et al., 1998; Sullivan et al., 2001).
CD38 is a transmembrane glycoprotein with enzymatic, adhesion and signalling
functions. It is upregulated on activated CD8 lymphocytes, is expressed on over
95% of CD8bnshtCD4d'm lymphocytes generated in vitro (Sullivan et al., 2001), and
also on the vast majority of CD8b"shtCD4dim lymphocytes found in association with
acute viral infections (Ortolani et al., 1993). The expression of CD38 is much less
transient than that ofCD69, with approximately 2/3 of CD8 lymphocytes specific for
a lytic EBV antigen remaining CD38+ a year after acute infectious mononucleosis
(Bharadwaj et al., 2001). In HIV infection CD38 expression is a poor prognostic
marker and is associated with residual viral turnover in subjects on combination
antiviral therapy (Giorgi et al., 1993; Liu et al., 1997; Benito et al., 2004).
There are a number ofmechanisms by which HIV could influence the
CD8bnghtCD4dim lymphocyte population. First, given that these cells are generated on
activation, chronic presence ofHIV antigen and the persistent immune activation
characteristic ofHIV infection, could lead to an expanded CD8bnghtCD4dirn
lymphocyte population. Alternatively, HIV infection of CD8bnghtCD4dim
lymphocytes could, if cytopathic, decrease the lifespan of these cells leading to an
overall diminution of the population size. Finally, HIV infection of the
CD8b"gbtCD4d,m lymphocytes could have more subtle effects such as interference
with differentiation, or downregulation of CD4 expression (Kitchen et al., 2004). To
assess whether there is any evidence supportive of these potential effects, the
prevalence and phenotype of CD8bnghtCD4d,m lymphocytes was determined in 16
HIV infected subjects and compared with healthy controls.
5.2 Materials and Methods
5.2.1 Subjects and samples.
Blood samples from eight healthy controls, were used to assess the activation and
differentiation phenotype of circulating CD8bnghtCD4dirn lymphocytes. The effect of
HIV infection on these parameters was assessed using samples from 17 HIV infected
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subjects, 16 samples were used to assess differentiation and four to assess activation,
(Table 5-1). In addition the prevalence of CD8bnghtCD4dim lymphocytes was assessed
in one subject with primary HIV infection. All but one of the HIV infected subjects
also donated blood for the experiments described in chapter 4, and details of the
recruitment process are given in section 4.2. The healthy controls were recruited
from the staffof the Laboratory ofClinical and Molecular Virology, Edinburgh, and
were age matched with the HIV+ve subjects: mean age of controls = 36, mean age of
HIV infected subjects used to assess differentiation phenotype = 40, (independent
samples T test: p = 0.3), mean age ofHIV infected subjects used to assess activation
phenotype = 38 (independent samples T test: p = 0.4).
The prevalence, activation and differentiation phenotype of CD8bnghtCD4dim
lymphocytes was obtained for healthy controls and eleven of the HIV infected
subjects by flow cytometry of appropriately stained PBMCs (Table 5-1). For the
remaining six HIV infected subjects insufficient cells were available to use a PBMC
aliquot. In these subjects PBMCs immunomagnetically enriched for CD8
lymphocytes were stained with differentiation markers for cell sorting (section 2.2),
prevalence and differentiation phenotype of CD8brightCD4dim lymphocytes was then
assessed on the sorted CD8 lymphocytes. The method for isolation of PBMCs is
























24 none PBMC yes yes
2 1 48 none PBMC yes yes
3 1 27 conjunctivitis PBMC yes yes
4 1 50 none PBMC yes
5 1 34 none PBMC yes
6 1 38 none PBMC yes yes
7 1 33 gastroenteritis PBMC yes
8 1 35 none PBMC yes
1
2
2 75,000 47 Pulmonarytuberculosis PBMC
2
2
17 750,000 29 Pyrexia ofunknown origin
PBMC









6 2 117 75,000 31 Oral candidiasis PBMC
7 2 123 330,000 32 None CD8 lymphocytes
9 2 328 <50 43 None PBMC
10 2 334 <50 34 None PBMC yes
11 2 339 14,900 37 None CD8 lymphocytes
12 2 364 304 37 None PBMC
13 2 385 153 40 None PBMC yes
14 2 393 403 40 Cellulitis PBMC







17 2 531 <50 38 None CD8 lymphocytes
18 2 647 13400 41 None PBMC yes yesb
21 2 501 <50 36 None yes
20c 2 630 3,500,500 34 PHI
Table 5-1. Subject Characteristics, (a) Group 1 are healthy controls, group 2 are HIV infected
subjects, (b) PBMCs stained with monoclonal antibodies against CD69, CD71 and HLAII. (c) This




5.2.2.1 Preparation and staining of cells.
Flow cytometry was used to assess the prevalence, differentiation and activation
phenotype of CD8br,ghtCD4d,m and CD8bnghtCD4" lymphocyte. All cells were
prepared and stained for flow cytometry by the standard method (section 2.3). In






Fluorescent conjugated monoclonal antibodies
Differentiation
APC isotype3 CD27-FITC; CD8P-PE; CD45RA-cychrome; isotype-APC
Test sample CD27-FITC; CD8P-PE; CD45RA-cychrome; CD4-APC
Activation
Isotype APC CD27-FITC; CD8P-PE; CD45RA-cychrome; isotype-APC
Isotype FITC isotype-FITC; CD8P-PE; CD45RA-cychrome; CD4-APC
Test CD69 CD69-FITC; CD8p-PE; CD45RA-cychrome; CD4-APC
Test CD38 CD38-FITC; CD8P-PE; CD45RA-cychrome; CD4-APC






Test sample CD4-FITC, CD8beta-PE, CD3-cychrome.
Table 5-2. Antibodies used to stain cells for assessment ofCDS^'^'CD^"" lymphocytes. Of note
the monoclonal antibody used to detect CD8 expression was specific for the p subunit which is only
expressed on CD8 lymphocytes, (a) APC isotype was included for most PBMC samples, (b)
Prevelence of CD8bnBhtCD4tl'm lymphocytes in all other subjects was assessed on the sample stained
for differentiation phenotype.
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5.2.2.2 Defining CD8brightCD4dim lymphocytes.
The prevelance of CD8bnghtCD4dim lymphocytes, defined as the number of
CD8bnghtCD4dmi lymphocytes divided by the total number of CD8br,ght lymphocytes,
was assessed in 8 healthy controls and 16 HIV positive subjects. As insufficient cells
were available to allow staining of a separate PBMC sample for assessment of CD4
expression in all HIV infected subjects, the prevalence of CD8bnghtCD4dim
lymphocytes was assessed on sorted CD8 samples in six subjects. As these subsets
had been sorted using a standard fsc/ssc lymphocyte gate, this gate was also used in
all PBMC samples. Use of this lymphocyte gate excluded up to 65% (median 27%)
of live CD8b"gbtCD4dim lymphocytes which lay outside the gate due to increased cell
size. However, reanalysis of 8 control and 4 HIV infected samples using a wider gate
did not alter the conclusions reached, and therefore the standard lymphocyte gate was
retained.
As isotype APC samples were not available for all samples, CD8bllghtCD4d,rn
lymphocytes were gated by eye (Figure 5-1A). Where an APC isotype sample was
available this was used to check the position of the CD8bnghtCD4dim lymphocyte gate
which typically contained no events. The CD8bllghtCD4dirn gate was drawn to exclude
CD4b"ghtCD8dim events, which were prominent in a few subjects (Figure 5-1B). Due
to spectral overlap between APC and CyChrome appropriate compensation lead to
spreading of the CyChrome high events along the APC axis. This obscured up to






















































Figure 5-1. Defining CD8brightCD4 and CD8brightCD4dim lymphocytes. (A) The gating strategy
used to define CD8bnshtCD4" and CD8bnBhtCD4dlm lymphocytes is shown, (i) A standard lymphocyte
gate was used to ensure that data from PBMCs and sorted CD8 lymphocyte populations were
comparable, (ii) CD8bnBhtCD4" and CD8bnghtCD4dlm lymphocytes were then gated by eye. (iii) Where
an APC isotype stain was available this was used to check the position of the CD8brlghtCD4" and
CD8bnghtCD4d"" gates. (B) CD8dlmCD4br'sht lymphocytes were not included. (C) Spectral overlap
between CyChrome and APC meant that up to 50% of the CD8d""CD4br'8ht lymphocytes were not
assessed, dotplots of samples with (i), and without (ii) CD45RA cychrome staining are shown.
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5.2.2.3 Defining the differentiation phenotype of CD8b"ghtCD4d,m lymphocytes.
The differentiation phenotype of CD8bnghtCD4d,m lymphocytes was defined in terms
of CD27 and CD45RA expression (Figure 5-2).
Region % of gated events
R3 = 'Naive' 20%
R4 = 'Effector' 2%
R5 = 'Memory' 59%
Not R3 = antigen 80%
experienced
Region % of gated events
R3 ='Naive' 21%
R4 = 'Effector' 19%
R5 = 'Memory' 26%
Not R3 = antigen 79%
experienced
Figure 5-2. Defining differentiation phenotype of CD8bnghtCD4 and CD8bngh,CD4dim
lymphocytes. A standard lymphocyte gate was used to ensure that data from PBMCs and sorted
CD8 lymphocyte populations were comparable. CD8bnshtCD4" and CD8br,8htCD4dlm lymphocytes were
then gated by eye, and the proportion of these events expressing 'naive' (CD45RA+CD27high),
memory (CD45RA-CD27+) or 'effector' (CD45RA+CD27-) phenotypes was determined. Data from
one healthy control subject.
5.2.2.4 Defining activated lymphocytes in terms of cell size.
The size of CD8brigbtCD4dim and CD8bngbtCD4" lymphocytes was measured by flow
cytometry in terms of fsc. To ensure that the population ofCD8 lymphocytes with
increased fsc did not contain increased numbers of dead cells (which could lead to
non-specific staining and biased results) the fsc/ssc distribution of dead cells was
determined by tubulin staining in one healthy and three HIV infected subjects. This
demonstrated that in populations with increased ssc dead cells were common, while
in those lying within a standard lymphocyte gate (termed 'small lymphocytes') or
with increased fsc but only marginally increased ssc (termed Targe lymphocytes')




























Figure 5-3. Distribution of dead cells in terms of fsc and ssc properties. Dead cells, defined by
tubulin staining, were found to contribute a high proportion of cells with increased ssc, but contributed
less the 1% of cells within a standard lymphocyte gate (small lymphocytes) or within an increased fsc
gate (large lymphocytes).
To determine the relative proportions of'small' and 'large' cells in the CD8
lymphocyte populations of interest, a two step process was used. First the position of
the marker defining Targe lymphocytes' was determined using all CD8 lymphocytes
with ssc characteristics of live cells. This marker position was then used to assess
the relative number of'large' and 'small' lymphocytes in CD8bnghtCD4dim and
CD8bllghtCD4" lymphocyte populations. The position of gates for a typical sample
are shown in the results section (Figure 5-8).
To confirm that the 'large' CD8 lymphocytes defined as described above, were
indeed more activated than their 'small' counterparts their expression of the
activation markers CD69, CD38 and the differentiation marker CD45RO were
compared. As expected, the proportion of cells expressing either the activation
marker CD38 or the differentiation marker CD45RO, was consistantly higher in the
CD8 lymphocytes with increased fsc than in small CD8 lymphocytes. This was true
for both the CD8brightCD4dim and the CD8brightCD4- subsets. CD69 was expressed on a
very small proportion of cells, and while numbers were too low to allow accurate
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comparison of subsets, it was clear that the expression was not dramatically











Figure 5-4. Proportion of 'large' and 'small' CD8 lymphocytes expressing activation markers.
To confirm that the Targe' and 'small' populations do represent activated and quiescent populations
respectively, the expression of activation markers on large and small CD8br'BhtCD4dlm lymphocytes and
CD8brightCD4" were assessed in four subjects. Results for CD8brigh,CD4dim and CD8brightCD4-
lymphocytes are combined. Differences between groups was tested using Wilcoxon Sign Rank Test
for paired cases.
5.2.2.5 Defining activated lymphocytes in terms of expression of activation
Expression of the activation markers CD69 and CD38 and the differentiation marker
CD45RO was determined for CD8brightCD4dim and CD8brightCD4" lymphocytes using
appropriately stained PBMCs from four healthy controls (Table 5-2). For this
analysis lymphocytes with increased size were not excluded. Gating was performed
as follows: (i) all events with a high ssc (largely dead cells) or a low fsc (cell
fragments, and platelettes) were excluded; ii) CD8b"ghtCD4dim lymphocytes were
gated by eye; iii) the marker defining the positive population for CD69, CD38 and
CD45RO was set using the FITC isotype control, such that approximately 0.5% of
events fell inside the marker bounds (Figure 5-10). To calculate the fraction of the
markers.
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test cells that expressed the activation marker of interest, the fraction of FITC
positive events in the isotype sample was subtracted from the proportion of FITC
positive events in the test samples. In the case of CD69, where expression was very
low, this sometimes resulted in a proportion less than zero.
5.2.3 Statistical analysis.
The distribution of differentiation and activation phenotypes within the lymphocyte
subpopulations did not follow a normal distribution, and therefore results are
described in terms ofmedian values and ranges, and statistical analysis was
performed by non-parametric tests: Mann-Whitney Test for unlinked cases or the
Wilcoxon Signed Rank Test for paired cases.
5.3 Results
5.3.1 Prevalence of CD8(3br'9htCD4dim lymphocytes in healthy and HIV infected
subjects.
The prevalence of CD8bnghtCD4d"TI lymphocytes ranged from 0.32 to 3.44% of total
CD8 lymphocytes, and there was no significant difference between HIV infected and
control subjects (median 0.7 and 1.1 for HIV infected and controls respectively, p=
0.34 Mann-Whitney test, Figure 5-5A). Within the HIV infected subjects no
association was found between the prevalence of CD8b"ghtCD4dlTTI lymphocytes and
either the CD4 lymphocyte count or the viral load, Figure 5-5B and C. The HIV
infected subjects fell into two groups with the majority (13/16) having relatively few
CD8bnghtCD4dim lymphocytes (less than 1% ofCD8 lymphocytes). One of the three
subjects with higher CD8brightCD4dim frequencies had acute pneumonia at the time of
sampling, but the other two had no recent intercurrent infection. The CD4 counts
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Figure 5-5. The proportion of CD8 lymphocytes expressing CD4 in HIV infected subjects and
healthy controls. (A) The proportion ofCD8 lymphocytes expressing CD4 was determined by flow
cytometry in 16 HIV infected and 8 healthy controls. There is no significant difference between the
two groups (p = 0.034, Mann-Whitney test). There was no significant association between the
proportion ofCD8 lymphocytes expressing CD4 and either CD4 lymphocyte count (B), or plasma
viral load (C).
5.3.1.1 The prevalence of CD8bnghtCD4dim lymphocytes in PHI.
In the single subject with PHI, the prevalence of CD8bnghtCD4dim lymphocytes
circulating in peripheral blood was 0.7% of CD8 lymphocytes, similar to that in
subjects with chronic HIV infection.
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5.3.2 Differentiation phenotype of CD8br'9htCD4dim lymphocytes circulating in
healthy and HIV infected subjects.
To investigate the normal differentiation of CD8brightCD4dim lymphocytes in vivo four
colour flow cytometry was used to assess CD45RA and CD27 expression on
CD8bnghtCD4dirn lymphocytes in PBMCs obtained from 8 healthy subjects. The
effect of HIV infection on this subset was then determined using either PBMCs or
sorted CD8 lymphocyte populations from 16 HIV infected subjects. No significant
difference (Mann-Whitney Test) was found between the differentiation phenotypes
displayed by CD8pbnghtCD4dim lymphocytes assessed by these two different methods
and thus the results were pooled and data is presented for all 16 subjects.
The majority of CD8bnghtCD4dim lymphocytes in both healthy and HIV infected
subjects displayed an antigen experienced phenotype (Figure 5-6A). This proportion
was significantly greater than that in the CD8bnghtCD4- lymphocytes in both the
healthy and HIV infected subjects Wilcoxon Signed Ranks Test: p=0.02 and p =
0.005 respectively, Figure 5-6B).
Within the antigen experienced subset, the majority of CD8brightCD4dim lymphocytes
were CD45RA-CD27+ suggesting memory function while a small proportion were
CD45RA+CD27- suggesting effector status. These figures represent a shift towards
memory and away from effector phenotype when compared to antigen experienced
CD8bllghtCD4" lymphocytes, which was significant for HIV infected subjects
(Wilcoxon Signed Ranks Test: p= 0.003 and p = 0.001 for the increase in memory
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Figure 5-6. Differentiation of CD8bn8h,CD4dlm and CD8bngh,CD4 lymphocytes in healthy and
HIV infected subjects. (A) The proportion of CD8briBhtCD4dlm and CD8br'BhtCD4~ lymphocytes at
various differentiation stages are shown as pie charts, the data used was the mean across all samples
tested in control and HIV infected groups. (B) The range of results and difference between groups is
shown as bar charts (B,C). The majority of CD8br'BhtCD4dlm lymphocytes had an antigen experienced
phenotype, and this represented a significant increase from that in CD8bnghtCD4" lymphocytes in both
HIV infected and healthy subjects (B). A greater proportion of CD8br,8htCD4d,m than CD8bnghtCD4"
antigen experienced lymphocytes had a memory phenotype, and less had an effector phenotype. This
is true for both healthy controls (Ci) and HIV infected subjects (Cii), and was statistically significant
for HIV infected subjects, p values are calculated using Wilcoxon Signed Rank test.
Direct comparison of the differentiation phenotype of CD8bnghtCD4dim lymphocytes
in HIV infected versus healthy controls demonstrated a significant increase in the
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proportion of cells with an antigen experienced phenotype (p = 0.005, Mann-Witney
Test). However, this difference was a reflection ofmore general changes in the CD8
lymphocyte population of the HIV infected subjects (HIV is known to generate
expanded antigen experienced lymphocyte populations), and when the prevalence of
CD8bnghtCD4dim lymphocytes was expressed as a proportion of CD8bnghtCD4-
lymphocytes within each differentiation phenotype, there was no significant
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Figure 5-7. Proportion of CD8 lymphocytes expressing CD4, divided by differentiation
phenotype. O represents outliers and * represents extreme outliers. Outliers are defined as values
that lie more than 1.5 interquartile ranges beyond the quartiles. Extreme values lie more than 3
interquartile ranges beyond the quartiles.
5.3.3 The activation status of CD8br'9htCD4dim lymphocytes and CD8br'9htCD4-
lymphocytes defined in terms of cell size.
CD8brightCD4dim lymphocytes generated in vitro displayed an activated phenotype
(Flamand et al., 1998; Sullivan et al., 2001). To determine whether the same was true
of CD8bnghtCD4dim lymphocytes in peripheral blood of healthy individuals, their
degree of activation was assessed in terms of cell size in 8 subjects, and through
expression of the activation markers CD69 and CD38 in four subjects (subjects 1,2,3
and 6). To assess whether HIV infection has any effect on the proportion of
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CD8bnghtCD4d,m lymphocytes that are activated, cell size was also assessed in 4 HIV
infected subjects.
CD8bnghtCD4dim lymphocytes had a clear biphasic fsc distribution in both HIV
infected subjects and controls (Figure 5-8). While a considerable proportion were
large (median 27%, range 7 - 65%), suggestive of blast transformation, the majority
were 'small' suggesting quiescence. A few CD8bnghtCD4" lymphocytes were also
large, but the proportion was significantly less (median 2%, range 1% - 4%) than
found for the CD8bnghtCD4dim lymphocytes (Wlcoxon signed ranks test: p = 0.002,
Figure 5-9A).
The proportion ofCD8b"shtCD4dirn lymphocytes with increased fsc in HIV infected
subjects was significantly less than that in healthy controls, (medians 11.6% and
29.5% respectively, Mann-Whitney U Test: p = 0.03) . This was not the case for
CD8bnghtCD4" lymphocytes, (medians 1.1% and 2.0% for HIV infected and controls
respectively; Mann-Whitney U Test: p = 0.21; Figure 5-9B).
The relative extent of activation of CD8b"ghtCD4dirn as compared to CD8bllghtCD4"
lymphocytes was also assessed by simply comparing the mean fsc of the two
populations, excluding cells with increased ssc. This allowed assessment of the
relative cell size without recourse to defining 'small' and 'large' populations and was
thus subject to less potential bias. Using this method the significant increase in size
of CD8bngbtCD4dim as compared to CD8bl,ghtCD4" lymphocytes was confirmed (mean
size 367 units and 307 units respectively, Wilcoxon Signed Ranks Test for paired
samples P = 0.002). Similarly the significantly greater increase in size of
CD8bllgbtCD4dim versus CD8bngbtCD4" lymphocytes in control subjects compared to
HIV infected subjects was confirmed (median proportional increase of fsc in
CD8brightCD4dim versus CD8brightCD4" lymphocytes were 1.23 and 1.11 and for
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Figure 5-8. Proportion of CD8bnEhtCD4d,m and CD8bnghtCD4 lymphocyte populations that have
increased cell size. Results for a typical sample are shown. Cells from each subject were initially
gated on CD8brlghtand ssc low, and a histogram of fsc obtained. This demonstrated a biphasic
distribution, allowing events to be divided by eye into those with a standard lymphocyte fsc 'small',
and those with increased fsc Targe'(A). The proportion of CD8brlghtCD4d,n1 and CD8bnshtCD4"
lymphocytes falling within the 'small' and 'large' markers was then determined, (B). CD8bnghtCD4dim
lymphocytes show a clear biphasic fsc distribution with the majority being 'small'.
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Figure 5-9. Cell size of CD8brightCD4dim and CD8brigh,CD4" lymphocytes. The proportion of
CD8brlghtCD4dlm and CD8bnghtCD4" lymphocytes that are 'large', suggesting blast transformation for
HIV infected and control subjects (A). The same data divided into HIV infected and control subjects
showing that the proportion of activated CD8bri8htCD4dlm lymphocytes in HIV infected subjects is
significantly less than that of healthy controls (B). The difference between CD8brlghtCD4d'm
lymphocytes ofHIV infected subjects and controls is also seen when activation is measured as a
relative increase in fsc (C).
5.3.4 Expression of activation markers.
The proportion of cells that expressed CD69, CD38 and CD45RO was assessed for
CD8bnghtCD4dim lymphocytes and CD8bnghtCD4" lymphocytes.
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Figure 5-10. Positioning of gates for analysis of activation markers on CD8bn8h,CD4dim and
CD8brigh,CD4" lymphocytes. Results for a typical sample are shown. Events with a high ssc or a low
fsc were excluded (A). CD8bnshtCD4dlm lymphocytes were gated (B) and the marker defining the
positive population for CD69, CD38 and CD45RO was set using the FITC isotype control (C). The
proportion of FITC positive events in the control sample was then subtracted from the proportion of
FITC positive events in the test samples to give a corrected proportion of the test population
expressing the activation or differentiation marker (D).
Surprisingly, despite the increased proportion of large cells in the CD8bnghtCD4d,m
populations compared to the CD8bnghtCD4" populations, the proportion of cells
expressing CD38 was no greater. This was in contrast to the expression of CD45RO
which was consistently higher in CD8br'8htCD4dim as compared to CD8bllghtCD4~
populations. Again the low level of staining with CD69 precluded accurate
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comparison, but a marked increase in expression in CD8bnghtCD4dirn lymphocytes























Figure 5-11. Expression of activation markers on CD8brigbtCD4d"n and CD8bngbtCD4
lymphocytes. The proportion of CD8br'shtCD4dlm lymphocytes and CD8br,8htCD4" lymphocytes
expressing the activation markers CD69 and CD38 or the differentiation marker CD45RO was
determined using appropriately stained PBMCs from four healthy controls.
Given the working hypothesis that CD8b"ghtCD4dim lymphocytes are generated by
antigen specific activation, the observation of CD8b"shtCD4dirn lymphocytes with a
nai've phenotype was unexpected. One explanation for this apparent contradiction is
that the CD8bnghtCD4dim lymphocytes displaying a naive phenotype are cells that
have recently encountered antigen (and thus upregulated CD4) but have not yet lost
their naive markers. If this were the case, one would expect naive CD8bnghtCD4dim
lymphocytes to show evidence of recent activation. This was assessed in the eight
healthy control subjects through measurement of the cell size. There were
insufficient naive CD8bnghtCD4d,m lymphocytes to perform these assessments in HIV
infected subjects.
Assessment of forward scatter demonstrated that a considerable proportion (median
58%, range 15 - 88%) of naive CD8bnghtCD4d,m lymphocytes were 'large',
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suggesting blast transformation. This was not a general feature of naive lymphocytes
as very few (median 2%, range 0% -3%) naive CD8bnghtCD4~ lymphocytes were
'large'. The increased size of naive CD8bn8htCD4dim lymphocytes as compared to
naive CD8bnghtCD4~ lymphocytes was confirmed by comparison of the mean fsc of
the two CD8 lymphocyte subsets (median fold increase = 1.4).
Interestingly the proportion of naive CD8bnghtCD4dirn lymphocytes that were
activated, as assessed by cell size, was significantly greater than that of antigen
experienced CD8b"ghtCD4d,m lymphocytes. Thus the proportion of experienced
CD8bnghtCD4dim lymphocytes that were large (median 18%, range 2 - 49%) was
significantly less than that for naive CD8bnghtCD4dim lymphocytes, (p = 0.001 Paired
Samples T Test, Figure 5-12), and this was confirmed by mean fsc measurements (p
= 0.001 Paired Samples T Test). This difference in cell size was not a general
feature of naive and experienced cells as there was no significant difference in cell








Figure 5-12. Size of naive and experienced CD8bn8htCD4d,m lymphocytes. The activation status of
naive and experienced CD8 cell subsets was assessed in terms of cell size.
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5.3.5 The level of CD4 expression on the CD8br'9htCD4dim lymphocytes.
The level of CD4 expression on the CD8br,ghtCD4d,m lymphocytes was just less than
half (mean 0.41) that on true CD4 lymphocytes. The relative level of expression
(level of expression on CD8bnghtCD4dim lymphocytes / level on true CD4
lymphocytes) was less in HIV infected subjects than healthy controls (means 0.37
and 0.5 respectively p = 0.03, T test).
5.4 Discussion.
5.4.1 Prevalence of CD8br'9htCD4dim lymphocytes
The data presented show that CD8bnghtCD4d,m lymphocytes make up an average of
1.1% of CD8 lymphocytes in a small sample of healthy subjects. This result is in
keeping with data from other series which have shown that CD8bnghtCD4dim
lymphocytes represent 0.15 - 0.9% ofPBMCs, (Nascimbeni et al., 2004). Other
investigators who have determined the prevalence of all CD4+CD8+ lymphocytes (ie
CD8bnghtCD4dim and CD4bnghtCD8d'm) have found higher levels, with average levels
of approximately 1 - 3% ofPBMCs (Blue et al., 1985), with prevalence increasing
with age (Laux et al., 2000).
5.4.2 Differentiation phenotype of CD8br'3htCD4dim lymphocytes
The results presented clearly show that the majority of circulating CD8bnghtCD4d,m
lymphocytes were antigen experienced, supporting the hypothesis that
CD8b"ghtCD4dim lymphocytes are generated through antigen specific stimulation.
Within the antigen experienced subset, the memory phenotype predominated. The
same observations were reported by Nascimbeni et al., (2004), using CD45RO and
CCR7 as markers of differentiation. They demonstrated that approximately 60% of
CD8bnghtCD4dim lymphocytes circulating in 10 healthy subjects displayed a memory
phenotype, and also showed these cells tended to have an effector memory (tissue
homing) rather than central memory (lymph node homing) expression pattern.
The relative lack of effector CD8b"ghtCD4dim lymphocytes suggests either that CD4
expression is lost on differentiation to effector status, or that expression ofCD4 on
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activation marks a branch point on the CD8 lymphocyte differentiation pathway,
generating a CD8 lymphocyte subtype with a tendency to retain a memory
phenotype. In a related finding, Zlosa et al., (2003), show that CD8bnghtCD4dim
lymphocytes generated in vitro contain higher levels of IL-4 than their CD4-ve
counterparts, with IL-4 secretion being a recognized function ofmemory but not
effector CD8 lymohcytes (Geginat et al., 2003). In swine, where mature CD4+CD8+
lymphocytes make up a significant proportion of circulating T lymphocytes, these
cells appear to have a memory function, and specifically respond to viral recall
antigens (Zuckermann & Husmann, 1996; Hernandez et al., 2001).
Given the hypothesis that CD4 expression on CD 8 lymphocytes occurs on antigen
specific activation, it was a surprise to find that a considerable proportion (mean 16%
over HIV infected and controls) of CD8br,ghtCD4dim lymphocytes displayed an
antigen naive phenotype. There are a number of possible explanations for this
observation and the evidence for each is considered.
i) CD45RA+CD27hl8hCD8bn8htCD4d"" lymphocytes are recently antigen experienced
but have either notyet lost their naive markers. In support a significant fraction of
the naive CD8bnghtCD4dirn lymphocytes were 'large' suggesting recent activation
(section 5.3.4). In addition it is known that early antigen experienced CD8
lymphocytes may retain CD45RA and CD27, that 10% of the cells designated
'naive' by these markers are not 'true naive' as assessed by further criteria, and that
12% of CD8bllghtCD4d"TI lymphocytes generated in vitro retain CD45RA expression
at least up to day 6 following stimulation (Sullivan et al., 2001). The lack of CD69
expression could be taken as evidence against recent activation as CD69 is
coexpressed with CD4 on mitogen stimulated CD8 lymphocytes in vitro. However it
is known that this marker is often rapidly downregulated (within 48 hours of
activation), and it is possible that in the in vivo environment CD69 expression is
largely lost prior to the activated lymphocytes entering the circulation. CD38
expression can not be used to illuminate this issue as CD38 is constitutively
expressed on naive CD8 lymphocytes (Benito et al., 1997).
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li) CD45RA+CD27hlgh CD8bnghlCD4d"n lymphocytes are naive CD8 lymphocytes
undergoing regenerative proliferation. The naive CD8 lymphocyte pool is
maintained largely through low frequency regenerative proliferation. The expression
ofCD4 on proliferating naive CD8 lymphocytes has not previously been described,
but would explain the observed phenotype.
Hi) CD45RA+CD27hlgh CD8bngh'CD4d"" lymphocytes are antigen experienced but
have reverted to a naive phenotype. Reversion of antigen experienced T lymphocytes
to phenotypically and functionally naive cells has been demonstrated in the rat (Bell
& Sparshott, 1990; Bunce & Bell, 1997) but there is no evidence that it occurs in
humans.
iv) Some ofthe CD8b"ghtCD4d"" lymphocytes are not generated on activation but by
some other mechanism. Mechanisms other than activation which could be
responsible for generation of the circulating naive CD8bnghtCD4dim lymphocytes
include leakage of immature double positive thymocytes into the circulation. This
was not investigated here, but previous studies have found no expression of thymic
markers on circulating CD8+CD4+ lymphocytes (Ortolani et al., 1993, Nascimbeni
et al., 2004).
v) Some ofthe CD8b"ghtCD4d"" lymphocytes observed byflow cytometry represent
either coincidence artefact or non-specific staining. Although considerable attention
was paid to ensuring that the observed CD8br,ghtCD4dim lymphocytes were not
artefactual (see section 3.1.2), it remains possible that artefact may be responsible for
some of the CD8bnghtCD4d'm events observed. Given that any non-specific staining
would tend to generate events positive for all four markers used, artefactual 'naive'
events would predominate. Arguing against this explanation, in a single subject
where a subset of PBMCs were stained for CD45RO, the number of CD8bnghtCD4dim
lymphocytes within the CD45RO-CD45RA+ population (which would exclude
indiscriminately stained events) was similar to that within the CD45RA+ population.
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5.4.3 Activation status of CD8br'9htCD4dim lymphocytes.
CD8bnghtCD4d'm lymphocyte populations produced in vitro have a fairly uniform
activated phenotype. Thus by day 6 post stimulation a high proportion 12 - 60%
(Flamand et al., 1998; Sullivan et al., 2001) expressed the early activation marker
CD69, and over 90% expressed the later activation marker CD38 (Sullivan et al.,
2001). Assessment of CD8bnghtCD4dim lymphocytes in subjects with a marked
expansion in this cell type following acute viral infection demonstrated a similar
phenotype to that seen in vitro, with over 90% expressing CD38 (Ortolani et al.,
1993).
This uniform activated phenotype was not found in the subjects assessed here. The
cell size data indicated that the circulating CD8bnghtCD4dirn lymphocytes in healthy
individuals was a mixed population, with a significant fraction (ranging from 6 -
65%) being 'large' suggesting activation, and the remainder being small in keeping
with quiescence. The proportion of 'large' cells was significantly greater than that in
CD8b"shtCD4" lymphocytes, supporting the hypothesis that CD8b"ghtCD4dim
lymphocytes in vivo are generated on activation. However, the presence of a
considerable activated component was not confirmed by expression of activation
markers. This could be due to the inability of the markers used to pick up the
activated population. CD69 expression could be lost prior to migration of activated
cells into the circulation, and as CD38 is constituitively expressed at a low level on
naive lymphocytes, any increased CD38 expression caused by activation could be
masked by the decrease in nai've cells. Alternatively the activation marker data could
correctly demonstrate the status of the CD8bnghtCD4dirn population and the cell size
data could be at fault. Whichever dataset is the true representation, both agree that a
large proportion of circulating CD8bnghtCD4d'm lymphocytes appear quiescent. Thus
rather than being a wholly short-lived population, as suggested by the in vitro data, it
appears that a subset of the CD8bllghtCD4dim lymphocytes generated during antigen
specific activation revert to a quiescent state and are thus likely to be long-lived. The
existence of long-lived CD8brightCD4d'm lymphocytes is supported by their increasing
prevalence with age, an increase which parallels the age related increment in memory
lymphocytes (Laux et al., 2000). Study of lymphocyte phenotype in a chimpanzee
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during hepatitis C virus infection demonstrated that in addition to the temporary
expansion in activated CD8+CD4+ lymphocytes during viraemia, there was a
background population of relatively quiescent CD8+CD4+ lymphocytes.
Nascimbeni et al., (2004), assessed expression of the activation markers DR, CD69,
CD56 and CD38 and also found no significant difference in expresson between
CD8brlghtCD4dim and CD8bnghtCD4"ve lymphocytes. This complete lack of increased
expression of activation markers is hard to reconcile with the cell size data presented.
It is possible that Nascimbeni et al. gated out activated cells by use of a tight
lymphocyte gate during their analysis. An earlier report of the activation status of
peripheral blood CD8 lymphocytes in healthy subjects did find a positive association
between expression of CD69 and expression of CD4 (Imlach et al., 2001). In this
paper the proportion ofCD8+CD4+ lymphocytes expressing each activation marker
was not given, but review of some of the flow cytometry data indicates that the
proportions were relatively low (Imlach,S. personal communication, 2004). Thus,
this paper concurs that the degree of activation in the CD8bllghtCD4d'm lymphocytes
circulating in healthy individuals is substantially less than that found in
CD8b"ghtCD4dim lymphocytes generated in vitro or associated with acute infection.
Imlach et al., (2001), also found a correlation between expression of the later
activation markers CD71 and HLAII, and expression of CD4 on CD8 lymphocytes.
Using these markers to stain PBMCs from a single HIV infected subjects this
association was not reproduced (data not shown).
A further difference between the CD8brisbtCD4d'm lymphocytes described here and
those of acutely infected subjects relates to CD7 expression. Ortolani et al., (1993),
show that the CD8br'sbtCD4dim lymphocytes which expand following acute infection
do not express CD7 (unlike their CD4-ve counterparts), while assessment of CD7
expression in CD8b,lghtCD4dim lymphocytes of a single HIV infected subject showed
high levels of expression similar to those in CD8bngbtCD4" lymphocytes. The
relevance of this change in CD7 expression is not known.
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5.4.4 Effect of HIV infection on CD8br'9htCD4dim lymphocytes.
The relatively high HIV DNA load observed in CD8bnghtCD4d,m lymphocytes renders
this population vulnerable to the cytopathic effects of the virus. However, in the
small number ofHIV+ve subjects and controls assessed there was no significant
difference in the prevalence of CD8br'shtCD4dirn lymphocytes, not for total CD8
lymphocytes or for any of the three differentiation stages assessed. This finding does
not preclude a cytopathic effect ofHIV on CD8b"ghtCD4dim lymphocytes, but
indicates that if such an effect is present, it is counterbalanced by an increase in
generation which would be a likely consequence of the high levels of immune
activation seen in HIV infection.
In this regard, the finding that a smaller proportion of CD8b"ghtCD4dim lymphocytes
were activated (as assessed by cell size) in HIV infected subjects compared to
controls is of interest. In CD4 lymphocytes HIV is cytopathic to activated cells
while quiescent cells may retain the provirus for long periods of time without ill
effect (Chun et al., 1995; Chun et al., 1997) If a similar scenario operates for
CD8b,lghtCD4dim lymphocytes, it could be responsible for the observed decrease in the
ratio of activated to non-activated cells. While intriguing, this finding should be
viewed with caution. It is based on a small sample size with HIV+ve subjects and
healthy controls being matched only by age.
Given the hypothesis that CD4bngbtCD8dirn lymphocytes are generated on activation,
and that activation markers such as CD38 have been shown to increase with HIV
disease progression (Levacher et al., 1992), one might expect there to be a
correlation between the proportion of CD8 lymphocytes expressing CD4 and
correlates of disease progression such as CD4 count or viral load. Such a correlation
was not found in the small dataset presented here. This may reflect a true lack of
association, but it is likely that any existent correlation could have been masked by
the heterogeneity of the subjects in terms of treatment history and acute infective
events. Of note Zloza et al., (2003), did not report any correlation between the levels
of CD8bngbtCD4dim lymphocytes and markers of disease progression in their analysis
of 150 HIV infected subjects.
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The observed significant decrease in intensity of CD4 expression on CD8
lymphocytes ofHIV infected as opposed to healthy controls is intriguing, though at
this stage its significance is unclear. One could speculate that HIV infection of these
cells is causing downregulation of the CD4 expression (as has been noted in
vzYro;(Kitchen et al., 2004)), a suggestion that gains some support from a trend
towards decreased CD4 intensity in subjects with increased CD8 lymphocyte viral
load. However this trend does not reach significance (Spearman's rank correlation R
= 0.54, p = 0.17), and further conclusions would need a much larger dataset.
The overall proportion ofCD8 lymphocytes expressing CD4 found in HIV infected
subjects here was lower than those reported in large retrospective surveys, but this is
likely to be due to methodological differences. Zlosa et al., (2003), showed that 0.4
- 3.4% ofT cells are CD8+CD4+ in the majority of 150 HIV positive subjects, but
this included CD4brightCD8dim aswell as the CD8brightCD4dim lymphocytes analysed
here. They also reported a small number of subjects with higher frequencies, one
reaching 16% of all T cells.
5.4.5 Limitations of the methods used.
While the four colour flow cytometry used here is an extremely powerful method to
assess phenotype of lymphocyte subsets, the results presented do not reflect the
entire population CD8b"gbtCD4dim lymphocytes for a number of reasons. First, in
order to avoid contamination of the CD8b"shtCD4dim lymphocyte population with
non-specifically stained cells, CD8 bright lymphocytes with increased side scatter
were excluded from all analyses. This excluded a mean of 56% of the total
CD8b"ghtCD4d'm events from the final assessment, with approximately half of the
excluded events being tubulin positive (based on tubulin staining in a single subject,
Figure 5-3). Given that COS^'^'CDd13"11 lymphocytes generated in vitro have been
shown to have blast characteristics, which can increase side scatter aswell as fsc the
exclusion of high ssc events is likely to have excluded a proportion of true
CD8bnghtCD4dim lymphocytes in addition to the artefactual events. In addition, cells
with increased fsc (which represented on average 14% of CD8bnghtCD4d,m
lymphocytes) were excluded from the analysis of the prevalence ofCD8b"ghtCD4dim
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lymphocytes and their differentiation status. These exclusions, while necessary to
ensure that the population examined did not contain artefactual events, may have
skewed the results away from recently activated cells.
Secondly, as explained in section 5.2.2.2, compensation between spectral overlap of
CyChrome and APC lead to spreading of the CyChrome high events along the APC
detection axis. This made it more difficult to define a clear CD8b,lghtCD4dim
population, and meant that a proportion of the lymphocytes with low levels of CD4
expression will have been missed, (Figure 5-1).
In addition to the exclusion of events of interest, the potential for artefactual events
must be considered. As already discussed, the inclusion ofhigh fsc events in the
analysis of activation phenotype allows the possibility of inclusion of events
representing doublets or coincidence error. While no evidence for this was found in
mixing experiments (3.1.2), their possible confounding influence should be kept in
mind.
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Chapter 6: General Discussion
In this chapter the major findings of the experimental data are stated and a model of
the dynamics ofHIV infection of CD8 lymphocytes is proposed. The significance of
HIV infection of CD8 lymphocytes is then considered in terms of immunodeficiency,
viral reservoirs and viral replication. Finally potential directions for future research
in this field are discussed.
6.1 Major findings of thesis.
In 16 subjects with chronic HIV infection, 0.3 - 3.4 % of blood derived CD8
lymphocytes expressed low levels of cell surface CD4, presenting a CD8bnghtCD4dim
phenotype. In general, these lymphocytes were infected with HIV at a level similar
to that of CD4 lymphocytes. The frequency of infection increased with disease
progression, and in subjects with advanced disease CD8 lymphocytes contained up to
25% of the total T lymphocyte proviral load. In the majority of subjects HIV
infection of CD8bnghtCD4" lymphocytes was not found, and where provirus was
detected there were less than 20 copies per million cells. One subject with PHI also
had HIV infected CD8br,ghtCD4d'm lymphocytes, with levels of infection similar to
those in chronic infection. As discussed in chapter 4, this pattern of infection of CD8
lymphocytes suggests infection following activation rather than export of
intrathymically infected precursors.
In both healthy and HIV infected subjects, the majority ofCD8br,ghtCD4dim
lymphocytes were antigen experienced, and in contrast to the in vitro data, a
significant proportion appeared quiescent. Chronic HIV infection had no
demonstrable effect on their frequency or phenotype, and this cell type was not
expanded in the subject with PHI.
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6.2 Model of the dynamics of HIV infection of CD8
lymphocytes.
A proposed model of the dynamics ofHIV infection of CD8 lymphocytes is given in
Figure 6-1 and the accompanying table. The model is based on the data presented in
this thesis, and published data, with the source of evidence given. As indicated, many
of the events in the model occur in lymph nodes or at sites of inflammation, and
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6.3 Significance of HIV infection of CD8 lymphocytes.
6.3.1 Immunodeficiency
HIV infection results in an as yet unexplained progressive decline in CD8
lymphocyte numbers and function. As reviewed in the introduction (sections 1.6.1
and 1.6.7.4), the decline in numbers largely affects naive CD8 lymphocytes, and the
functional defects include impaired proliferation and cytotoxicity. Various
explanations for these deficits have been proposed, including lack ofCD4 help,
increased apoptosis and anergy, but none are backed by robust experimental
evidence. The model presented above, where CD 8 lymphocytes responding to
antigen become infected with HIV, clearly has the potential to have a profound
impact on the ability of CD8 lymphocytes to control pathogens.
Proponents of the 'tap and drain' or 'accelerated destruction' model argue that HIV
induced death of activated CD4 lymphocytes leads to a decline in naive CD4
lymphocyte numbers by an as yet undefined mechanism (see section 1.6.6.1) (Mohri
et ai, 2001). While it is possible that infection of antigen experienced
CD8b"ghtCD4dim lymphocytes could induce nai've CD8 lymphocyte decline in a
similar manner, it is more likely that the decline in naive cell numbers (both CD4 and
CD8) is a consequence ofHIV induced generalized immune activation (section
1.6.6.2). Alternatively, ifCD4 is expressed on naive lymphocytes undergoing
regenerative proliferation, it is possible that HIV infection of these cells could
directly impair naive CD8 lymphocyte homeostasis. This hypothesis is supported by
the finding, presented in section 5.4.1 and reported by Nascimbeni et al., (2004), that
significant numbers of circulating CD8br'shtCD4d,m lymphocytes have a naive
phenotype, and by the observation ofHIV infection of naive CD8 lymphocytes
(presented in chapter 4). However upregulation ofCD4 on regenerative proliferation
has not been previously documented.
The extent of the impact depends to a large degree on four factors: the frequency of
CD4 upregulation on CD8 lymphocytes, the proportion of CD8b"shtCD4dim
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lymphocytes that become infected, the function of CD8b,lghtCD4dim lymphocytes, and
the consequences ofHIV infection at a cellular level.
6.3.1.1 Frequency and duration of CD4 upregulation on CD8 lymphocytes
In vitro bulk stimulation ofCD8 lymphocytes with mitogen, CD3 and CD28 or
allogenic cells results in CD4 upregulation on between 20 and 80% of cells (Flamand
et al., 1998; Kitchen et al., 1998; Laux et al., 2000; Sullivan et al., 2001) but whether
a similar proportion upregulate CD4 in response to antigen specific stimulation in
vivo remains unknown. The stimulants used in vitro act through the TCR (Flamand
et al., 1998) and therefore mimic antigen specific priming, but the differences in
receptor binding, the high concentrations of stimulant used, and the lack of additional
costimulatory or inhibitory signals provided by the lymph node environment, mean
that the in vitro studies can only provide an indirect indication of the extent of CD4
upregulation in vivo.
Animal studies have demonstrated that stimulation of lymphocytes in vivo, for
example through vaccination, does lead to expansion of a CD8+CD4+ lymphocyte
population (Periwal & Cebra, 1999). However, there is considerable interspecies
variation in the extent of the expansion and the lineage of the CD8+CD4+ cells, for
example CD8+CD4+ lymphocytes in mice and rats may be produced by premature
release of thymocytes into the periphery (Bonomo et al., 1994; Jimenez et al., 2002),
or in response to antigen specific activation (Periwal & Cebra, 1999), while in swine
there is evidence that CD8+CD4+ lymphocytes are CD4 lymphocytes that have
upregulated CD8 (Zuckermann & Husmann, 1996) (Hernandez et al., 2001).
The observation of expanded CD8bnghtCD4dim lymphocyte populations in subjects
with acute EBV and CMV infections demonstrate that CD4 upregulation can occur
on greater than 15% of circulating CD8 lymphocytes in in vivo (Ortolani et al.,
1993). However it is not known what proportion of subjects with acute EBV, CMV
or other viral or bacterial infection have increased levels of CD8bnghtCD4dim
lymphocytes as no systematic study has been performed.
Levels of circulating CD8bnghtCD4dim lymphocytes may under-represent total body
frequencies, with greater frequencies expected in lymph nodes where nai've CD 8
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lymphocytes are primed. Again there is very little published data to support or refute
this suggestion. In an SIV infected macaque with unusually high frequencies of
CD8bnghtCD4d,m lymphocytes, the frequency in blood was greater than that in lymph
node (Khatissian et al., 2003). Conversely in a single HIV infected person, the
proportion of CD8 lymphocytes expressing CD4 in lymph node was 4.6%,
considerably more than is commonly found in blood (Hughes, G. 2005).
It is also reasonable to suppose that levels of CD8bnshtCD4dllTI lymphocytes may be
greater in the tissues than in blood, as tissues are the site of activation of primed CD8
lymphocytes, and CD8bllghtCD4dirn lymphocytes have increased expression of the
tissue homing molecule CXCR3 (Nascimbeni et al., 2004). Arguing against this,
Semenzato found that CD8+CD4+ made up only 0.1 - 0.04% of bronchio-alveolar
lavage cells in 35 HIV infected subjects with pulmonary symptoms (Semenzato et
al., 1995).
The duration of CD4 upregulation on CD8 lymphocytes would be expected to
correlate with the likelihood of their becoming HIV infected. The lack of activation
markers and small cell size of the majority of circulatng CD8brightCD4dim
lymphocytes (data presented in section 5.3.3), suggests that CD4 expression may be
retained for a considerable period on cells that 'rest down' after antigen specific
activation, a conclusion supported by the observed accumulation of CD8bri8htCD4dirn
lymphocytes with age (Laux et al., 2000). Whether these quiescent type cells remain
susceptible to infection, or whether they enter phase G(o) of the cell cycle rendering
them HIV resistant is unknown.
6.3.1.2 Frequency ofHIV infection of CD8br'8htCD4d,m lymphocytes.
Data presented in chapter 4 demonstrated that the average level of infection of
circulating CD8bnghtCD4dirn lymphocytes was 1197 proviral copies per 106 CD8
lymphocytes, or assuming a single proviral copies per cell (Simmonds et al., 1990), a
prevalence of infection of 0.1%. At first sight this appears a low infection
prevalence, and one unlikely to have a profound impact on function of this CD8
lymphocyte subset. However, this 0.1% refers only to the proportion infected in the
blood at the time the blood was drawn, it gives no indication of the proportion
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infected in other tissues, and gives no indication of the incidence of infection, or the
turnover of infected cells. Given that HIV infection is more efficient in activated
cells which are prevalent in lymph nodes and inflamed tissue, it is likely that the
proportion of CD8bnghtCD4dim lymphocytes infected in these areas is greater than that
in blood. This supposition is supported by reports ofproviral loads in CD8
lymphocytes isolated from lung that were 2-6 fold higher than those in CD8
lymphocytes isolated from blood (Semenzato et al., 1995; Semenzato et al., 1998).
Further support is provided by comparison with HIV and SIV infection of CD4
lymphocytes. Thus, in chronic infection the prevalence ofHIV infected CD4
lymphocytes in lymph nodes is 3 - 10 fold that in blood (Pantaleo et al., 1991), while
in acute SIV infection up to 60% ofCD4 lymphocytes residing in gut are infected
compared to 30% in blood {Veazey, Tham, et al. 2000 19717 /id}. Infection
incidence is much harder to ascertain, and is not known for any lymphocyte subset in
HIV or SIV infection.
Of note, the proviral load in CD8b"shtCD4dmi lymphocytes was similar to that in CD4
lymphocytes, and given that direct infection is argued to be one of the causes ofCD4
lymphocyte decline (Mohri et al., 2001) the same case could be made for
CD8brightCD4dim lymphocytes.
6.3.1.3 Function of CD8brightCD4dim lymphocytes
If CD8bnghtCD4d,m lymphocytes have specific functional abilities that do not overlap
those of CD8bnghtCD4" lymphocytes or CD4 lymphocytes, then even if they represent
a small fraction of the total CD8 population, their loss could jeopardize immune
integrity. Studies of the function of in vitro generated CD8bnshtCD4d,m lymphocytes
have demonstrated antigen specific binding and a cytokine secretion profile
dominated by IL-4, with minimal or absent secretion of IL-2, IL-10 and IFN-y. 10-
30% of CD8bnghtCD4dim lymphocytes contained perforin (as did a similar proportion
of CD8bnghtCD4" lymphocytes) {Zloza, Sullivan, et al. 2003 23916 /id}). This profile
is in contrast to that observed in ex vivo CD8bnghtCD4dim lymphocytes where
secretion of IFN-y and TNF-a but not IL-4 or IL-10 was observed in response to a
variety of recall and persistent antigens (Nascimbeni et al., 2004). These discrepant
findings are not altogether unsurprising given the different histories of the cell
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populations tested, but do indicate that assigning function to this subset is likely to be
a complex task. A specific function is supported by animal studies, in swine the
double positive cells generated on activation function as memory cells with T helper
function (Zuckermann & Husmann, 1996; Hernandez et al., 2001), and in mice they
have antigen specific cytotoxic ability (Periwal & Cebra, 1999).
In CD4 lymphocytes the CD4 molecule plays a vital part in activation, adhesion and
migration (Center et al., 2000; Konig & Zhou, 2004), and there is now evidence that
it has similar functions in CD8bnshtCD4dirn lymphocytes. Using microarrays, Kitchen
et al. demonstrated that CD4 ligation on CD8bnghtCD4dirn lymphocytes led to
upregulation of genes encoding IFN-y and Fas-L, while blocking ofCD4-MHC-II
interaction inhibited CD8b"ghtCD4dim lymphocyte cytotoxicity (Kitchen et al., 2004).
CD8b"gbtCD4dim lymphocytes were also shown to migrate along an IL-16 gradient by
a CD4 dependent mechanism (Kitchen et al., 2002). IL-16 is secreted by epithelial
cells and eosinophils at sites of inflammation, and is known to induce migration of
CD4 lymphocytes to these sites (Franz et al., 1998). Interestingly, CD4 also directs
the migration of both CD4 lymphocytes and CD8b"ghtCD4dim lymphocytes along
gpl20 gradients, leading these cells towards sources ofHIV virions, and potentially
increasing the likelihood of their infection (Kitchen et al., 2002). Thus it appears
that expression ofCD4 on CD8 lymphocytes may generate cells with the cytotoxic
ability ofCD8 cells but the migration patterns ofCD4 lymphocytes.
6.3.1.4 Consequences ofHIV infection of CD8b"ghtCD4dim lymphocytes at a
cellular level.
In order for HIV infection of CD8 lymphocytes to contribute directly to
immunodeficiency, HIV infection must either kill the infected cell or impair its
function. HIV infection has been shown to be cytotoxic to CD8 lymphocytes in vitro
(Zerhouni et al., 2004), and infection of in vitro generated CD8bnghtCD4dim
lymphocytes led to downregulation ofCD4 expression (leading to impaired control
of IFN-y and Fas-L production), and impaired cytotoxicity (Kitchen et al., 2004).
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6.3.1.5 Summary of section 6.3.1
In summary, the available evidence demonstrates that CD8bnghtCD4dim lymphocytes
are functioning cells with distinct migration and effector characteristics, and suggests
that the level ofHIV infection of these cells observed in blood may belie a much
greater level of infection in tissues. Thus HIV infection of CD8bnshtCD4d,m
lymphocytes could have a significant impact on the CD8 lymphocyte response to
acute and chronic pathogens.
6.3.2 CD8 lymphocytes as a reservoir of HIV infection.
As described in section 1.9, quiescent CD4 lymphocytes are currently thought be the
longest lived HIV infected cells, forming a reservoir ofprovirus which is hidden
from antiretroviral and immune attack. These quiescent CD4 lymphocytes can either
be naive lymphocytes infected during regenerative proliferation (Brenchley et al.,
2004a), or antigen experienced cells that were infected during activation but
subsequently return to a quiescent state as long lived memory cells. The findings
presented in chapter 5 show that the majority of circulating CD8br,ghtCD4dim
lymphocytes have a memory phenotype and do not display activation markers,
suggesting that CD8bnghtCD4dirn lymphocytes can similarly 'rest down' following
antigen specific activation. In general CD8 lymphocytes are much more likely to
'rest down' than CD4 lymphocytes (Homann et al., 2001; Foulds et al., 2002),
making them a more efficient conduit for generation of a viral reservoir.
As yet there is no direct evidence that quiescent CD8 lymphocytes are infected, but
data showing that the CD8 lymphocyte proviral load was stable over months of
follow up, and the detection of ancestral HIV variants in CD8 lymphocytes both
suggest infection of a longlived population (McBreen et al., 2001; Potter et al.,
2003).
6.3.3 CD8 lymphocytes as a source of virus.
As demonstrated in chapter 4, in subjects with advanced HIV disease CD8
lymphocytes contribute a substantial proportion (approximately 25%) of circulating
proviral load. This finding is in keeping with results reported by other investigators.
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If the proportions seen in blood are reflected in the total lymphocyte population, and
if these infected CD8 lymphocytes generate progeny virions at rates similar to (or
greater than) CD4 lymphocytes, then CD8 lymphocytes would represent a significant
source of new virus. As discussed above the little data available supports greater
levels ofHIV infection ofCD8 lymphocytes in the tissues than in the blood.
As discussed in section 1.10, although HIV replication has not been observed in CD8
lymphocytes in vivo, productive infection has been amply demonstrated in vitro both
by staining for p24 and detection ofHIV budding from CD8 lymphocytes by electron
microscopy (Flamand et al., 1998). Phylogenetic studies have the potential to
demonstrate the degree to which a proviral population (such as HIV infected CD8
lymphocytes) contributes to the circulating viraemia, but these studies have shown
marked interpatient variability (see section 1.11.3). Thus Potter et al., (2003), report
that in two of four subjects assessed, CD8 lymphocyte sequences were closely
related to plasma sequences (suggesting either recent infection of the CD8
lymphocytes or productive infection of CD8 lymphocytes), but in the other two the
plasma and CD8 lymphocyte derived sequences were segregated. Of interest
different cell types do have marked variation in their efficiency of virion generation,
for example, while monocytes are infected with HIV at relatively low frequency
(McElrath et al., 1991), they can contribute greater than 10% of the systemic viral
load, with their contribution increasing during opportunistic infection (Lawn et al.,
2000).
6.4 Future Direction
The data presented in this thesis, together with an increasing body of published data,
has identified CD8bnghtCD4dim lymphocytes as cells with a major role in HIV
immunopathogenesis. Future research should focus on improving our understanding
of the natural history of these cells, and determining the extent to which there
infection can influence disease progression or response to treatment.
There has been extensive characterisation of phenotype and function of in vitro
generated CD8bnghtCD4dim lymphocytes, and research could usefully refocus on the
situation in vivo. Perhaps the most pressing questions regard the extent ofCD4
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upregulation in lymph nodes and inflamed tissues, especially during acute infection.
Also of interest would be elucidation of the circumstances resulting in CD4
upregulation, for example, whether CD4 is upregulated during regenerative
proliferation or only on antigen specific activation, and whether activation of
memory as well as nai've CD8 lymphocytes results in CD4 expression.
The question of the relevance ofHIV infection of CD8bnghtCD4dim lymphocytes to
disease progression, would be furthered by investigation of the extent ofHIV
infection of CD8br'shtCD4dim lymphocytes in lymph node and solid tissues, and
confirmation that infection is productive. Conclusive evidence that infection of
CD8bnghtCD4d'm lymphocytes has a role in CD8 lymphocyte dysfunction will be
difficult to generate, and whether yet another study of correlates of disease
progression would be particularly informative is debatable.
The influence of therapeutics on HIV infected CD8 lymphocytes is of clear
importance, both in terms ofpenetration of antiretrovirals, and effects of immune
stimulants. To date zidovudine has been shown to be active against HIV infecting
CD8 lymphocytes (Mercure et al., 1994), but to my knowledge other antiretrovirals
have not been specifically tested in these cells. Also of concern is the effect of
immune stimulants such as hydroxyurea and IL-2. It is conceivable that these
interventions may increase CD4 expression on CD8 lymphocytes thus providing
further targets for HIV to infect.
188
Abreviations List
AIDS Acquired Immunodeficiency Syndrome
ACP Allophycocyanin
APC Antigen presenting cell
CAF CD8 cell antiviral factor
CCR CC chemokine receptor
CD Cluster of differentiation
CMV cytomegalovirus
CNS central nervous system
CTL Cytotoxic T lymphocyte




FACS Fluorescent activated cell sorting
FITC fluoroscein isothyocyanate
FSC Forward scatter
Gag Group specific antigen gene
ICAM Intracellular adhesion molecule
IFN Interferon
IL Interleukin
LTR Long terminal repeat
LTNP Long term non-progressor
HAART Highly active antiretroviral therapy
HIV Human Immunodeficiency Virus
HLA Human leukocyte antigen
MACS Magnetic activated cell sorting
MHC Major histocompatibility complex
NNRTI Non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
NSI Non-syncytium inducing
PBL Peripheral blood lymphocyte
PBMC Peripheral blood mononuclear cell
PCR Polymerase chain reaction
PE Phycoerythrin
PHA Phytohaemaglutinin
PHI Primary HIV infection
PIC Pre-integration complex
Pol polymerase gene
Rev Regulator of viral protein expression
RNA RiboNucleic Acid
RT Reverse transcriptase
RTC Reverse transcription complex
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SI Syncytium inducing
SIV Simian Immunodeficiency Virus
SHIV SrV/HIV fusion virus
SSC Side scatter
SEB Staphylococcal enterotoxin B
STI Structured treatment interruption
Tat Retroviral transactivator of transcription
TNF Tumor necrosis factor
Vif Viral infectivity factor
Vpr viral protein R
Vpu viral protein U
Vpx viral protein X
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Human immunodeficiency virus (HlV)-infected CD8 lymphocytes have been reported in vivo, but the mech¬
anism of infection remains unclear. Experiments using the thy/hu mouse model support export of intrathy-
mically infected CD8 precursors, while recent in vitro data suggest that mature CD8 lymphocytes uprcgulate
CD4 upon activation (generating a CD8bright CD4d,m phenotype) and are susceptible to HIV infection. To
determine whether these mechanisms operate in vivo and to assess their relative importance in the generation
of circulating HIV-infected CD8 lymphocytes, we quantified HIV long terminal repeat (LTR) DNA in CD8+
CD4- and CD8br'8ht CD4d,m lymphocytes isolated from HIV-infected individuals by fluorescence-activated cell
sorting. HIV infection of CD8 lymphocytes was demonstrated in 17 of 19 subjects, with a significant inverse
relationship between level of infection and CD4 lymphocyte count (R = —0.73; P < 0.001). The level of HIV
infection of CD8bri8ht CD4d,m lymphocytes was significantly higher (median, 1,730 HIV LTR copies/106 cells;
n = 9) than that of CD8+ CD4~ lymphocytes (undetectable in seven of nine individuals; P < 0.01) and
approached that of CD4 lymphocytes from the same individuals (median, 3,660 HIV LTR copies/106 cells).
CD8br'sht CD4d,m lymphocytes represented 0.8 to 3.3% of total CD8 lymphocytes and were most prevalent in
the memory subset. Thus, HIV-infected CD8 lymphocytes commonly circulate in HIV-infected individuals and
are generated through infection of activated CD8 lymphocytes rather than through export of intrathymically
infected precursors. The high level of infection of CD8bri8h' CD4d,m lymphocytes could have a direct role in the
decline in CD8 lymphocyte function that accompanies HIV disease progression.
Although the major cellular target of human immunodefi¬
ciency virus type 1 (HIV-1) is the CD4 lymphocyte, there is
increasing in vitro (8,17, 33, 35, 36) and in vivo (3, 8,14, 20, 21,
29, 30) evidence that CD8 lymphocytes are also susceptible to
HIV-1 infection. It is well established that in chronic HIV
infection, deterioration in CD8 lymphocyte function accompa¬
nies progression to symptomatic disease (12,19, 24). While this
is generally ascribed to lack of CD4 lymphocyte help or to
soluble viral factors, it is also possible that direct infection of
CD8 lymphocytes by HIV may contribute to their functional
decline. In addition to the potential immunosuppressive effect,
infection of CD8 lymphocytes generates a reservoir of circu¬
lating HIV-infected cells, with implications for virus dissemi¬
nation and antiviral escape (25).
Various mechanisms for HIV entry into CD8 lymphocytes
have been proposed, including cell-to-cell transfer (5), selec¬
tion of CD8-tropic HIV variants (34, 35), or entry through a
conventional CD4-dependent pathway. Two opportunities for
CD4-dependent HIV entry into CD8 lymphocytes have been
identified. The first occurs during intrathymic CD8 lymphocyte
development and the second upon activation of the mature
CD8 lymphocyte. Intrathymic CD8 lymphocyte precursors ex¬
* Corresponding author. Mailing address: Laboratory for Clinical
and Molecular Virology, University of Edinburgh, Edinburgh EH9
1QH, United Kingdom. Phone: 44 (0)131 650 7945. Fax: 44 (0)131 650
7965. E-mail: alex.cochrane@ed.ac.uk.
t Present address: Moredun Research Institute, Pentlands Science
Park, Bush Loan, Penicuik EH26 0PZ, United Kingdom.
press CD4 and are susceptible to HIV infection in vitro (7). In
the thy/hu mouse model, maturation and export of HIV-in¬
fected lymphocyte precursors have been shown to generate cir¬
culating HIV-infected naive lymphocytes (4). Such cells could
survive in a resting state for years, acting as a reservoir of
provirus unaffected by antiretroviral agents.
A number of investigators have shown that activation of
mature CD8 lymphocytes in vitro leads to CD4 expression on
the cell surface (8, 17, 31), and this mechanism is thought to
generate the circulating CD8briBht CD4d,m lymphocytes ob¬
served in vivo (14). HIV infection of in vitro-activated CD8
lymphocytes has been demonstrated (8,17, 35, 36). Infection of
CD8 lymphocytes by this mechanism would target infection to
cells responding to antigens, and thus, infection of a relatively
small number of cells could have a disproportionately high
impact on immune function.
To determine the relative importance of these different
mechanisms of infection in the generation of circulating HIV-
infected CD8 lymphocytes in vivo, we used PCR to quantify
HIV long terminal repeat (LTR) DNA in CD8 lymphocyte
subsets sorted on the basis of differentiation phenotype or CD4
expression. This method detects HIV provirus and HIV pre-
integration complexes, with each HIV DNA genome contain¬
ing 2 LTR copies. It provides a measure of the level of HIV
infection within a given cell population. Differentiation phe¬
notype was defined in terms of CD45RA and CD27 expression,
allowing cells to be divided into antigen-naive, memory, and
effector subsets. Intrathymic infection would be expected to
generate HIV-infected naive CD8 lymphocytes with no pref-
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TABLE 1. Clinical profiles of HIV-infected subjects"
Study CD4 Plasma viral Combination
subject6 count/pl load/ml antiretroviral therapy"
1 2 75,000 No
2 17 750,000 Yes
3 39 309 Yes
4 51 23,100 No
5 66 75,000 Yes
6 117 75,000 Yes
7 123 330,000 Yes
8 296 470 Yes
9 328 <50 Yes
10 334 <50 No
11 339 14,900 Yes
12 364 304 No
13 385 153 Yes
14 393 403 Yes
15 396 862 No
16 509 <50 Yes
17 531 <50 Yes
18 647 13,400 No
19A 824 1,900 Yes
19B 887 <50 Yes
Ranked by CD4 count (from low to high).
b Identification numbers of long-term nonprogrcssors arc italicized. Blood
samples were drawn from subject 19 on two occasions.
c Yes, subject was prescribed at least three antiretroviral agents at the time
when the sample was drawn.
erence for CD8 lymphocytes expressing CD4. In contrast, in¬
fection during activation would be expected to generate HIV-
infected, antigen-experienced CD8 lymphocytes, with higher
levels of infection in CD8 lymphocytes expressing CD4.
We also used four-color flow cytometry to investigate the
differentiation phenotype of CD4-expressing CD8 lymphocytes
isolated from HIV-infected subjects. CD8 lymphocytes in¬
duced to express CD4 in vitro have been shown to have cyto¬
kine expression profiles in keeping with a significant role in
immune function (18, 36), but little is known about the rela¬
tionship between CD4 expression and progression from naive
to memory or effector status in vivo.
MATERIALS AND METHODS
Subjects. Twenty 30- to 50-ml blood samples were drawn from 19 HIV-
infected individuals attending health care services in Scotland (Table 1). Because
each sample contained insufficient CD8 lymphocytes to assess HIV infection of
all the cell subsets of interest, the samples were divided into two groups. CDS
lymphocytes in the first group were sorted on the basis of CD4 expression (n =
9), and those in the second were sorted on the basis of differentiation phenotypc
(n = 11). Subjects were selected in such a way as to ensure a range of disease
stages, from asymptomatic to advanced AIDS, in each group. Three individuals
were long-term nonprogressors (defined as persons who had maintained a CD4
count above 300 without antiretroviral therapy despite more than 10 years of
infection), and 13 were receiving combination antiretroviral therapy at the time
of sampling. The mean age of the subjects was 39 (range, 29 to 54).
Isolation of lymphocyte populations. Each blood sample was taken into tubes
containing EDTA. Peripheral blood mononuclear cells (PBMCs) were obtained
by density ccntrifugation over Histopaque (Sigma Diagnostics, St. Louis, Mo.)
and washed twice in phosphate-buffered saline (Invitrogen, Paisley, United King¬
dom), and lymphocyte subsets were isolated. In order to achieve very high cell
population purity, the populations of interest were first enriched by using im-
munomagnctic technology and then isolated by fluorescence-activated cell sort¬
ing (FACS). This two-stage process was performed for all subjects except subject
10, for whom cell sorting was performed directly on PBMCs.
Where CD8 lymphocytes were to be separated by differentiation phenotype,
cell populations were enriched by the following steps: (i) 78 T lymphocytes were
removed by negative selection using a magnetic cell sorting (MACS) 78 T-
lyuipliucyle isolation kit (Miltenyi Biotec Ltd. [UK], Bisley, United Kingdom);
(ii) from the 78 T-lymphocyte-ncgative population, CD8 lymphocytes were en¬
riched by using MACS CD8 microbeads (Miltenyi Biotec); (iii) from the CD8-
ncgativc population, CD4 lymphocytes were enriched by using MACS CD4
microbeads (Miltenyi Biotec). Where CD8 lymphocytes were to be separated
into populations on the basis of CD4 expression, steps ii and iii of this protocol
were used.
Enriched populations were incubated for 30 min at 4°C with appropriate
fluorescent dye-conjugated monoclonal antibodies (Table 2). Cells were then
fixed in 0.75% paraformaldehyde (Sigma Diagnostics) at 4°C for 1 h, after which
they were resuspended in phosphate-buffered saline and stored for a maximum
of 4 days prior to flow sorting. High-purity CD4 lymphocytes and CD8 lympho¬
cyte subpopulations were then isolated by using a FACSVantage (Bccton Dick¬
inson, Crawley, United Kingdom) flow sorter (Fig. 1). To ensure that the sorted
CD8 lymphocytes were not contaminated by minor populations of other cell
types expressing CD8 (such as CD4 lymphocytes and NK cells), the anti CDS
monoclonal antibody used was directed against the 3 chain of the CDS molecule,
which has been shown to define true CD8 lymphocytes (13). In sorting of the
CD8bnght CD4dun population, a tight lymphocyte gate and a low flow rate (ap¬
proximately 2,000 events/s) were used in order to avoid cell aggregates and to
minimize coincidence error.
Nucleic acid extraction and HIV DNA quantification. DNA was isolated from
the cell subsets by phenol-chloroform extraction and ethanol precipitation, and
the DNA concentration was measured by using a GeneQuant II spectrophotom¬
eter (Amcrsham Biosciences, Cambridge, United Kingdom). Real-time PCR was
used to quantify HIV LTR DNA copies per microgram of DNA, and the copy
number was then confirmed at limiting dilution. The real-time PCR was per¬
formed using a nested approach with a conventional primary reaction and a
real-time secondary reaction. The primary reaction used primers GRAACC
CACTGCTTAASSCTCAA (sense) and AAGCCGAGYCCTGCGTCGAGAG
(antisense) (5' base positions 506 and 686 of the HXB2 genome) with an an¬
nealing temperature of 55°C and ran for 18 cycles. The secondary reaction used
primers CTCAATAAAGCTTGCCTTGAG (sense) and TGTTCGGGCGCCA
CTGCTAGAGA (antisense) (5' base positions 524 and 626 of the HXB2 ge-
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FIG. 1. FACS of CD4 lymphocytes and CD8 lymphocyte subsets. (A) CD8 lymphocytes sorted on the basis of CD4 expression; (B and C) CD8
lymphocytes sorted on the basis of differentiation phenotype; (D) CD4 lymphocytes. Sorting on the basis of differentiation phenotype was
performed in two stages: first, enriched CD8 lymphocytes were sorted into antigen-naive and antigen experienced subsets (B); then a portion of
the antigen-experienced subset was retained for HIV DNA analysis, and the remainder was further sorted into memory and effector subtypes (C).
FSC, forward scatter; SSC, side scatter.
nomc) (obtained from Oswcll, Southampton, United Kingdom) and hybridiza¬
tion probes LCRcd705-ACTCTGGTARCTAGAGATCCCTCAGA-phosphatc
and AAGTAGTGTGTGCCCGTCTGTTGT-fluorescein (Tib Molbiol, Berlin,
Germany) and was performed on a Light Cycler (Roche, Mannheim, Germany)
annealing at 55°C, with external standards. This method was sensitive to a single
copy, as assessed against National Institute for Biological Standards and Control
(N1BSC) HIV-1 DNA standards (provided by the European Union Programme
EVA/MRC Centralised Facility for AIDS Reagents, NIBSC, Potters Bar, Hert¬
fordshire, United Kingdom [grants QLK2-CT-1999-00609 and GP828102]; do¬
nated by J. Bootman), and was validated against serial dilutions of cloned
full-length HIV-1.
Limiting-dilution PCR was then performed to confirm the estimated LTR
copy number by using published Pan-LTR primers and thcrmocycling conditions
(14). Ten replicate reactions were performed at the DNA concentration ex¬
pected to contain 0.5 copy per reaction. Further dilutions were performed if
necessary to produce replicates containing both positive and negative results.
HIV DNA load and standard error were then estimated by using the QUALITY
program (27) and were expressed as LTR DNA copies per 106 cells, assuming 6.6
p,g of DNA per 106 cells. For samples where only a single positive replicate was
generated due to limited availability of viral DNA, no standard error is provided.
The correlation between the original real-time PCR estimate and the final result
provided by limiting dilution was 0.79 (P < 0.001) (Spearman's rank correlation).
This DNA extraction and LTR quantification protocol was found to have high
reproducibility when tested on five replicate samples of paraformaldehyde-fixed
PBMCs from an HIV-infected subject (mean, 60 LTR DNA copies/106 cells;
range, 26 to 100).
Purity of cell subsets and calculation of attributable HIV DNA loads. The level
of CD4 lymphocyte contamination of CD8 lymphocyte subsets (defined as the
percentage of cells that were CD4+ CD83"~) was assessed by flow cytometry and
was found to be low (mean, 0.05% [Tables 3 and 4]). For subsets with adequate
cell numbers (naive and experienced CD8 lymphocytes and CD8p+ CD4~ lym¬
phocytes), at least 1,000 (mean, 4,880) ungated events were assessed. Within
subjects, the purity of memory and effector populations was taken to be equiv¬
alent to that of antigen-experienced populations. For populations of rare cells
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TABLE 3. Levels of CD4 lymphocyte contamination of
CD8(3+ CD4" and CD8pbri^' CD4dim lymphocytes
% CD4 lymphocyte contamination0 of:
Study subject CD8p+ CD4" CD8pbrighl CD4dim
lymphocytes lymphocytes
1 <5 X KT3 NA









a NA, not available.
(CD8bnght CD4dun), sufficient cells were available to assess purity in four sub¬
jects. At least 500 (mean, 860) events were assessed, and due to the high ratio of
background to cellular events, events falling outside the lymphocyte gate (de¬
fined on light scatter properties) were excluded. Where purity was not measured
directly, the purity of CD8br,ght CD4dim lymphocytes was taken to be equivalent
to that of CD8p+ CD4~ lymphocytes. Where no purity data were available
(subjects 9 and 17), a level of 0.2%, which represents the 75th percentile of the
available CD4 contamination data, was used. Microscopic examination of sorted
CD8bright CD4dim lymphocytes from one subject confirmed that they represented
a single cell suspension free from aggregates.
For each CD8 lymphocyte subset, the HIV DNA load attributable to CD4
lymphocyte contamination was calculated from the cell population purity data
and the CD4 lymphocyte HIV DNA load. This figure was then subtracted from
the observed HIV DNA load in the CD8 lymphocyte subset to give the HIV
DNA load attributable to CDS lymphocytes. Where CD8 lymphocytes were
found to be infected, the HIV DNA load observed in the CD8 lymphocyte subset
was >5 times that attributable to CD4 contamination in all but three cases. All
HIV DNA loads given in Results for CD8 lymphocyte subsets are attributable to
the CDS lymphocytes.
Distribution of CD8 lymphocytes expressing CD4. The differentiation pheno-
type, in terms of CD45RA and CD27 expression (Fig. 1), of CD8 lymphocytes
expressing CD4 was assessed for 13 subjects by using a FACScalibur flow cy-
tometer (Becton Dickinson). For seven subjects this assessment was performed
on sorted naive and experienced CD8 lymphocyte populations, while for the
remainder appropriately stained PBMCs were used (Table 2). Populations were
gated according to the differentiation phenotypes given (Fig. 1), and the per¬
centage of CD8 lymphocytes expressing CD4 in each population was determined.
A tight lymphocyte gate was used to exclude cell aggregates.
RESULTS
Extent of HTV infection of CD8 lymphocytes. To assess the
level of HIV infection of CD8 lymphocytes in subjects with a
range of disease stages, HIV LTR copies were quantified in
CD8 lymphocytes isolated from HIV-infected subjects. HIV
infection of CD8 lymphocytes was demonstrated in 17 out of
19 subjects. The level of infection was low (median, 16 HIV
LTR DNA copies per 106 CD8 lymphocytes; range, undetect¬
able to 436 [Fig. 2A]), significantly lower than that of CD4
lymphocytes from the same subjects (median, 3,660 LTR DNA
copies/106 cells; range, 16 to 25,512 [P < 0.001 by the Wilcoxon
signed rank test] [Fig. 2A]). The possibility that the viral DNA
found within the CD8 lymphocyte subsets represented contam¬
ination from CD4 lymphocytes was excluded by determining
the purity of the CD8 lymphocyte populations and calculating
attributable HIV DNA loads (see Materials and Methods). No
significant correlation was found between HIV DNA loads in
CD4 and CD8 lymphocytes (Spearman's correlation coeffi¬
cient, 0.3; P > 0.1).
There was an inverse correlation between CD4 lymphocyte
counts and CD8 lymphocyte HIV DNA loads (Spearman's
correlation coefficient [R], —0.73; P < 0.001 [Fig. 3A]), indi¬
cating a progressive increase in the prevalence of infected CD8
lymphocytes with advancing disease. In individuals with ad¬
vanced disease, the higher prevalence of infected CD8 lym¬
phocytes, together with dwindling CD4 lymphocyte numbers,
increased the contribution of CD8 lymphocytes to the total
circulating HIV DNA load. Thus, for the individuals with the
lowest CD4 lymphocyte counts, CD8 lymphocytes contributed
more than 25% of the total HIV DNA load in circulating
lymphocytes (Fig. 3B). In contrast, the CD8 lymphocytes of
long-term nonprogressors appear relatively resistant to infec¬
tion, with virtually no LTR copies detected.
Phenotype of HIV-infected (JD8 lymphocytes. In order to
determine the relative contributions of intrathymic infection
versus infection of activated cells in the generation of circulat¬
ing HIV-infected CD8 lymphocytes, HIV LTR DNA was
quantified in subsets of CD8 lymphocytes. For the first nine
subjects, CD8 lymphocyte subsets were divided on the basis of
CD4 expression (Fig. 2B). CD8 lymphocytes expressing CD4
(CD8brlght CD4dun) were found to be infected in seven out of
nine subjects (78%) with relatively high levels of infection
(median, 1,730 LTR DNA copies/106 cells; range, undetectable
to 7,902), approaching those in the CD4 lymphocytes of the
same nine subjects (Fig. 4A). In contrast, only two of nine
subjects (22%) showed infection of CD8[I+ CD4~ lympho¬
cytes, and this was at low levels (10 and 4 LTR DNA copies/106
cells). The increase in HIV DNA load in CD8bright CD4dim
lymphocytes compared to that in CD8p+ CD4~ lymphocytes
was significant (P < 0.01 where undetectable values were as¬
signed a value half the lower limit of detection, and P < 0.05
where undetectable values were assigned a value of zero, by
the Wilcoxon signed rank test).
For the remaining 11 subjects, levels of HIV infection were
compared in CD8 lymphocyte subsets divided on the basis of
differentiation phenotype (Fig. 2C and 4B). Infection levels
TABLE 4. Levels of CD4 lymphocyte contamination of naive
and antigen-experienced CD8 lymphocytes
% CD4 lymphocyte contamination" of:














° NA, not available.
b PBMCs from subject 10 were not enriched prior to FACS.
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FIG. 2. Levels of HIV infection in CD4 lymphocytes and CD8 lymphocyte subsets. (A) CD4 and CD8 lymphocytes; (B) CD8pbn8ht CD4dim and
CD8p+ CD4~ lymphocytes; (C) CD8 lymphocytes divided by differentiation phenotype. Solid diamonds, attributable HIV DNA load. Shaded
diamonds, samples where no virus was detected; the value given is half the lower limit of detection, which varies with the number of cells available
for analysis. P values shown were calculated using the Wilcoxon signed rank test.
were generally quite low (range, <3 to 274 LTR DNA copies/
106 cells), and although HIV DNA was more frequently de¬
tected in antigen-experienced than in antigen-naive popula¬
tions, there was no significant difference in HIV DNA loads (P
= 0.7 by the Wilcoxon signed rank test). Further subdivision of
the antigen-experienced cells into memory and effector subsets
was performed for four of the subjects with detectable HIV
DNA. Of these, three demonstrated infection in the memory
subset and one demonstrated infection in the effector subset
(Fig. 2C), again with no significant difference in viral DNA loads.
Prevalence and differentiation status of CD8 lymphocytes
expressing CD4. In order to investigate the relationship be¬
tween CD8 lymphocyte differentiation and CD4 expression in
vivo, we used four-color flow cytometry to assess CD4, CD8p,
CD45RA, and CD27 expression in 13 HIV-infected subjects.
Distinct CD8brlght CD4dlm populations were detected in all
study subjects, and the density of CD4 expression on CD8bnght
CD4dlm lymphocytes was approximately half (mean, 0.4; range,
0.3 to 0.6) that on true CD4 lymphocytes. The proportion of
CD8 lymphocytes found to express CD4 was between 0.8 and
3.3% and was not found to correlate with CD4 or CD8 lym¬
phocyte counts.
In keeping with the hypothesis of CD4 expression following
activation, the vast majority of CD8bnght CD4dim lympho¬
cytes had an antigen-experienced phenotype (mean, 92%;
range, 47 to 99%). Interestingly, most of the antigen-experi¬
enced CD8brlght CD4dlm lymphocytes displayed a memory
(mean, 75%; range, 47 to 96%) as opposed to an effector
(mean, 12%; range, 0 to 31%) phenotype. This preponderance
of antigen-experienced and memory phenotypes is not simply a
reflection of the distribution of phenotypes in the total CD8
lymphocyte population, because the proportion of CD8 lym¬
phocytes expressing CD4 was significantly greater in the anti-
gen-experienced population than in the antigen-naive popula¬
tion (P < 0.05 by paired t test) and significantly greater in the
memory subset than in the effector subset (P < 0.01 by paired
t test [Fig. 5]).
The differentiation phenotype of CD8bnght CD4dlm lympho¬
cytes was also assessed in three healthy volunteers. All three
demonstrated a differentiation pattern similar to that observed
in the majority of HIV-infected subjects, with the greatest pro¬
portion of CD8 lymphocytes expressing CD4 observed in the
memory subset (range, 3.8 to 6.3%) and markedly less found in
the effector (range, 1.0 to 2.0%) and naive (range, 1.1 to 2.8%)
subsets.
DISCUSSION
This study confirms that CD8 lymphocytes are infected with
HIV in vivo and demonstrates that CD8 lymphocytes express¬
ing CD4 have a high frequency of infection. It is the first study
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FIG. 3. Increased HIV infection of CD8 lymphocytes with disease progression. (A) Correlation between CD8 lymphocyte HIV DNA load and
CD4 count (Spearman's rank correlation coefficient [/?]). Cases with undetectable proviral loads were given a value of half the lower limit of
detection. (B) Relative contributions of CD4 and CD8 lymphocytes to overall circulating HIV DNA loads were calculated from CD4 and CD8
lymphocyte HIV DNA loads and from CD4 and CD8 lymphocyte counts. Undetectable viral loads were given a value of zero.
to correct the level of infection of CD8 lymphocytes for directly
measured CD4 lymphocyte contamination and therefore rep¬
resents a methodological advance over previous studies (14,
21). The high infection levels found in CD8brlght CD4dun lym¬
phocytes support the hypothesis that infection of this subset
could have a direct role in the AIDS-related decline in CD8
lymphocyte function.
Route of CD8 lymphocyte infection. CD4-dependent HIV
infection of CD8 lymphocytes has been demonstrated during
intrathymic development (4, 7) and following activation of
mature lymphocytes (8, 14, 17, 35). Given that CD8 lympho¬
cyte precursors would be expected to lose CD4 before leaving
the thymus, our observation of very low or undetectable viral








5 6 7 11 13 14 15
(66) (117) (123) (339) (385) (393) (396)








2 3 4 8 9 10 12 16 17 18 19A
(17) (39) (51) (296) (328) (334) (364) (509) (531) (647) (824)
Subjects (CD4 count given in parenthesis)
FIG. 4. HIV DNA loads for each subject. HIV DNA loads for CD4 lymphocytes and CD8 lymphocyte subsets for each subject (ordered by
ascending CD4 lymphocyte count) are given. (A) CD8 lymphocytes were divided on the basis of CD4 expression; (B) CD8 lymphocytes were
divided by differentiation phenotype. Error bars indicate standard errors (see Materials and Methods); they are absent from samples where
insufficient cells were available. Stars indicate samples where no virus was detected; the value given is half the lower limit of detection.
















FIG. 5. Phenotype of CD8pbnEht CD4dhn lymphocytes. (A) The differentiation phenotype of CD8pbr'6ht CD4d,m lymphocytes was assessed in
terms of CD45RA and CD27 expression. Dot plots from PBMCs of a representative subject (subject 10) are shown comparing the distribution of
all CD8 lymphocytes (i) against that of CD8p 81,1 CD4dlm lymphocytes (ii). The lack of expression of CD4 on the CD45RA+ CD27- (effector)
subset is clearly seen. (B) Percentages of CD8 lymphocytes found to express CD4 in antigen-naive, antigen-experienced, memory, and effector
subsets are shown for 13 subjects. Circles, outliers; stars, extreme outliers. P values were calculated by using the paired / test.
route is contributing little to the circulating HIV-infected CD8
lymphocytes. In contrast, the higher viral DNA levels observed
in the CD8brlght CD4dim population suggests frequent infection
of this subset of mature CD8 lymphocytes. This distribution of
HIV DNA is in keeping with previous results from our group
in which CD8+ CD4+ cells isolated by immunomagnetic meth¬
ods were found to contribute a higher proportion to the overall
proviral load than their CD4-negative counterparts (14). Sim¬
ilarly, in a recent paper, Brenchley et al. observed that there
are 5- to 100-fold more HIVgag DNA copies in CD8+ CD4du"
lymphocytes than in CD8 lymphocytes lacking CD4 expression
(3).
The distribution of HIV DNA between CD8 lymphocytes at
sequential stages of differentiation can also provide informa¬
tion regarding the likely route of infection. The use of pheno-
typic markers to define differentiation stages of CD8 lym¬
phocytes has been a topic of much debate (11). CD27 and
CD45RA have been demonstrated to define populations
with distinct cytokine profiles, and a differentiation pathway
from CD27+ CD45RA+ (antigen naive) to CD27+ CD45RA-
(memory) and then to CD27- CD45RA+ (effector) has been
proposed (9, 10, 15). Further experiments indicated that
>90% of CD27+ CD45RA"1" CD8 lymphocytes were "true
naive" as defined by a panel of three further phenotypic
markers (6), though early antigen-experienced cells may retain
the CD27high CD45RA+ (naive) phenotype (1). The relation¬
ship between differentiation markers and memory versus ef¬
fector function remains unclear (1), and we therefore recog¬
nize that while we retain the labels "memory" and "effector"
for the CD27+ CD45RA" and CD27" CD45RA+ subsets,
respectively, a degree of functional overlap is likely.
Given the observed distribution of HIV DNA in CD8brlght
CD4dim versus CD8|3 + CD4~ lymphocytes, and the evidence
that CD4 upregulation on CD8 lymphocytes follows antigen
recognition (8, 17, 31), one would expect HIV DNA levels to
be relatively high in antigen-experienced CD8 lymphocytes but
very low in the antigen-naive subset. Interestingly, although
HIV DNA was more frequently detected in the antigen-expe¬
rienced populations, it was also demonstrated in the naive
subset for 4 out of 11 subjects. These HIV-infected naive CD8
lymphocytes are likely to be cells early in the activation process
that have upregulated CD4 but have not yet lost their naive
markers. This interpretation is supported by our finding of
CD4 expression on lymphocytes with the CD45RA+ CD27hlgh
(naive) phenotype (Fig. 5) and suggests that, at least in some
subjects, HIV infection of CD8 lymphocytes is occurring very
early in the activation process. Recently published data showed
negligible HIV DNA levels in naive CD8 lymphocyte popula¬
tions from which cells expressing CD4 had been removed (3),
supporting our suggestion that CD4-expressing cells are re-
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FIG. 6. Proposed infection route of CD8 lymphocytes circulating in vivo. We propose that circulating HIV-infected CDS lymphocytes are
generated through CD4-mediated infection of activated CD8 lymphocytes and that export of HIV-infected CD8 precursors from the thymus occurs
rarely if at all. Since only a minority of memory CD8 lymphocytes express CD4, we propose that expression is transient and therefore show a
CD4-negative "later " memory CD8 lymphocyte. It is also possible that CD4 is expressed on a stable minority ofmemory CD8 lymphocytes. Dotted
arrows represent possible lineage associations between cell types.
sponsible for the HIV observed in our naive CD8 lymphocyte
populations. Alternatively, the HIV DNA observed in our naive
cell populations may originate in contaminating nonnai've cells
which were excluded in the Brenchley et al. experiment
through use of a more stringent definition of naive cells (3).
The lack of correlation between the level of infection in CD4
and CD8 lymphocytes suggests that, although we propose that
HIV enters both cells via the CD4 receptor, different factors
influence the frequency of this event in the two cell types. The
observation of a clear inverse correlation between CD8 lym¬
phocyte HIV DNA load and CD4 count indicates that disease
progression may be one factor that favors CD8 lymphocyte in¬
fection. Teasing out the relative importance of the many other
host, viral, and therapeutic factors that are likely to influence
CD8 lymphocyte infection would be of major value in future
studies.
Phenotype of CD8br,ght CD4dlm lymphocytes. Given the find¬
ing that CD8brlght CD4dun lymphocytes are a major target for
HIV infection, a clear understanding of the natural history of
these cells in HIV-infected subjects is a priority. In vitro, CD4
is markedly upregulated upon costimulation of naive CD8 lym¬
phocytes, with CD4 expression accompanying the appearance
of activation markers and a change from a naive to an antigen-
experienced phenotype (17, 31). Our observation that the ma¬
jority of CD8bnght CD4dlm lymphocytes circulating in vivo have
an antigen-experienced phenotype is in keeping with this in
vitro finding. CD4 expression was also observed in a small
proportion of naive CD8 lymphocytes, and, as discussed ear¬
lier, it is likely that these were recently activated, suggesting
that CD4 expression is an early event in the activation process.
Within the antigen-experienced population, CD4 was ex¬
pressed in a much higher proportion of CD27+ CD45RA-
(memory) than terminally differentiated CD27- CD45RA+
(effector) CD8 lymphocytes. In the context of the proposed
linear pathway of CD8 lymphocyte differentiation from naive
to memory and then to effector function (9, 10), these findings
suggest that memory CD8 lymphocytes expressing CD4 either
fail to differentiate to effector status or downregulate CD4
expression prior to further differentiation. Failure to differen¬
tiate could reflect deletion of CD4-expressing cells through
HIV infection; however, the decreased frequency of CD4 ex¬
pression in effector cells was also observed in three healthy
volunteers, suggesting that non-HIV-related mechanisms are
involved.
In 2 out of the 13 subjects assessed, an unusually high pro¬
portion of effector CD8 lymphocytes was found to express CD4
(indicated as outliers in Fig. 5B). These subjects had the high¬
est overall proportion of CD8brlght CD4dlm lymphocytes (>4%
of all CD8 lymphocytes), and, in contrast to the remaining 11
subjects, the proportion in the effector population was greater
than that in the memory population. It is possible that the high
levels of CD8brlght CD4dlm lymphocytes in these subjects re¬
flected acute responses to intercurrent infection (23), and one
of the subjects had clinical diagnoses of pneumonia and otitis
media at the time of sampling.
Taken together, the HIV DNA load and the CD4 expression
data allow us to put forward a model for the route of HIV
infection of circulating CD8 lymphocytes (Fig. 6). We propose
that export of HIV-infected CD8 lymphocyte precursors from
the thymus occurs rarely if at all and that the vast majority of
infected CD8 lymphocytes acquire HIV through expression of
CD4 during activation. CD4 expression can be induced early in
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the activation of naive cells, and HIV infection can be rapid, in
some cases occurring before the loss of naive markers. The
relationship between effector CD8 lymphocytes and both CD4
expression and HIV infection is interesting. Although we iso¬
lated effector cells from only four subjects, we have shown that
in general, effector cells do not express CD4, and CD4-nega-
tive cells are rarely HIV infected. From this we can infer that
effector cells are infrequent carriers of HIV. This suggests
either that HIV infection of CD8 lymphocytes blocks progres¬
sion to effector status (through, for example, cell death or
interference with differentiation signals) or that CD4 expres¬
sion occurs only on a subset of activated CD8 lymphocytes
which have a different differentiation pathway. The picture is
complicated by the two subjects with high levels of CD4 ex¬
pression on effector lymphocytes and the one subject whose
isolated effector CD8 lymphocytes were found to carry HIV
DNA. Clearly, the dynamics of CD4 expression and HIV in¬
fection of this important subset of CD8 lymphocytes is an area
where further study is a priority.
Impact of HIV infection of CD8bright CD4dlm lymphocytes.
The importance of CD8 lymphocytes in the control of HIV
replication and the decline in CD8 lymphocyte function with
progression to AIDS have been clearly demonstrated (16, 22,
32). The decline in CD8 lymphocyte function is commonly
ascribed to lack of CD4 lymphocyte help and viral escape
(reviewed in reference 22), but our group and others (8, 14,17,
20, 21, 30, 35) have proposed that, in addition to the mecha¬
nisms referred to above, infection of CD8 lymphocytes with
HIV may directly compromise CD8 lymphocyte function. The
present finding of HIV infection in CD8bright CD4dim lympho¬
cytes demonstrates targeted infection of cells responding to
antigen. This process could clearly have a significant effect on
the immune control of both HIV and opportunistic pathogens
and may contribute to the observed correlation between im¬
mune activation and poor outcome (2).
Implications for therapeutic advances. As the limitations of
current antiviral therapies have become apparent, there has
been increasing interest in therapeutic immune activation as a
mechanism for achieving improved viral control. Strategies in¬
clude the use of immune stimulants in conjunction with anti-
retroviral agents (26) and structured treatment interruptions
where antiviral therapy is stopped to allow HIV to replicate
and thus stimulate an anti-HIV immune response (28). In the
light of our findings, it is clear that such therapies should be
developed with caution, with evaluation of their effect on in¬
fection of CD8 lymphocytes. Structured treatment interrup¬
tions should be viewed as particularly hazardous, because they
allow immune activation in the presence of actively replicating
HIV.
In conclusion, we have shown that CD8 lymphocytes ex¬
pressing CD4 contain high levels of HIV DNA in vivo, while
CD8 lymphocytes lacking CD4 expression have low or unde¬
tectable levels. This finding supports the infection of activated
mature CD8 lymphocytes over infection of thymic precursors
as the major mechanism responsible for the generation of
circulating HIV-infected CD8 lymphocytes. In the future it will
be important to investigate factors influencing the expression
of CD4 on CD8 lymphocytes and to formally assess the impact
of infection of these cells on HIV immunopathogenesis.
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First evidence of HIV infection of CD8 lymphocytes expressing CD4 during primary HIV-1 infection
Activated CD8 lymphocytes express CD4 generating a
CD8bnEhtCD4dim phenotype that is susceptible to HIV
infection both in vitro [1-3] and in vivo [4]. Here we
demonstrate for the first time that CD8 lymphocytes in a
patient with primary HIV infection express CD4 and are
infected with HIV. This finding has implications for the
immune control of HIV during primary infection, and
for the generation of a long-lived viral reservoir.
The patient presented with a typical HIV seroconversion
illness, consisting of fever, rash and lymphadenopathy
approximately 4 weeks after HIV exposure through
unprotected heterosexual intercourse. Primary HIV
infection was confirmed by two weakly reactive HIV
antibody tests with a negative Western blot (fourth
generation HIV combo assay, Abbott Diagnostics, Abbott
Park, Illinois, USA; fourth generation Vidas Duo assay,
BioMerieux, Boulogne, France; and New LAV Blot 1,
BioRad, Hercules, California, USA). HIV p24 antigen
was positive (Vidas p24 antigen assay, BioMerieux) and
could be neutralized with specific antiserum. The initial
HIV viral load was 3.5 X 106 RNA copies/ml serum
(Roche Cobas Monitor HIV-RNA assay, Roche
Diagnostics, Mannheim, Germany) rising to 6.3 x 106
a week later, then dropping to 2 X 104 after one month.
Blood was drawn for this study during the phase of rising
viraemia, 3 weeks after the onset of symptoms. The
prevalence of CDS^'^'CDd11™ lymphocytes circulating
in peripheral blood was determined on a FACSVantage
flow cytometer (Becton Dickenson, Franklin Lake, New
Jersey, USA) using fluorescent conjugated monoclonal
antibodies: CD4-FITC (Molecular Probes, Paisley, UK),
CD8beta-PE (Coulter Immunotech, Beckman Coulter,
Inc. Miami, Florida) and CD3-cychrome (BD Bios¬
ciences). Of the total T lymphocytes (defined as CD3
expressing cells with forward and side scatter properties
typical of lymphocytes) 26% were CD4 lymphocytes,
67% were CD8 lymphocytes, and 0.4% were
CD8br'EhtCD4dim lymphocytes (Fig. la). This frequency
of CD8br'BbtCD4dim lymphocytes was similar to levels
found previously both in the general population [5] and in
individuals with chronic HIV infection [6]. This single
subject thus demonstrated CD4 cell expression on CD8
lymphocytes, but does not suggest that primary HIV
infection leads to the exceptionally high levels of
expression described for primary Epstein-Barr virus
and cytomegalovirus infection [7].
The level of HIV infection of CD8bnghtCD4dk" and
CD8+CD4_ negative lymphocytes was determined using
a method previously validated in chronic HIV infection
[4]. Briefly, highly purified populations of CD4
lymphocytes, CD8 lymphocytes expressing CD4
(CD8(3bnghtCD4dim) and CD8 lymphocytes not expres¬
sing CD4 (CD8[3brigbtCD4~) were isolated. The
HIV-DNA copies per million cells in each of the isolated
populations were determined by the extraction of DNA
followed by quantitative polymerase chain reaction for
HIV long terminal repeat (LTR) repeat DNA.
The HIV DNA load in CD4 lymphocytes was 697 (SE
225) HIV DNA copies per million CD4 lymphocytes, a
frequency in keeping with results from a previous series of
16 subjects with primary HIV infection [8]. Interestingly,
the level of infection of CD8brlghtCD4dlm lymphocytes
was similar to that ofCD4 lymphocytes at 523 (SE 160)
HIV DNA copies per million CD8brlghtCD4dim lympho¬
cytes, with only two HIV DNA copies per million cells
being attributable to CD4 lymphocyte contamination.
No HIV DNA was found in the CD8 lymphocytes not
expressing CD4 (Fig. lb) [9],
The frequency of infection of CD4 lymphocytes
circulating in the blood during primary HIV infection
substantially underrepresents the level of HIV infection
occurring in lymph nodes and mucosal lymphoid tissue
[10], The same is likely to be true ofCD8 lymphocytes,
particularly as the susceptible (CD8brlghtCD4 ™) phe¬
notype is generated on antigen-specific activation in
lymph tissue. Therefore, the proportion of circulating
CD8 lymphocytes infected with HIV observed in this
study may reflect much greater frequencies of infection in
lymph tissue.
Events during primary HIV infection have a major
influence on the course of disease, with poor viraemic
control being prognostic of rapid progression [11]. CD8
lymphocytes are vital in the control of initial viraemia
[12,13], and thus any compromise of CD8 lymphocyte
function at this stage could have a profound effect on
prognosis. HIV infection of CD8b"E 'CDd111111 lympho¬
cytes leads to the downregulation ofCD4 expression, the
deregulation of IFN-y and FAS ligand expression, and
decreased effector function [14]. The infection of
CD8bngbtCD4dim lymphocytes demonstrated here could
thus significantly compromise the primary anti-HIV
CD8 lymphocyte response.
In addition, the infection of CD8 lymphocytes has
implications for the generation of a long-lived HIV
reservoir. Unlike CD4 lymphocytes where activation is
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Fig. 1. The extent of CD4 expression on CD8 lymphocytes and the level of HIV infection of these cells are shown for the study
subject with primary HIV infection, (a) Expression of CD4 and CD8|3 on T lymphocytes (gated on light scatter characteristics and
CD3 expression from peripheral blood mononuclear cells). The proportions of CD4 lymphocytes (PI), CD8 lympocytes not
expressing CD4 (P2) and CD8hr'8htCD4d,m lymphocytes (P3) are shown, (b) HIV DNA load attributable to CD4 lymphocytes,
CD8brlghtCD4dlm lymphocytes and CD8+CD4~ lymphocytes. Filled bars represent detected attributable HIV DNA loads, the
unfilled bar represents undetectable viral DNA, and half the lower limit of detection is given. Error bars show standard errors
estimated using the program 'Quality' [9].
rapidly followed by apoptosis, a significant proportion of
activated CD8 lymphocytes differentiate into memory
cells [15]. While resting, these memory cells are invisible
to immune surveillance, can form a long-lived refuge for
HIV [16], and therefore could contribute to the failure of
antiretroviral therapy to achieve complete HIV clearance,
even when treatment is started soon after seroconversion
[17].
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Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France
Kaposi's sarcoma-associated herpesvirus or human her¬
pesvirus 8 (HHV8) is a vasculotrope virus associated with
Kaposi's sarcoma, HIV-associated Castleman's disease
and primary effusion lymphoma. Other associations, in
particularly multiple myeloma, have been clearly dis¬
proved by additional analysis after initial positive reports
[1], Cool et al. [2] have recently demonstrated the
presence of HHV8 in the lungs of patients with
pulmonary arterial hypertension (PAH) ascertained
by immunochemistry with antibody directed against
latency-associated nuclear antigen 1 (LANA-1) and poly¬
merase chain reaction assay to detect the viral cycline
gene of HHV8. In that study, evidence of HHV8 was
found in 10 out of 16 patients with idiopathic PAH, in
one out of three patients with PAH related to HIV
infection, and in none of 12 patients with PAH related to
other conditions. The authors suggested a role for HHV8
in the development of PAH [2], Later, the presence of
HHV8 antibodies, against a structural HHV8 protein
called K8.1 and against LANA-1, was tested in plasma
samples from non-HIV-infected German patients with
PAH, but no difference was found between patients and
controls [3], In addition, HHV8-DNA sequences were
not detected by polymerase chain reaction in nine PAH
lungs studied in Japan, indicating that other factors than
HHV8 are more likely to be the cause of PAH in that
population [4], Moreover, whereas the geographical
distribution of Kaposi's sarcoma mirrors HHV8
prevalence, it seems unlikely for PAH in which no
ethnic predisposition has been observed to date. As
Mediterranean countries have higher prevalence rates of
HHV8 infection, we studied a cohort of French patients
with PAH in order to test whether there were possible
links between HHV8 and PAH in this country. The aim
of the study was to evaluate the prevalence of HHV8
antibodies in plasma samples from HIV and non-HIV-
infected patients with PAH.
Ninety-three patients with PAH were enrolled in the
study: 47 with idiopathic or familial PAH, 34 with PAH
related to HIV infection, and 12 with PAH associated
with other conditions. Antibodies directed against
LANA-1 were detected using an immunofluorescence
assay on the primary effusion lymphoma BC-3 cell line,
and the positive samples were confirmed using an
immunofluorescence assay that detects antibodies to
HHV8 lytic antigens (KSHV IgG IFA; Biotrin, Dublin,
Ireland).
HHV8 antibodies were detected in one out of 47
[2.1%; confidence interval (CI) 0—6.3%] patients with
idiopathic or familial PAH and in two out of 12
(16.7%; CI 0-38.7%) patients with PAH related to
other conditions. In the 34 patients with PAH related
to HIV infection, eight had HHV8 antibodies (23.5%;
CI 9.3—37.8%). These results indicate that the prevalence
of antibodies for HHV8 in HIV-infected and non-HIV-
infected patients with PAH is similar to that previously
reported for corresponding individuals without PAH.
The seroprevalence of HHV8 in healthy individuals in
France has been estimated at 2%, and between 22 and
35% among HIV-infected individuals from the United
States and northern Europe using LANA tests [5,6], This
suggests that there is no trend in favour of an increased
serological evidence of HHV8 infection in PAH in
HIV-infected patients or in non-HIV-infected patients.
In addition, a reduced immunological response to viruses
has never been reported in PAH, and there is no scientific
basis supporting the hypothesis of a defective humoral
response to HHV8, which could explain the low
prevalence of HHV8-specific antibodies in plasma
samples of PAH patients. Our present results are based
on serological evidence ofHHV8 infection, and one may
hypothesize that HHV8 infection could be restricted to
patients' lungs. However, such compartmentalized
HHV8 infection without serological evidence has not
been reported to date. We conclude that there is no
evidence in favour of an association between PAH and
HHV8 in a French cohort of HIV-seropositive and
seronegative patients.
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